"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q4_nSJR","Q3_nSJR","Q1_percSJR","Q2_percSJR","Q4_percSJR","Q3_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","medianAltmetricScore","cited_by_accounts_count_mean_top25AltmScore","cited_by_accounts_count_min_top25AltmScore","cited_by_accounts_count_max_top25AltmScore","cited_by_fbwalls_count_mean_top25AltmScore","cited_by_fbwalls_count_min_top25AltmScore","cited_by_fbwalls_count_max_top25AltmScore","cited_by_feeds_count_mean_top25AltmScore","cited_by_feeds_count_min_top25AltmScore","cited_by_feeds_count_max_top25AltmScore","cited_by_gplus_count_mean_top25AltmScore","cited_by_gplus_count_min_top25AltmScore","cited_by_gplus_count_max_top25AltmScore","cited_by_msm_count_mean_top25AltmScore","cited_by_msm_count_min_top25AltmScore","cited_by_msm_count_max_top25AltmScore","cited_by_patents_count_mean_top25AltmScore","cited_by_patents_count_min_top25AltmScore","cited_by_patents_count_max_top25AltmScore","cited_by_peer_review_sites_count_mean_top25AltmScore","cited_by_peer_review_sites_count_min_top25AltmScore","cited_by_peer_review_sites_count_max_top25AltmScore","cited_by_policies_count_mean_top25AltmScore","cited_by_policies_count_min_top25AltmScore","cited_by_policies_count_max_top25AltmScore","cited_by_posts_count_mean_top25AltmScore","cited_by_posts_count_min_top25AltmScore","cited_by_posts_count_max_top25AltmScore","cited_by_rdts_count_mean_top25AltmScore","cited_by_rdts_count_min_top25AltmScore","cited_by_rdts_count_max_top25AltmScore","cited_by_rh_count_mean_top25AltmScore","cited_by_rh_count_min_top25AltmScore","cited_by_rh_count_max_top25AltmScore","cited_by_tweeters_count_mean_top25AltmScore","cited_by_tweeters_count_min_top25AltmScore","cited_by_tweeters_count_max_top25AltmScore","cited_by_videos_count_mean_top25AltmScore","cited_by_videos_count_min_top25AltmScore","cited_by_videos_count_max_top25AltmScore","cited_by_wikipedia_count_mean_top25AltmScore","cited_by_wikipedia_count_min_top25AltmScore","cited_by_wikipedia_count_max_top25AltmScore","cohorts.com_mean_top25AltmScore","cohorts.com_min_top25AltmScore","cohorts.com_max_top25AltmScore","cohorts.doc_mean_top25AltmScore","cohorts.doc_min_top25AltmScore","cohorts.doc_max_top25AltmScore","cohorts.pub_mean_top25AltmScore","cohorts.pub_min_top25AltmScore","cohorts.pub_max_top25AltmScore","cohorts.sci_mean_top25AltmScore","cohorts.sci_min_top25AltmScore","cohorts.sci_max_top25AltmScore","readers.citeulike_mean_top25AltmScore","readers.citeulike_min_top25AltmScore","readers.citeulike_max_top25AltmScore","readers.connotea_mean_top25AltmScore","readers.connotea_min_top25AltmScore","readers.connotea_max_top25AltmScore","readers.mendeley_mean_top25AltmScore","readers.mendeley_min_top25AltmScore","readers.mendeley_max_top25AltmScore","readers_count_mean_top25AltmScore","readers_count_min_top25AltmScore","readers_count_max_top25AltmScore"
"IRCCS_PASCALE",2000,68,8.92647058823529,3.16176470588235,0.316279069767442,0.25,0.294117647058824,0.0441176470588235,0.308823529411765,1,26,15,21,5,0.38,0.22,0.31,0.07,45,0.99269864366263,0.308823529411765,0.75,NA,0.397323290064454,0.316071428571429,0.302083333333333,0.266666666666667,"ALFREDO FUSCO;GENNARO CHIAPPETTA;ORLANDO CATALANO;MASSIMO SANTORO;G. FRASCI;GERARDO BOTTI;FABIO SANDOMENICO;GIUSEPPE VIGLIETTO;ANTONIO NUNZIATA;GIUSEPPE PALMIERI;ALFREDO SIANI;PAOLA BRUNI;SILVIA FRANCESCHI;GIANCARLO VECCHIO;ROSA MARINA MELILLO;GIOVANNI PAGANO;BIANCA CUSATI;CIRO MANZO;GUSTAVO BALDASSARRE;CARLO LA VECCHIA","8;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","ORLANDO CATALANO;GIOVANNI PAGANO;FABIO SANDOMENICO;ANTONIO NUNZIATA;ALFREDO FUSCO;GENNARO CHIAPPETTA;ALFREDO SIANI;SECONDO LASTORIA;BIANCA CUSATI;MASSIMO SANTORO;PIETRO MUTO;SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;GERARDO BOTTI;GIUSEPPE VIGLIETTO;ANNUNZIATA GLOGHINI;GIANLUCA GAÏDANO;FRANCO IONNA;G. LUCA COLUCCI‐D'AMATO","1.28;1.23;0.98;0.9;0.74;0.66;0.65;0.62;0.58;0.56;0.5;0.43;0.43;0.43;0.4;0.35;0.33;0.33;0.32;0.31","ALFREDO FUSCO;GENNARO CHIAPPETTA;ORLANDO CATALANO;MASSIMO SANTORO;G. FRASCI;GERARDO BOTTI;FABIO SANDOMENICO;GIUSEPPE VIGLIETTO;PAOLA BRUNI;ROSA MARINA MELILLO;GIOVANNI PAGANO;CIRO MANZO;GUSTAVO BALDASSARRE;GIUSEPPE D’AIUTO;ADRIANO GRAVINA;IMMACOLATA CAPASSO;FRANCESCO SCOGNAMIGLIO;LILIANA LAPENTA;GIULIANA SALVATORE;EMIDDIO BARLETTA","8;6;6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","ORLANDO CATALANO;GIOVANNI PAGANO;FABIO SANDOMENICO;ALFREDO FUSCO;GENNARO CHIAPPETTA;SECONDO LASTORIA;MASSIMO SANTORO;GERARDO BOTTI;GIUSEPPE VIGLIETTO;GIANLUCA GAÏDANO;FRANCO IONNA;ANTONIO D′ANTONIO;CIRO MANZO;FRANCESCO IZZO;G. FRASCI;ROSA MARINA MELILLO;LUIGI BUONAGURO;IMMACOLATA SALATIELLO;MARIA LINA TORNESELLO;FRANCO M. BUONAGURO","1.28;1.23;0.98;0.74;0.66;0.62;0.56;0.4;0.35;0.33;0.32;0.31;0.31;0.3;0.29;0.28;0.28;0.28;0.28;0.28","PAOLO VALLONE;FRANCESCO IZZO;JEAN‐NICOLAS VAUTHEY;LEE M. ELLIS;STEVEN A. CURLEY;G. FRASCI;GIUSEPPE COMELLA;PASQUALE COMELLA;ANDREA BIANCO;ANNUNZIATO IANNELLI;B. MASSIDDA;DOMENICO BILANCIA;FRANCOVITO PIANTEDOSI;G.P. NICOLELLA;GIUSEPPE DE CATALDIS;M BELLI;MARIO DE LENA;NICOLA PANZA;VITO LORUSSO;ALFREDO FUSCO","776;748;742;742;742;522;478;478;457;457;457;457;457;457;457;457;457;457;457;408","PAOLO VALLONE;FRANCESCO IZZO;G. FRASCI;GENNARO CHIAPPETTA;GERARDO BOTTI;GIUSEPPE D’AIUTO;GIUSEPPE VIGLIETTO;PAOLA BRUNI;ALFREDO FUSCO;MARIA VINCENZA CARRIERO;SIMONA LOSITO;GUSTAVO BALDASSARRE;F SFERRATORE;GIOVANNI PAGANO;GIULIANA SALVATORE;LORENZO CHIARIOTTI;MASSIMO SANTORO;ROSA MARINA MELILLO;SUSANNA DOLCI;CIRO MANZO","776;748;467;317;210;190;186;172;162;135;106;104;94;94;94;94;94;94;94;92","GENNARO CHIAPPETTA;FABIO SANDOMENICO;GIOVANNI PAGANO;GIUSEPPE VIGLIETTO;GERARDO BOTTI;GIUSEPPE D’AIUTO;ORLANDO CATALANO;CIRO MANZO;PAOLA BRUNI;ADRIANO GRAVINA;ALFREDO FUSCO;ANNALISA LAMBERTI;DANIELA CALIFANO;DE LUTIO DI CASTELGUIDONE E;ELKE BETH‐GIRALDO;FRANCESCA PENTIMALLI;FRANCESCO FIORE;FRANCESCO IZZO;FRANCO IONNA;FRANCO M. BUONAGURO","5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;GEOLOGY;MATERIALS SCIENCE","53;31;7;6;3;2;1;1","INTERNAL MEDICINE;CANCER RESEARCH;SURGERY;GENETICS;RADIOLOGY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;CELL BIOLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;VIROLOGY;DEMOGRAPHY;GYNECOLOGY;PSYCHIATRY;UROLOGY","41;17;17;16;16;14;13;12;12;10;10;9;9;5;4;4;4;3;3;3;3","CANCER;CHEMOTHERAPY;GENE;TOXICITY;LUNG CANCER;CELL;CELL CULTURE;HEPATOCELLULAR CARCINOMA;IN VITRO;CARCINOMA;IMMUNE SYSTEM;POPULATION;RECEPTOR;THYROID;IMMUNOHISTOCHEMISTRY;OXIDATIVE STRESS;STAGE (STRATIGRAPHY);VIRUS;ABLATION;ANEMIA;CASE-CONTROL STUDY;COMPUTED TOMOGRAPHY;DISEASE;HORMONE;INTERVENTIONAL RADIOLOGY;MELANOMA;NEUROLOGY;REACTIVE OXYGEN SPECIES;SIGNAL TRANSDUCTION","18;14;12;8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CISPLATIN;GEMCITABINE;NEUTROPENIA;BREAST CANCER;THYROID CARCINOMA;CELL CYCLE;COLORECTAL CANCER;CYTOTOXIC T CELL;DNA REPAIR;MUTATION;NEURORADIOLOGY;OVARIAN CANCER;PACLITAXEL;PHASES OF CLINICAL RESEARCH;CD8;CELLULAR DIFFERENTIATION;CERVICAL CANCER;CYTOSKELETON;DOCETAXEL;GENE EXPRESSION;GLUTATHIONE;GRANULOCYTE COLONY-STIMULATING FACTOR;HEPATITIS C VIRUS;LEUKOPENIA;LIVER CANCER;NEUROTROPHIC FACTORS;PERFORMANCE STATUS;PROTEIN KINASE A;RECEPTOR TYROSINE KINASE;T CELL","7;7;7;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VINORELBINE;FANCONI ANEMIA;METASTATIC BREAST CANCER;CD28;CD40;CD86;FEBRILE NEUTROPENIA;GENITAL WARTS;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;ONCOGENE;SPECTRIN;ABLATION THERAPY;AMPHIREGULIN;ANTHRACYCLINE;ANTIGEN-PRESENTING CELL;AUTOPHOSPHORYLATION;BREAST CARCINOMA;BREAST DISEASE;CABERGOLINE;CARMUSTINE;CD3;CDKN2B;CTL*;CYCLIN D1;EMBRYONAL CARCINOMA;ENHANCER;EPIRUBICIN;GERMLINE MUTATION;HLA-G;INTERFERON ALFA;JURKAT CELLS;LOSS OF HETEROZYGOSITY;MAMMARY GLAND;MICROSATELLITE;MITOGEN-ACTIVATED PROTEIN KINASE 3;MOLECULAR MEDICINE;MONOCLONAL;PARATHYROIDECTOMY;PRIMER EXTENSION;PROMOTER;REED–STERNBERG CELL;RETINOIC ACID RECEPTOR;SECONDARY HYPERPARATHYROIDISM;TGF ALPHA;TRETINOIN;TUMOR SUPPRESSOR GENE;UNTRANSLATED REGION","4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;DEOXYCYTIDINE;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;LIVER NEOPLASMS;CARCINOMA, HEPATOCELLULAR;HODGKIN DISEASE;PACLITAXEL;TUMOR CELLS, CULTURED;VINBLASTINE;BREAST NEOPLASMS;TOMOGRAPHY, X-RAY COMPUTED;ANIMALS;CISPLATIN","58;32;31;29;28;25;25;24;22;18;15;14;14;14;14;14;13;13;12;12","ADVANCEMENTS IN LUNG CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MECHANOSENSITIVE ION CHANNELS IN PHYSIOLOGY AND DISEASE;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;;AQUATIC ECOTOXICOLOGY AND BIOMARKERS OF POLLUTION;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;COLORECTAL CANCER RESEARCH AND TREATMENT;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS","5;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MICROTUBULE-TARGETING AGENTS;HEPATOCELLULAR CARCINOMA;TREATMENT;TREATMENT GUIDELINES;VINORELBINE;INTERVENTIONAL RADIOLOGY;NEURORADIOLOGY;NK CELL ACTIVATION;THYROID NODULES;BREAST CANCER;CD154;CD80;CD86;CO-STIMULATION;ERYTHROCYTE;GENITAL WARTS;LEUKOPENIA;LIVER CANCER;MEDULLARY THYROID CANCER;MELANOMA","5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;PHASE II;CELL LUNG;BREAST CANCER;CASE-CONTROL STUDY;CELL LINES;COMPUTERIZED TOMOGRAPHY;HEPATOCELLULAR CARCINOMA;II STUDY;OVARIAN CANCER;SECOND-LINE TREATMENT;ADVANCED BREAST;COMPUTED TOMOGRAPHY;FANCONIS ANEMIA;GROWTH FACTORS;HODGKINS DISEASE;ITALIAN CASE-CONTROL;LEUKEMIA CELLS;NON-SMALL CELL;SPIRAL COMPUTED;TUMOR CELL;ABLATION PROCEDURES;ACETATE INCREASES;ACID INDUCES;ACTION MECHANISMS;ACTIVATED CDT;ADENOMAS PREDICTIVE;ADULT COMPUTERIZED;ADVANCED NON-SMALL;ADVANCED NON-SMALL-CELL","7;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CELL LINES;OVARIAN CANCER;GRAVES DISEASE;MEDICAL TREATMENT;PHYSICAL ACTIVITY;NF-KAPPA BREL;THYROID CARCINOMA;BREAST CANCER;CANCER PATIENTS;GEM VIN;THYROID CARCINOMAS;ADVANCED BREAST;ANAPLASTIC THYROID;CARCINOMA CELL;CELL LINE;EYE DISEASE;FA CELLS;GROWTH FACTOR;HCV INFECTED;INFECTED PATIENTS;RESPONSE RATE;SERUM CONCENTRATIONS;TGFALPHA AR;THYROID EYE;VERSUS CONTROLS;WOMEN AGED;ACTIVE SPERMATOGENESIS;ANTHRACYCLINE-BASED CHEMOTHERAPY;BREL ACTIVITY;BREL NUCLEAR","8;8;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2",5,0.07,3,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1,2.5,2,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,40,9,71,40,9,71
"IRCCS_PASCALE",2001,61,9,3.31147540983607,0.301980198019802,0.344262295081967,0.360655737704918,0.0655737704918033,0.163934426229508,0,15,14,20,8,0.25,0.23,0.33,0.13,43.23,0.946097835504205,0.360655737704918,0.819672131147541,NA,0.356859630803613,0.330246913580247,0.345238095238095,0.166666666666667,"ALFREDO FUSCO;GERARDO BOTTI;SILVIA FRANCESCHI;ANNA CRISPO;CARLO LA VECCHIA;MARIO TAMBURINI;SECONDO LASTORIA;FRANCESCO IZZO;MAURIZIO MONTELLA;CORRADO CARACÒ;GABRIELLA FABBROCINI;GENNARO CHIAPPETTA;FRANCO IONNA;GIUSEPPE VIGLIETTO;EVA NEGRI;A. DE BIASE;CIRO GALLO;DOMENICO RONGA;MONICA FEDELE;GIOVANNA DE BELLIS","5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3","SECONDO LASTORIA;FRANCESCO IZZO;SILVIA FRANCESCHI;CARLO LA VECCHIA;GERARDO BOTTI;ANNA CRISPO;MARIO TAMBURINI;MAURIZIO MONTELLA;CORRADO CARACÒ;EVA NEGRI;LUIGI MANSI;GIANFRANCO PELUSO;FRANCO IONNA;ALFREDO FUSCO;A. DE BIASE;GIOVANNI PAGANO;MARIO IACCARINO;MICHEL WARNAU;GABRIELLA FABBROCINI;RENATO TALAMINI","0.75;0.7;0.65;0.65;0.52;0.51;0.51;0.51;0.5;0.5;0.5;0.5;0.47;0.46;0.44;0.44;0.44;0.44;0.41;0.4","GERARDO BOTTI;ANNA CRISPO;MARIO TAMBURINI;SECONDO LASTORIA;FRANCESCO IZZO;MAURIZIO MONTELLA;CORRADO CARACÒ;GABRIELLA FABBROCINI;GENNARO CHIAPPETTA;FRANCO IONNA;GIUSEPPE VIGLIETTO;A. DE BIASE;CIRO GALLO;DOMENICO RONGA;GIOVANNI PAGANO;MARIO IACCARINO;MAURIZIO MONTELLA;GIUSEPPE D’AIUTO;NICOLA MOZZILLO;N MOZZILLO","5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2","SECONDO LASTORIA;FRANCESCO IZZO;GERARDO BOTTI;ANNA CRISPO;MARIO TAMBURINI;MAURIZIO MONTELLA;CORRADO CARACÒ;GIANFRANCO PELUSO;FRANCO IONNA;A. DE BIASE;GIOVANNI PAGANO;MARIO IACCARINO;GABRIELLA FABBROCINI;MAURIZIO MONTELLA;GIUSEPPE VIGLIETTO;GENNARO CHIAPPETTA;CURLEY SA;MONICA PINTO;BARNETT CC;ROSSANA IODICE","0.75;0.7;0.52;0.51;0.51;0.51;0.5;0.5;0.47;0.44;0.44;0.44;0.41;0.39;0.35;0.35;0.33;0.33;0.33;0.33","MAURIZIO MONTELLA;GERARDO BOTTI;GIUSEPPE D’AIUTO;CARLO LA VECCHIA;SILVIA FRANCESCHI;FRANCESCO IZZO;ALFREDO FUSCO;MASSIMO SANTORO;EVA NEGRI;GIUSEPPE VIGLIETTO;MONICA FEDELE;ANNA CRISPO;MARIO TAMBURINI;PAOLO DELRIO;STEVEN A. CURLEY;RENATO TALAMINI;GENNARO CHIAPPETTA;ANNA DECHIARA;MASSIMO RINALDO;PAOLO VALLONE","502;392;391;390;390;388;339;330;326;292;271;269;269;263;263;258;252;246;246;246","GIUSEPPE D’AIUTO;GERARDO BOTTI;FRANCESCO IZZO;MAURIZIO MONTELLA;GIUSEPPE VIGLIETTO;PAOLO DELRIO;GENNARO CHIAPPETTA;ANNA DECHIARA;MASSIMO RINALDO;PAOLO VALLONE;PINA CORTINO;RENATO THOMAS;FRANCESCO CAPONIGRO;CESARE GRIDELLI;ANDREA VERONESI;DAVIDE LOMBARDI;M. PIZZORUSSO;SECONDO LASTORIA;FEDERICA PERRONE;CIRO GABRIELE MAINOLFI","391;342;329;298;292;263;252;246;246;246;246;246;231;152;149;149;145;132;127;103","SECONDO LASTORIA;MAURIZIO MONTELLA;GENNARO CHIAPPETTA;CORRADO CARACÒ;FRANCESCO IZZO;FRANCO IONNA;GERARDO BOTTI;GIUSEPPE VIGLIETTO;A. DE BIASE;GIOVANNI PAGANO;GIUSEPPE D’AIUTO;NICOLA MOZZILLO;A. DE MATTEIS;ANTONIO AVALLONE;BRUNO DANIELE;CESARE GRIDELLI;CIRO GALLO;DOMENICO RONGA;FLAVIA RIVELLINI;FRANCESCO PERRONE","5;5;4;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;SOCIOLOGY;MATERIALS SCIENCE","52;27;6;4;2;2;2;2;2;1","INTERNAL MEDICINE;PATHOLOGY;GENETICS;ONCOLOGY;SURGERY;GASTROENTEROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;IMMUNOLOGY;CANCER RESEARCH;RADIOLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;OPTICS;PHARMACOLOGY;BIOTECHNOLOGY;ORGANIC CHEMISTRY","45;16;14;13;13;12;11;9;9;8;7;6;6;5;5;5;4;4;3;3","CANCER;GENE;CHEMOTHERAPY;TOXICITY;DISEASE;THYROID;CARCINOMA;IMMUNOHISTOCHEMISTRY;MELANOMA;ODDS RATIO;RECEPTOR;VIRUS;ANTIGEN;CASE-CONTROL STUDY;CONFIDENCE INTERVAL;IN VIVO;INCIDENCE (GEOMETRY);SOMATOSTATIN;BIOPSY;DNA;HEPATOCELLULAR CARCINOMA;IMMUNE SYSTEM;MULTIPLE MYELOMA;MULTIVARIATE ANALYSIS;POPULATION","29;15;9;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","BREAST CANCER;OVARIAN CANCER;COLORECTAL CANCER;GENE EXPRESSION;LIVER CANCER;NEUTROPENIA;CELL CYCLE;CISPLATIN;DNA DAMAGE;GOITER;HEPATITIS C VIRUS;OCTREOTIDE;SOMATOSTATIN RECEPTOR;CARCINOGENESIS;CELLULAR DIFFERENTIATION;CHROMATIN;EXON;FETUS;FLUOROURACIL;HEAD AND NECK CANCER;HUMAN LEUKOCYTE ANTIGEN;MESSENGER RNA;METASTASIS;MUTATION;PACLITAXEL;PHASES OF CLINICAL RESEARCH;POLYMERASE CHAIN REACTION;PROTEIN KINASE A;RADIOFREQUENCY ABLATION;RECOMBINANT DNA;REPRODUCTIVE TOXICITY;THYROID CANCER;THYROID CARCINOMA;TRANSGENE","9;6;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CARBOPLATIN;DEVELOPMENTAL TOXICITY;GENETICALLY MODIFIED MOUSE;ONCOGENE;ACROMEGALY;ADENOMATOUS POLYPOSIS COLI;ALLELE FREQUENCY;ANTHRACYCLINE;BREAST CARCINOMA;CA15-3;CIRCULATING TUMOR CELL;COLONOSCOPY;DEBULKING;DUCTAL CARCINOMA;EMBRYONAL CARCINOMA;ENDOCRINE DISEASE;EPIRUBICIN;EPITHELIAL OVARIAN CANCER;ESTROGEN RECEPTOR;FAMILIAL ADENOMATOUS POLYPOSIS;FUSION PROTEIN;GANGLIONEUROMA;GENE MUTATION;HIV VACCINE;IRINOTECAN;KAPOSI'S SARCOMA;LASER CAPTURE MICRODISSECTION;MAMMARY GLAND;METASTATIC BREAST CANCER;MOLECULAR MEDICINE;NEOPLASTIC TRANSFORMATION;NUCLEAR PROTEIN;OPEN READING FRAME;PAPILLARY THYROID CANCER;PENETRANCE;PITUITARY NEOPLASM;POLYPLOID;PROMOTER;PSEUDOMEMBRANOUS COLITIS;REVERSE TRANSCRIPTASE;SECONDARY HYPERPARATHYROIDISM;SENTINEL LYMPH NODE;SENTINEL NODE;TAXANE;THYMIDYLATE SYNTHASE;VINORELBINE;VIRUS-LIKE PARTICLE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;LIVER NEOPLASMS;NEOPLASM PROTEINS;ITALY;NEOPLASMS;OVARIAN NEOPLASMS;THYROID NEOPLASMS;ANIMALS;CARCINOMA, HEPATOCELLULAR;HIGH MOBILITY GROUP PROTEINS;TRANSCRIPTION FACTORS;INTERLEUKIN-6;MELANOMA","49;34;29;23;22;22;22;21;21;21;16;16;16;16;13;13;11;11;10;10","GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;COLORECTAL CANCER RESEARCH AND TREATMENT;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HEPATITIS C INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;REGULATION OF CHROMATIN STRUCTURE AND FUNCTION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANTIBIOTIC RESISTANCE IN AQUATIC ENVIRONMENTS AND WASTEWATER;AQUATIC ECOTOXICOLOGY AND BIOMARKERS OF POLLUTION;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DEVELOPMENT OF ANTIFOULING COATINGS FOR MARINE APPLICATIONS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFECTS OF CAFFEINE ON HUMAN HEALTH","5;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","LIVER CANCER;MELANOMA;MICROTUBULE-TARGETING AGENTS;OVARIAN CANCER;ATTENDANCE;BREAST CANCER SCREENING;CANCER;CANCER INCIDENCE;CARBOPLATIN;DEVELOPMENTAL TOXICITY;ECOTOXICITY;HEPATOCELLULAR CARCINOMA;KAPOSI'S SARCOMA;MITOMYCIN C;REPRODUCTIVE TOXICITY;SOMATOSTATIN ANALOGUES;TUMOR MODELS;ULTRASOUND;ABDOMINAL WALL DEFECTS;ACUTE PAIN","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","OVARIAN CANCER;BREAST CANCER;CASE-CONTROL STUDY;CANCER PATIENTS;ADVANCED BREAST;CELL GROWTH;EPITHELIAL OVARIAN;HEPATOCELLULAR CARCINOMA;LUNG CANCER;MOUSE MAMMARY;MULTIPLE LETTERS;PROTEIN EXPRESSION;RADIOFREQUENCY ABLATION;SEA URCHIN;SOMATOSTATIN ANALOGS;ADENOMATOSIS COLI;ADIPOCYTIC CELL;ADRENAL MASSES;ADVANCED NON-SMALL-CELL;ADVANCED SOLID;ALCOHOL INTAKE;ALLELES FREQUENCY;ANALOGS BIOLOGY;ANTI-MELANOMA MONOCLONAL;ANTICANCER ACTIVITY;ANTIDEPRESSANT ACTION;APC GENE;ASPIRATION SAMPLES;B-MICROGLOBULINE GENE;BALLOON-OCCLUSION TECHNIQUE","6;5;5;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CELL GROWTH;HMGIY PROTEIN;HMGIY PROTEINS;RET EXPRESSION;MONTHS NA;ADIPOCYTIC CELL;ADVANCED BREAST;BREAST TUMORS;CANCER PATIENTS;HMGI PROTEINS;NSEHIL- MICE;SECONDARY HPT;THYROID CELLS;THYROID DISEASE;THYROID DISORDERS;AGE RANGE;BREAST CARCINOMA;CNS INVOLVEMENT;CNS METASTASES;COAGULATIVE NECROSIS;CRITICAL ROLE;GENE EXPRESSION;GROWTH FACTOR;GROWTH RATE;HEALTH PROVIDER;HIPK INHIBITORY;HMGI GENES;HMGI-C GENE;INHIBITORY EFFECT","7;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",7,0.11,3,3.5,3,4,0,0,0,1,1,1,0,0,0,0,0,0,2,2,2,1,1,1,1,1,1,4,3,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,23,27,25,23,27
"IRCCS_PASCALE",2002,62,9.03225806451613,2.61290322580645,0.382716049382716,0.274193548387097,0.241935483870968,0.0806451612903226,0.274193548387097,3,27,14,15,6,0.44,0.23,0.24,0.1,62.53,1.13347325828419,0.370967741935484,0.854838709677419,NA,0.435838882681805,0.364285714285714,0.331428571428571,0.428571428571429,"ALFREDO FUSCO;GENNARO CHIAPPETTA;SANDRO PIGNATA;SECONDO LASTORIA;MASSIMO SANTORO;SILVIA FRANCESCHI;GIOVANNI PAGANO;CARLO LA VECCHIA;FRANCESCO PERRONE;SÜREYYA MERIÇ;FRANCESCO PAOLO D’ARMIENTO;CAMILLO PALMIERI;CIRO GALLO;LUIGINO DAL MASO;LUIGI BUONAGURO;PAOLO MAIONE;PAOLA BRUNI;DANIELA CALIFANO;ADA GIULIANO;FRANCA MARIA TUCCILLO","11;8;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","GENNARO CHIAPPETTA;GIOVANNI PAGANO;ALFREDO FUSCO;FRANCESCO CAPONIGRO;SECONDO LASTORIA;FRANCESCO IZZO;STEVEN A. CURLEY;PIETRO MUTO;SÜREYYA MERIÇ;MASSIMO SANTORO;SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGI BUONAGURO;SANDRO PIGNATA;GIUSEPPE D’AIUTO;CAMILLO PALMIERI;FRANCA MARIA TUCCILLO;SALVATORE VENUTA;PATRIZIA BONELLI;PIERFRANCESCO TASSONE","1.6;1.43;1.03;1;0.83;0.54;0.5;0.5;0.43;0.42;0.41;0.41;0.4;0.39;0.35;0.34;0.34;0.34;0.34;0.34","ALFREDO FUSCO;GENNARO CHIAPPETTA;SANDRO PIGNATA;SECONDO LASTORIA;GIOVANNI PAGANO;FRANCESCO PERRONE;LUIGI BUONAGURO;PAOLO MAIONE;PAOLA BRUNI;DANIELA CALIFANO;ADA GIULIANO;FRANCA MARIA TUCCILLO;PATRIZIA BONELLI;GIUSEPPE VIGLIETTO;ANTONIO AVALLONE;GIUSEPPE D’AIUTO;IMMACOLATA CAPASSO;NICOLA NORMANNO;MASSIMO DI MAÏO;ANTONELLA DE LUCA","11;8;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","GENNARO CHIAPPETTA;GIOVANNI PAGANO;ALFREDO FUSCO;FRANCESCO CAPONIGRO;SECONDO LASTORIA;FRANCESCO IZZO;PIETRO MUTO;LUIGI BUONAGURO;SANDRO PIGNATA;GIUSEPPE D’AIUTO;FRANCA MARIA TUCCILLO;PATRIZIA BONELLI;DANIELA BERNARDI;SERGIO PICCOLO;ANDREA CIARMIELLO;DANIELA CALIFANO;FRANCESCO PERRONE;PAOLA BRUNI;GIUSEPPE VIGLIETTO;PAOLO MAIONE","1.6;1.43;1.03;1;0.83;0.54;0.5;0.4;0.39;0.35;0.34;0.34;0.33;0.33;0.31;0.31;0.3;0.3;0.3;0.29","ALFREDO FUSCO;MASSIMO SANTORO;GENNARO CHIAPPETTA;ROSA MARINA MELILLO;PAOLA BRUNI;DANIELA CALIFANO;GIUSEPPE VIGLIETTO;MARIA LETIZIA MOTTI;ALFONSO BELLACOSA;AMELIA D’ALESSIO;FLORIANA VINCI;PHILIP N. TSICHLIS;FRANCESCO PAOLO D’ARMIENTO;GIUSEPPE DI LORENZO;A R BIANCO;FORTUNATO CIARDIELLO;GAETANO DE ROSA;GIAMPAOLO TORTORA;GIUSEPPE CATALANO;MASSIMO D’ARMIENTO","1450;1364;1301;806;777;744;732;695;691;691;691;691;471;468;458;458;458;458;458;458","GENNARO CHIAPPETTA;DANIELA CALIFANO;AMELIA D’ALESSIO;MICHELINO DE LAURENTIIS;STEFANO GREGGI;ADA GIULIANO;ANNA CRISPO;MARIA NAPOLITANO;ANTONELLA DE LUCA;NICOLA NORMANNO;MAURIZIO MONTELLA;SANDRO PIGNATA;SECONDO LASTORIA;FRANCESCO PERRONE;GIOVANNI PAGANO;ROSA TAMBARO;IDA AMENDOLA;MARIO MONACO;ANNAROSARIA DE CHIARA;LUIGI BUONAGURO","1301;744;691;458;341;267;224;215;213;213;186;186;155;121;115;109;101;101;100;78","GENNARO CHIAPPETTA;SANDRO PIGNATA;SECONDO LASTORIA;GIOVANNI PAGANO;LUIGI BUONAGURO;ADA GIULIANO;DANIELA CALIFANO;FRANCA MARIA TUCCILLO;FRANCESCO PERRONE;GIUSEPPE D’AIUTO;PATRIZIA BONELLI;MAURIZIO MONTELLA;A. DE BIASE;ANDREA CIARMIELLO;ANNA CRISPO;ANNA CURCI;ANTONELLA DE LUCA;ANTONIO AVALLONE;FRANCESCO IZZO;G. COMELLA","8;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;ENVIRONMENTAL SCIENCE;MATHEMATICS;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","52;33;12;4;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;GENETICS;ONCOLOGY;PATHOLOGY;SURGERY;BIOCHEMISTRY;ENDOCRINOLOGY;CELL BIOLOGY;PALEONTOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GYNECOLOGY;ORGANIC CHEMISTRY;PSYCHIATRY;VIROLOGY;CARDIOLOGY;ECOLOGY;IMMUNOLOGY;OPTICS;PHARMACOLOGY","42;18;14;14;14;10;9;8;6;6;6;4;4;4;4;4;4;3;3;3;3;3","CANCER;CHEMOTHERAPY;THYROID;GENE;CARCINOMA;IMMUNOHISTOCHEMISTRY;TOXICITY;CELL;CONFIDENCE INTERVAL;RECEPTOR;SIGNAL TRANSDUCTION;CELL GROWTH;ENZYME;ODDS RATIO;PATHOLOGICAL;RADIATION THERAPY;STAGE (STRATIGRAPHY);ANTIGEN;CASE-CONTROL STUDY;CELL CULTURE;DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);LOGISTIC REGRESSION","32;10;10;8;7;7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","CELL CYCLE;BREAST CANCER;COLORECTAL CANCER;THYROID CARCINOMA;OVARIAN CANCER;CARCINOGENESIS;CISPLATIN;TYROSINE KINASE;CERVICAL CANCER;CLEAR CELL;CYCLOPHOSPHAMIDE;CYTOPATHOLOGY;FLUOROURACIL;NEUROTROPHIC FACTORS;ONCOCYTOMA;PHASES OF CLINICAL RESEARCH;ADENOCARCINOMA;ADJUVANT THERAPY;ALLELE;ALZHEIMER'S DISEASE;ANTIMETABOLITE;AUTOCRINE SIGNALLING;BETHESDA SYSTEM;CANCER CELL;CARCINOMA IN SITU;CD8;CELL NUCLEUS;CEREBRAL PERFUSION PRESSURE;CERVIX;CHEMORADIOTHERAPY;CLINICAL ENDPOINT;COLORECTAL SURGERY;COMPLEMENTARY DNA;CONVENTIONAL PCI;CYTOTOXIC T CELL;DNA DAMAGE;DOCETAXEL;DOXORUBICIN;EMBRYOGENESIS;ENDOCRINE SURGERY;EPIDERMAL GROWTH FACTOR;EPIDERMAL GROWTH FACTOR RECEPTOR;ETOPOSIDE;FETUS;FINE-NEEDLE ASPIRATION;GEMCITABINE;GENE EXPRESSION;GENE REARRANGEMENT;GENOTYPE;GERMLINE;GLUTATHIONE;GLYCEMIC;HAZARD RATIO;HETEROLOGOUS;HISTIOCYTOSIS;HUMORAL IMMUNITY;HYPERVARIABLE REGION;HYPOCALCAEMIA;IMMUNIZATION;IMMUNOGENICITY;IMMUNOPHENOTYPING;INSULIN RESISTANCE;LANGERHANS CELL HISTIOCYTOSIS;LEFT PULMONARY ARTERY;LIVER CANCER;LYMPHADENECTOMY;MICROBICIDE;MUTATION;NEURORADIOLOGY;OCTREOTIDE;PACLITAXEL;PARATHYROID HORMONE;PHYLOGENETIC TREE;PI3K/AKT/MTOR PATHWAY;POLYMERASE;POLYMERASE CHAIN REACTION;PRENYLATION;PROGRAMMED CELL DEATH;PROSTATE;PROSTATE CANCER;PROTEIN KINASE B;PROTEIN TYROSINE PHOSPHATASE;PULMONARY INFARCTION;QUARTILE;RADICAL SURGERY;RADIOFREQUENCY ABLATION;REACTIVE INTERMEDIATE;RECEPTOR TYROSINE KINASE;RESTENOSIS;RIGHT PULMONARY ARTERY;SALVAGE THERAPY;SEDIMENTATION;SIALOGLYCOPROTEIN;SIGNAL TRANSDUCING ADAPTOR PROTEIN;SLEEP DISORDER;SOMATOSTATIN RECEPTOR;THYROID CANCER;THYROID NODULES;THYROIDECTOMY;TOPOISOMERASE;TRANSCRIPTION FACTOR;TRANSFORMING GROWTH FACTOR BETA;TUMOR PROGRESSION;TYROSINE-KINASE INHIBITOR;UNIVARIATE ANALYSIS;VACCINE TRIAL;VIRAL LOAD;WAIST;XENOBIOTIC","9;8;7;7;5;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ONCOGENE;OXALIPLATIN;CARBOPLATIN;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;MOLECULAR MEDICINE;PAPILLARY CARCINOMA;PAPILLARY THYROID CANCER;AMPHIREGULIN;AMYLOID PRECURSOR PROTEIN;ANDROGEN RECEPTOR;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;CD3;CDNA LIBRARY;CLADE;COLOANAL ANASTOMOSIS;CORONARY RESTENOSIS;CYCLIN-DEPENDENT KINASE;EPIRUBICIN;EPITHELIAL OVARIAN CANCER;ESTROGEN RECEPTOR;FARNESYLTRANSFERASE;FOLINIC ACID;GASTRULATION;GERMLINE MUTATION;GLYCEMIC INDEX;HIV VACCINE;HORMONE RECEPTOR;HYPERINSULINEMIA;IRINOTECAN;LASER CAPTURE MICRODISSECTION;MALE BREAST CANCER;MAMMOGRAPHY;METASTATIC BREAST CANCER;MICROSATELLITE;MOLECULAR EPIDEMIOLOGY;NEOPLASTIC TRANSFORMATION;NUCLEAR EXPORT SIGNAL;NUCLEAR PROTEIN;OVARIAN CARCINOMA;PARATHYROIDECTOMY;POLY ADP RIBOSE POLYMERASE;PROBAND;PROPHYLACTIC CRANIAL IRRADIATION;PROSTATECTOMY;RADICAL HYSTERECTOMY;SECONDARY HYPERPARATHYROIDISM;SENTINEL NODE;SEXUAL TRANSMISSION;SMAD2 PROTEIN;TAMOXIFEN;TAXANE;TOTAL THYROIDECTOMY","6;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;THYROID NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;CARCINOMA, PAPILLARY;OVARIAN NEOPLASMS;PROTO-ONCOGENE PROTEINS;RECEPTOR PROTEIN-TYROSINE KINASES;HIV INFECTIONS;ITALY;ONCOGENE PROTEINS, FUSION;ADENOCARCINOMA;ANIMALS;ANTINEOPLASTIC AGENTS;ENZYME INHIBITORS","52;33;25;25;24;21;21;19;17;17;17;17;13;10;10;10;9;9;9;9","MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ASSESSMENT OF SURFACE WATER QUALITY;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIFFUSION MAGNETIC RESONANCE IMAGING;ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME","6;4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER THERAPY;MEDULLARY THYROID CANCER;THYROID NODULES;CHEMORADIOTHERAPY;HIV;BREAST CANCER;CANCER RISK;CARBOPLATIN;CYTOPATHOLOGY;HEPATOCELLULAR CARCINOMA;HIV TRANSMISSION;ONCOGENE;PROTO-ONCOGENE PROTEINS C-RET;RALTITREXED;THYROID SURGERY;TUMOR SUPPRESSION;ADJUVANT THERAPY;ALUMINUM TOXICITY;ANTIBODIES;ANTIBODY ENGINEERING","6;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","BREAST CANCER;OVARIAN CANCER;RETPTC ONCOGENE;THYROID CARCINOMA;THYROID TUMORS;BAUXITE MANUFACTURING;CANCER PATIENTS;CELL ADENOMAS;CERVICAL CANCER;FREQUENTLY ACTIVATED;GROWTH FACTOR;HURTHLE CELL;HYPERPLASTIC LESIONS;KINASE INHIBITOR;LOCALLY ADVANCED;LUNG CANCER;ONCOCYTIC HYPERPLASTIC;ONCOCYTIC THYROID;PAPILLARY THYROID;SEA URCHIN;TUMORS HURTHLE;URCHIN EMBRYOS;ACID TRIPLET;ACTIVATES NODAL-;ADDED FATS;ADVANCED BREAST;ADVANCED HUMAN;ADVANCED RECTAL;ADVANCED REFRACTORY;ADVANCED SQUAMOUS","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;PAPILLARY CARCINOMA;BIOL CHEM;CHEM -ABSTRACT;CELL CYCLE;PAPILLARY THYROID;PUBMED GOOGLE;THYROID NODULES;TS GENE;DE CANDIA;THYROID NODULE;GENE PROMOTER;WELL-DEVELOPED PTC-NC;CYCLE PROGRESSION;RETTK IMMUNOREACTIVITY;DEVELOPED PTC-NC;THYMIDYLATE SYNTHASE;THYROID CARCINOMA;CELL HISTIOCYTOSIS;GENE EXPRESSION;LANGERHANS CELL;PTC-NC INVOLVING;RET ACTIVATION;RET IMMUNOREACTIVITY;TRANSCRIPTION FACTOR;CARCINOMA FEATURES;FE OVEREXPRESSION;POORLY DEVELOPED;TYROSINE KINASE","51;32;27;22;22;20;20;20;20;18;15;13;11;11;10;10;9;9;9;8;8;8;8;8;8;8;7;7;7;7",10,0.16,3,9.33,8,10,0,0,0,0,0,0,0,0,0,0,0,0,7,6,8,0,0,0,0,0,0,9.33,8,10,0,0,0,1,1,1,0,0,0,0,0,0,1.67,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0.67,0,2,0.33,0,1,99,56,155,100,57,157
"IRCCS_PASCALE",2003,84,9.63095238095238,3.1547619047619,0.316981132075472,0.30952380952381,0.30952380952381,0.0476190476190476,0.202380952380952,1,24,12,36,7,0.29,0.14,0.43,0.08,37.57,0.709860533953727,0.261904761904762,0.738095238095238,NA,0.399519195037797,0.287365177195686,0.303191489361702,0.125,"FRANCESCO IZZO;GERARDO BOTTI;GAETANO APICE;PAOLO DELRIO;NICOLA NORMANNO;ALFREDO FUSCO;EGIDIO CELENTANO;CARLOTTA SACERDOTE;­ROSARIO ­TUMINO;GENNARO CHIAPPETTA;RAFFAÉLE PALAIA;DOMENICO PALLI;ROCCO GALASSO;NICOLA MOZZILLO;VALERIA PALA;SALVATORE PANICO;GRAZIELLA FRASCA;FRANCO BERRINO;ANNA CRISPO;SABINA SIERI","8;7;7;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4","FRANCESCO IZZO;HEATHER M. BOND;GAETANO APICE;ANNAROSARIA DE CHIARA;ANNA CRISPO;NICOLA MOZZILLO;PAOLO DELRIO;VITO NINFO;MAURIZIO MONTELLA;GERARDO BOTTI;RAFFAÉLE PALAIA;ALFREDO FUSCO;UGO MARONE;ANTONINO DE PAOLI;ANGELA BUONADONNA;S. FRUSTACI;GENNARO CHIAPPETTA;FRANCESCA PENTIMALLI;G. ROMANO;CARLO RICCARDO ROSSI","1.1;1.08;1.04;0.75;0.75;0.68;0.65;0.64;0.62;0.6;0.59;0.54;0.51;0.5;0.5;0.5;0.47;0.46;0.44;0.43","FRANCESCO IZZO;GERARDO BOTTI;GAETANO APICE;PAOLO DELRIO;NICOLA NORMANNO;EGIDIO CELENTANO;GENNARO CHIAPPETTA;RAFFAÉLE PALAIA;NICOLA MOZZILLO;ANNA CRISPO;ALESSANDRO OTTAIANO;FRANCESCA PENTIMALLI;F. RUFFOLO;ANNAROSARIA DE CHIARA;STEFANO GREGGI;ANTONELLA DE LUCA;ALFREDO BUDILLON;VITO NINFO;A. CHIARA;BRUNO DANIELE","8;7;7;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3","FRANCESCO IZZO;HEATHER M. BOND;GAETANO APICE;ANNAROSARIA DE CHIARA;ANNA CRISPO;NICOLA MOZZILLO;PAOLO DELRIO;VITO NINFO;MAURIZIO MONTELLA;GERARDO BOTTI;RAFFAÉLE PALAIA;UGO MARONE;S. FRUSTACI;GENNARO CHIAPPETTA;FRANCESCA PENTIMALLI;G. ROMANO;CARLO RICCARDO ROSSI;MONICA CANTILE;GIUSEPPE D’AIUTO;NICOLA NORMANNO","1.1;1.08;1.04;0.75;0.75;0.68;0.65;0.64;0.62;0.6;0.59;0.51;0.5;0.47;0.46;0.44;0.43;0.42;0.4;0.39","CARLOTTA SACERDOTE;DOMENICO PALLI;EGIDIO CELENTANO;­ROSARIO ­TUMINO;FRANCO BERRINO;LAURA FIORINI;ROCCO GALASSO;GRAZIELLA FRASCA;SABINA SIERI;VALERIA PALA;SIMONETTA SALVINI;VITTORIO KROGH;NICOLA NORMANNO;FRANCESCO IZZO;STEVEN A. CURLEY;MANUELA BELLEGOTTI;CATERINA BIANCO;DAVID S. SALOMON;MICHELE SANICOLA;SALVATORE PANICO","520;520;520;520;509;509;509;491;491;491;480;480;445;390;347;345;323;323;323;310","EGIDIO CELENTANO;NICOLA NORMANNO;FRANCESCO IZZO;GENNARO CHIAPPETTA;ANTONELLA DE LUCA;ALFREDO BUDILLON;ELENA DI GENNARO;MARCELLA BARBARINO;ANTONIO AVALLONE;GIUSEPPE D’AIUTO;FRANCESCO CAPONIGRO;FRANCESCA BRUZZESE;PASQUALE COMELLA;MARIA VITTORIA BARONE;SANDRO PIGNATA;MAURIZIO MONTELLA;FRANCESCA PENTIMALLI;HEATHER M. BOND;ANDREA CIARMIELLO;F. LEDDA","520;445;390;301;224;202;192;169;161;158;133;132;132;130;118;110;95;91;87;87","FRANCESCO IZZO;GERARDO BOTTI;GAETANO APICE;EGIDIO CELENTANO;GENNARO CHIAPPETTA;NICOLA MOZZILLO;PAOLO DELRIO;NICOLA NORMANNO;MAURIZIO MONTELLA;ANNA CRISPO;ANNAROSARIA DE CHIARA;RAFFAÉLE PALAIA;ALFREDO BUDILLON;A. CHIARA;ANTONELLA DE LUCA;ANTONIO AVALLONE;FRANCESCA PENTIMALLI;MARIA GRAZIA CHIOFALO;UGO MARONE;ALESSANDRO OTTAIANO","8;7;7;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;ENGINEERING;MATHEMATICS;ART;COMPUTER SCIENCE;MATERIALS SCIENCE;GEOGRAPHY;POLITICAL SCIENCE","70;32;5;4;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CANCER RESEARCH;GENETICS;BIOCHEMISTRY;RADIOLOGY;ONCOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;GENERAL SURGERY;IMMUNOLOGY;MOLECULAR BIOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;ANATOMY;DEMOGRAPHY;PALEONTOLOGY;PHARMACOLOGY","52;27;21;19;18;14;14;13;12;8;7;7;7;6;5;5;4;4;4;4","CANCER;CHEMOTHERAPY;GENE;SIGNAL TRANSDUCTION;BIOPSY;CARCINOMA;RADIATION THERAPY;RECEPTOR;CELL CULTURE;CELL GROWTH;CONFIDENCE INTERVAL;IMMUNOHISTOCHEMISTRY;KINASE;NEUROLOGY;ODDS RATIO;POPULATION;RESECTION;STAGE (STRATIGRAPHY);THYROID;APOPTOSIS;CASE-CONTROL STUDY;INCIDENCE (GEOMETRY);MALIGNANCY;MELANOMA;RECTUM;REGIMEN;SOFT TISSUE","40;13;13;8;7;6;6;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","BREAST CANCER;CISPLATIN;COLORECTAL CANCER;OVARIAN CANCER;PROSTATE CANCER;PROTEIN KINASE B;TYROSINE KINASE;ADENOCARCINOMA;CANCER CELL;CARCINOGENESIS;CHROMOSOMAL TRANSLOCATION;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;MUTATION;NEUTROPENIA;PROSTATE;PROTEIN KINASE A;PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC;THYROID CANCER;THYROID CARCINOMA;TRANSCRIPTION FACTOR","8;6;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAKPOINT;OVARIAN CARCINOMA;ANDROGEN RECEPTOR;CARBOPLATIN;EPIRUBICIN;FAMILIAL ADENOMATOUS POLYPOSIS;GERMLINE MUTATION;HMGA2;IFOSFAMIDE;PARATHYROIDECTOMY;VINORELBINE;ADENOMATOUS POLYPOSIS COLI;ANTIRETROVIRAL THERAPY;AROMATASE;CASPASE;CELL CYCLE CHECKPOINT;CERVICAL LYMPH NODES;COMPARATIVE GENOMIC HYBRIDIZATION;CROSSOVER STUDY;CYCLIN D1;CYCLIN-DEPENDENT KINASE;CYCLIN-DEPENDENT KINASE 2;DNA MISMATCH REPAIR;ESTROGEN RECEPTOR;EXTERNAL ANAL SPHINCTER;EXTERNAL BEAM RADIOTHERAPY;FAMILY PLANNING;FARNESYLTRANSFERASE;FLOXURIDINE;FLUORESCENCE IN SITU HYBRIDIZATION;GENOTYPING;HEMATOPOIETIC CELL;HEPATIC ARTERIAL INFUSION;HOMEOBOX;HUMAN BREAST;INTERSTITIAL PREGNANCY;LENTIVIRUS;LNCAP;LOSS OF HETEROZYGOSITY;MAP KINASE KINASE KINASE;METHACRYLATE;MICROSATELLITE;MISSENSE MUTATION;MITOGEN-ACTIVATED PROTEIN KINASE KINASE;MULTICENTER TRIAL;MULTINODULAR GOITER;NEOADJUVANT THERAPY;NEUROENDOCRINE DIFFERENTIATION;NON-HISTONE PROTEIN;NUCLEAR PROTEIN;OVARIAN TUMOR;PAPILLARY THYROID CANCER;PARATHYROID NEOPLASM;PENILE CARCINOMA;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;POLIO VACCINATION;PROSTATE-SPECIFIC ANTIGEN;RECTAL EXAMINATION;REVERSE TRANSCRIPTASE;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;RUBELLA;SENTINEL LYMPH NODE;SENTINEL NODE;SH3 DOMAIN;SIDA;SOMATOSTATIN RECEPTOR 2;TAMOXIFEN;TELOMERASE REVERSE TRANSCRIPTASE;TISSUE FACTOR PATHWAY INHIBITOR;TOTAL MESORECTAL EXCISION;TUMOR SUPPRESSOR GENE;VINCRISTINE;ZINC FINGER","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;STOMACH NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;BREAST NEOPLASMS;NEOPLASMS;OVARIAN NEOPLASMS;PROSTATIC NEOPLASMS;THYROID NEOPLASMS;SARCOMA;SOFT TISSUE NEOPLASMS;TREATMENT OUTCOME;AGED, 80 AND OVER;CARCINOMA;LIVER NEOPLASMS","75;46;40;37;30;27;26;24;23;21;15;14;14;14;13;13;13;12;12;12","ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;GASTRIC CANCER RESEARCH AND TREATMENT;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BONE TISSUE ENGINEERING AND BIOMATERIALS;CANCER OF UNKNOWN PRIMARY SITE;CARDIOTOXICITY OF CANCER TREATMENTS;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CLINICAL AND MOLECULAR CHARACTERISTICS OF GLOMUS TUMORS;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS","5;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","GASTRIC CANCER;HEALTHY EATING INDEX;METASTATIC GASTRIC CANCER;BREAKPOINT;BREAST CANCER;REGIMEN;SOFT TISSUE SARCOMA;ADJUVANT THERAPY;CANCER;CANCER GENOMICS;CANCER TREATMENT;CARBOPLATIN;CELL GROWTH;CHEMORADIOTHERAPY;DRUG DEVELOPMENT;EPIRUBICIN;GROWTH INHIBITION;HMGA2;INTERVENTIONAL RADIOLOGY;MANDIBULAR RECONSTRUCTION","5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER CELLS;GASTRIC CANCER;SOFT TISSUE;ADVANCED GASTRIC;ANTIBODY BLOCKADE;CELL GROWTH;CFC DOMAIN;CLINICAL EXPERIENCE;CRIPTO CFC;DOMAIN SUPPRESSES;EPIDERMAL GROWTH;EXPRESSION LEVEL;FACTOR RECEPTOR;FIRST-LINE CHEMOTHERAPY;GROWTH FACTOR;ITALIAN EPIC;KINASE INHIBITOR;LOCALLY ADVANCED;LYMPH NODE;NEOADJUVANT CHEMOTHERAPY;OVARIAN CANCER;PATHOLOGIC QUIZ;PROSTATE CANCER;RADIOFREQUENCY ABLATION;RANDOMIZED TRIAL;SOUTHERN ITALY;SUPPRESSES TUMOR;TISSUE SARCOMAS;TUMOR CELL","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;HMGA PROTEIN;CELL LINES;HMGA PROTEINS;TRANSCRIPTIONAL ACTIVITY;CFC DOMAIN;EXPRESSION LEVEL;HMGA GENE;PANCREATIC TISSUE;RESECTION COMBINED;TGF-Β LIGAND;TUMOR CELL;TUMOR SUPPRESSOR;CANCER CELLS;CELL GROWTH;CRC FAMILIES;HMGA EXPRESSION;IFNΑ-INDUCED APOPTOSIS;NON-NEOPLASTIC PANCREATIC;PROTEIN EXPRESSION;SIGNALING PATHWAYS;SUPPRESSOR GENE;TUMORS INCLUDING;ACTIVIN BINDUCED;ACTIVIN SIGNALING;ADENOMATOUS POLYPOSIS;ADULT TISSUES;AG INHIBITED;ANTAGONIZING ACTIVIN;ANTIBODY AG","11;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2",15,0.18,4,35.5,2,132,5,5,5,3.5,1,6,1,1,1,20,20,20,3,3,3,0,0,0,1,1,1,37.75,2,141,1,1,1,1,1,1,92,92,92,0,0,0,7,7,7,2,2,2,5,5,5,63,63,63,22,22,22,0,0,0,0,0,0,43.75,28,55,43.75,28,55
"IRCCS_PASCALE",2004,71,10.4647887323944,2.38028169014085,0.420118343195266,0.211267605633803,0.197183098591549,0.028169014084507,0.28169014084507,1,33,18,11,6,0.46,0.25,0.15,0.08,44.52,0.946178707038624,0.47887323943662,0.901408450704225,NA,0.471644943842329,0.267399267399267,0.364285714285714,0,"SILVIA FRANCESCHI;EVA NEGRI;CARLO LA VECCHIA;RENATO TALAMINI;LUIGI BUONAGURO;ALFREDO FUSCO;LUIGINO DAL MASO;MAURIZIO MONTELLA;CLAUDIO ARRA;CRISTINA BOSETTI;NICOLA NORMANNO;GERARDO BOTTI;GENNARO CHIAPPETTA;FRANCESCA PENTIMALLI;FRANCESCO IZZO;MAURIZIO MONTELLA;MASSIMO DI MAÏO;CIRO GALLO;GAETANO DE ROSA;PAOLO A. ASCIERTO","10;10;9;9;8;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3","LUIGI BUONAGURO;EVA NEGRI;MARCO MONTELLA;SILVIA FRANCESCHI;RENATO TALAMINI;CARLO LA VECCHIA;ITALIAN HPV WORKING GROUP;MAURIZIO MONTELLA;ALFREDO FUSCO;CIRO GALLO;CRISTINA BOSETTI;LUIGINO DAL MASO;FRANCESCO PERRONE;MAURIZIO MONTELLA;FRANCESCO IZZO;CLAUDIO ARRA;NICOLA NORMANNO;ANNA CRISPO;PAOLO VALLONE;FRANCESCA PENTIMALLI","1.7;1.12;1.09;1.08;1.02;1.02;1;0.69;0.64;0.62;0.62;0.6;0.55;0.5;0.49;0.47;0.43;0.38;0.36;0.35","LUIGI BUONAGURO;MAURIZIO MONTELLA;CLAUDIO ARRA;NICOLA NORMANNO;GERARDO BOTTI;GENNARO CHIAPPETTA;FRANCESCA PENTIMALLI;FRANCESCO IZZO;MAURIZIO MONTELLA;MASSIMO DI MAÏO;CIRO GALLO;PAOLO A. ASCIERTO;ALFREDO BUDILLON;ANNA CRISPO;MARIO MONACO;PAOLO VALLONE;PAOLO MARRA;ANTONELLA DE LUCA;ROSA PASQUINELLI;FEDERICA PERRONE","8;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2","LUIGI BUONAGURO;MARCO MONTELLA;ITALIAN HPV WORKING GROUP;MAURIZIO MONTELLA;CIRO GALLO;FRANCESCO PERRONE;MAURIZIO MONTELLA;FRANCESCO IZZO;CLAUDIO ARRA;NICOLA NORMANNO;ANNA CRISPO;PAOLO VALLONE;FRANCESCA PENTIMALLI;GENNARO CHIAPPETTA;GERARDO BOTTI;DANIELA CALIFANO;PAOLO MARRA;MASSIMO DI MAÏO;GIANFRANCO PELUSO;FRANCESCO FIORE","1.7;1.09;1;0.69;0.62;0.55;0.5;0.49;0.47;0.43;0.38;0.36;0.35;0.34;0.32;0.29;0.29;0.27;0.25;0.25","SILVIA FRANCESCHI;EVA NEGRI;RENATO TALAMINI;MAURIZIO MONTELLA;CARLO LA VECCHIA;LUIGINO DAL MASO;CLAUDIO ARRA;FRANCESCO IZZO;FRANCESCO FIORE;PAOLO VALLONE;VINCENZO DE ROSA;COURTNEY L. SCAIFE;EDDIE K. ABDALLA;JEAN‐NICOLAS VAUTHEY;LEE M. ELLIS;PAOLO MARRA;STEVEN A. CURLEY;BRUNO DANIELE;CHAN RAUT;EVELYNE M. LOYER","697;666;627;621;554;418;403;381;373;373;370;366;366;366;366;366;366;358;358;358","MAURIZIO MONTELLA;FRANCESCO IZZO;CLAUDIO ARRA;FRANCESCO FIORE;PAOLO MARRA;BRUNO DANIELE;PAOLO VALLONE;SANDRO PIGNATA;VINCENZO DE ROSA;ALFREDO BUDILLON;ANDREA AFFUSO;GENNARO CHIAPPETTA;MARIO MONACO;SIMONA LOSITO;NICOLA NORMANNO;ANNA CRISPO;GERARDO BOTTI;ANTONIO PINTO;MASSIMO DI MAÏO;LUIGI BUONAGURO","621;381;375;373;366;358;358;358;358;251;237;207;184;174;170;169;158;155;148;128","MAURIZIO MONTELLA;LUIGI BUONAGURO;CLAUDIO ARRA;FRANCESCO IZZO;GERARDO BOTTI;NICOLA NORMANNO;MASSIMO DI MAÏO;PAOLO A. ASCIERTO;ALFREDO BUDILLON;ANNA CRISPO;GENNARO CHIAPPETTA;MARIO MONACO;PAOLO MARRA;ANDREA AFFUSO;ANTONIO GALLO;ANTONIO PINTO;D CIRILLO;DANIELA CALIFANO;ELENA NICOLA;EMILIA VUTTARIELLO","10;8;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;SOCIOLOGY;ECONOMICS;PHYSICS;ENVIRONMENTAL SCIENCE","56;39;7;4;4;4;3;3;2;2;1","INTERNAL MEDICINE;GENETICS;CANCER RESEARCH;PATHOLOGY;BIOCHEMISTRY;CELL BIOLOGY;IMMUNOLOGY;ONCOLOGY;SURGERY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;RADIOLOGY;VIROLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;LAW;ELECTRICAL ENGINEERING;FAMILY MEDICINE;BOTANY;CARDIOLOGY;DEMOGRAPHY;ECOLOGY;ECONOMIC GROWTH;ENGINEERING ETHICS;FOOD SCIENCE;GENERAL SURGERY;GERONTOLOGY;MATHEMATICAL ANALYSIS;OPERATING SYSTEM;OPTICS;ORGANIC CHEMISTRY;PHARMACOLOGY;PHYSIOLOGY","40;19;18;16;13;10;10;10;10;9;9;8;8;7;6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER;GENE;IMMUNOHISTOCHEMISTRY;CONFIDENCE INTERVAL;ODDS RATIO;BODY MASS INDEX;CASE-CONTROL STUDY;LOGISTIC REGRESSION;POPULATION;RECEPTOR;SIGNAL TRANSDUCTION;HUMAN IMMUNODEFICIENCY VIRUS (HIV);THYROID;VIRUS;ABLATION;CARCINOMA;CLINICAL TRIAL;CONFOUNDING;APOPTOSIS;CELL;CHEMOTHERAPY;COMPUTED TOMOGRAPHY;HUMAN PAPILLOMAVIRUS;HYPERPLASIA;IN VITRO;KINASE;LYMPHOMA;MELANOMA;PHOSPHORYLATION;RISK FACTOR;TRANSMISSION (TELECOMMUNICATIONS)","28;15;9;8;8;6;6;6;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","PROSTATE CANCER;PROSTATE;BREAST CANCER;CELL CYCLE;MUTATION;COLORECTAL CANCER;HEPATITIS C VIRUS;RADIOFREQUENCY ABLATION;ALLELE;CERVICAL CANCER;PROTEIN KINASE B;TRANSCRIPTION FACTOR;BLADDER CANCER;CELLULAR DIFFERENTIATION;CISPLATIN;EMBRYONIC STEM CELL;EPIDERMAL GROWTH FACTOR RECEPTOR;GENOTYPE;HAZARD RATIO;INFORMED CONSENT;LOCUS (GENETICS);MAPK/ERK PATHWAY;NEUROPEPTIDE;NEUTROPENIA;THYROID CARCINOMA;VIRAL LOAD","10;8;5;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GERMLINE MUTATION;ONCOGENE;MOLECULAR MEDICINE;ANTIRETROVIRAL THERAPY;BREAST CARCINOMA;DECLARATION OF HELSINKI;ESTROGEN RECEPTOR;MICROSATELLITE;VINORELBINE;ACETYL-COA CARBOXYLASE;ALLELE FREQUENCY;BOMBESIN;BOOSTER DOSE;CARNITINE O-PALMITOYLTRANSFERASE;CARNITINE PALMITOYLTRANSFERASE I;CD40;CDKN2B;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHOLECYSTOKININ B RECEPTOR;CHOLECYSTOKININ RECEPTOR;CHROMOSOME INSTABILITY;COLONOSCOPY;CYCLIN D1;DEOXYCYTIDINE;DNA MISMATCH REPAIR;DNA VACCINATION;DUCTAL CARCINOMA;DYSPLASTIC NEVUS;ELECTROPHORETIC MOBILITY SHIFT ASSAY;ENDODERM;EPITHELIAL–MESENCHYMAL TRANSITION;ERBB4;GENETIC HETEROGENEITY;GERMINAL CENTER;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;GLYCEMIC INDEX;HAPLOTYPE;HBSAG;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HELSINKI DECLARATION;INHIBITOR OF APOPTOSIS;INTRAEPITHELIAL NEOPLASIA;LENTIVIRUS;LNCAP;LY294002;MAMMARY GLAND;MAP KINASE KINASE KINASE;MARGINAL ZONE;MECHANICAL INDEX;MEDULLARY CARCINOMA;MESODERM;MITOCHONDRIAL MATRIX;MITOGEN-ACTIVATED PROTEIN KINASE 3;MOLECULAR EPIDEMIOLOGY;NFKB1;OVARIAN CARCINOMA;OXALIPLATIN;PAX8;PDGFRA;PERCUTANEOUS ETHANOL INJECTION;POINT MUTATION;PROMOTER;PROSTATE-SPECIFIC ANTIGEN;RECEPTOR ANTAGONIST;SOMATIC HYPERMUTATION;THROMBIN RECEPTOR;TRANSLOCASE;VASOACTIVE INTESTINAL PEPTIDE;VIRAL QUASISPECIES;WAIST–HIP RATIO;ZEAXANTHIN","4;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;PROSTATIC NEOPLASMS;MIDDLE AGED;AGED;FEMALE;ITALY;ADULT;PROTO-ONCOGENE PROTEINS;ANIMALS;BREAST NEOPLASMS;CASE-CONTROL STUDIES;;IMMUNOHISTOCHEMISTRY;NEOPLASM PROTEINS;THYROID GLAND;THYROID NEOPLASMS;AGED, 80 AND OVER;CELL CYCLE PROTEINS;DNA-BINDING PROTEINS","49;33;30;27;26;26;20;19;17;15;14;14;13;11;10;10;10;9;9;9","HEPATOCELLULAR CARCINOMA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;HEPATITIS C INFECTION AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;NF-?B SIGNALING IN INFLAMMATION AND CANCER;REGULATION OF CHROMATIN STRUCTURE AND FUNCTION;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHEMICAL GLYCOBIOLOGY AND THERAPEUTIC APPLICATIONS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DEVELOPMENT OF ANTIFOULING COATINGS FOR MARINE APPLICATIONS;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS","4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER RISK;RADIOFREQUENCY ABLATION;CANCER;PROSTATE CANCER;TREATMENT;BREAST CANCER;BREAST CARCINOMA;CANCER THERAPY;DECLARATION;DECLARATION OF HELSINKI;DIETARY PATTERNS;DNA MISMATCH REPAIR;ETHICAL GUIDELINES;EXPOSURE ASSESSMENT;HEPATITIS C;HIV;HUMAN PAPILLOMAVIRUS;INTRATUMOR HETEROGENEITY;LIVER CANCER;MELANOMA","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PROSTATE CANCER;CANCER RISK;CASECONTROL STUDY;LIVER TUMORS;RADIOFREQUENCY ABLATION;BENIGN PROSTATIC;BREAST CANCER;CERVICAL LESIONS;EPIDEMIC REPORT;ERICE SICILY;ETHICAL ISSUES;HIVAIDS EPIDEMIC;HUMAN PAPILLOMAVIRUSES;ITALIAN PATIENTS;ITALIAN POPULATION;LATE COMPLICATIONS;LUNG CANCER;MALIGNANT LIVER;MUTATION ANALYSIS;PROSTATIC HYPERPLASIA;SCIENTISTS ERICE;SICILY ITALY;SOUTHERN ITALY;THYROID CARCINOMA;WORLD FEDERATION;ABLATION PROCEDURES;ACID -GTIC;ACID ZOMETA;ACIDS CHOLESTEROL;ACUTE PELVIC","10;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;PROSTATE CANCER;PUBMED GOOGLE;MILAN ITALY;PAPILLARY THYROID;APOPTOTIC CELLS;FA PATIENTS;THYROID CARCINOMA;THYROID CARCINOMAS;FATTY ACIDS;HENSON PM;BIOL -CROSSREF;ENDOCRINE NEOPLASIA;INVEST -CROSSREF;MEDULLARY THYROID;MULTIPLE ENDOCRINE;NUCLEAR FACTOR;PHYSICAL ACTIVITY;RES -PUBMED;THYROID FOLLICULAR;BODY MASS;CANCER RISK;CARCANGIU ML;CLIN INVEST;ELECTRON MICROSCOPY;FOLLICULAR CELLS;NEOPLASIA TYPE;ODN DECOY;PC CL","60;59;19;15;12;12;11;11;9;9;8;8;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6",14,0.2,3,3,2,6,0,0,0,1,1,1,0,0,0,0,0,0,3,2,5,1,1,1,0,0,0,5.5,2,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.25,0,1,34,28,43,34.25,28,43
"IRCCS_PASCALE",2005,93,9.17204301075269,2.32258064516129,0.430555555555556,0.258064516129032,0.225806451612903,0.0860215053763441,0.311827956989247,1,41,17,23,8,0.44,0.18,0.25,0.09,52.02,0.982581067055234,0.462365591397849,0.806451612903226,NA,0.451227925246724,0.347402597402597,0.304054054054054,0.233333333333333,"SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;MAURIZIO MONTELLA;EVA NEGRI;MICHELE CARAGLIA;ALFREDO SIANI;ANTONIO PINTO;ORLANDO CATALANO;VALERIO RAMAZZOTTI;LUIGINO DAL MASO;LUIGI BUONAGURO;ANNA CRISPO;ALESSANDRA TAVANI;MAURIZIO MONTELLA;NICOLA NORMANNO;SILVANO GALLUS;RICCARDO AUTORINO;CRISTINA BOSETTI;MARIA LINA TORNESELLO","14;14;13;9;9;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4","ALFREDO SIANI;ORLANDO CATALANO;SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;MICHELE CARAGLIA;MAURIZIO MONTELLA;EVA NEGRI;LUIGI BUONAGURO;ANTONIO PINTO;MARIA LINA TORNESELLO;VALERIO RAMAZZOTTI;ALESSANDRA TAVANI;ANNA CRISPO;MAURIZIO MONTELLA;MARIA TAGLIAMONTE;NICOLA NORMANNO;LUIGINO DAL MASO;CRISTINA BOSETTI;ALESSANDRO OTTAIANO","1.9;1.9;1.69;1.69;1.59;1.52;1.12;1.11;0.82;0.76;0.65;0.56;0.56;0.55;0.55;0.54;0.52;0.52;0.52;0.51","MAURIZIO MONTELLA;MICHELE CARAGLIA;ALFREDO SIANI;ANTONIO PINTO;ORLANDO CATALANO;LUIGI BUONAGURO;ANNA CRISPO;MAURIZIO MONTELLA;NICOLA NORMANNO;RICCARDO AUTORINO;MARIA LINA TORNESELLO;ALESSANDRO OTTAIANO;ALBERTO ABBRUZZESE;SISTO PERDONÀ;PAOLO A. ASCIERTO;DOMENICO RONGA;ALFREDO BUDILLON;MARIA GRIMALDI;GIUSEPPE DI LORENZO;GIANFRANCO PELUSO","9;7;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","ALFREDO SIANI;ORLANDO CATALANO;MICHELE CARAGLIA;MAURIZIO MONTELLA;LUIGI BUONAGURO;ANTONIO PINTO;MARIA LINA TORNESELLO;ANNA CRISPO;MAURIZIO MONTELLA;MARIA TAGLIAMONTE;NICOLA NORMANNO;ALESSANDRO OTTAIANO;VINCENZO DE ROSA;GUGLIELMO NASTI;FRANCESCO PERRONE;FRANCO M. BUONAGURO;MAURO MATTACE RASO;FRANCESCO IZZO;RICCARDO AUTORINO;ANGELO ANTONIO MASTRO","1.9;1.9;1.52;1.12;0.82;0.76;0.65;0.55;0.55;0.54;0.52;0.51;0.5;0.5;0.5;0.49;0.45;0.44;0.43;0.39","ALISTAIR J. COCHRAN;BRENDON J. COVENTRY;CONSTANTINE P. KARAKOUSIS;DANIEL F. ROSES;DONALD L. MORTON;DOUGLAS S. REINTGEN;EDWIN C. GLASS;HARALD J. HOEKSTRA;HONG WANG;JOHN F. THOMPSON;NICOLA MOZZILLO;OMGO E. NIEWEG;RICHARD ESSNER;ROBERT M. ELASHOFF;CARLO LA VECCHIA;SILVIA FRANCESCHI;RENATO TALAMINI;MAURIZIO MONTELLA;EVA NEGRI;MICHELE CARAGLIA","694;694;694;694;694;694;694;694;694;694;694;694;694;694;651;651;607;477;423;354","BRENDON J. COVENTRY;NICOLA MOZZILLO;MAURIZIO MONTELLA;MICHELE CARAGLIA;GIUSEPPE PIROZZI;CLAUDIO ARRA;EGIDIO CELENTANO;LUIGI BUONAGURO;GENNARO CHIAPPETTA;MARCO MONTELLA;ALFREDO BUDILLON;FRANCESCO IZZO;ANGELO ANTONIO MASTRO;GAETANO ROCCO;PAOLO VALLONE;F. CREMONA;PAOLO MARRA;MARIA LINA TORNESELLO;CHIARA BOTTI;ANDREA CIARMIELLO","694;694;477;286;266;261;235;229;213;208;204;185;171;170;162;152;152;150;148;142","MAURIZIO MONTELLA;MICHELE CARAGLIA;ANNA CRISPO;LUIGI BUONAGURO;ORLANDO CATALANO;ANTONIO PINTO;ALESSANDRO OTTAIANO;ALFREDO SIANI;MARIA LINA TORNESELLO;ALFREDO BUDILLON;ANGELO ANTONIO MASTRO;FRANCO M. BUONAGURO;MARCO MONTELLA;NICOLA NORMANNO;DOMENICO RONGA;FRANCESCO IZZO;GIANPAOLO MARCACCI;MARIA GRIMALDI;MARIA TAGLIAMONTE;ALFONSO AMORE","14;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS","83;35;11;6;5;4;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;BIOCHEMISTRY;GENETICS;CANCER RESEARCH;GASTROENTEROLOGY;RADIOLOGY;IMMUNOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;VIROLOGY;UROLOGY;OBSTETRICS;PHARMACOLOGY","68;28;24;21;18;17;16;15;15;14;11;10;9;8;6;6;6;5;4;3","CANCER;ODDS RATIO;CHEMOTHERAPY;CONFIDENCE INTERVAL;GENE;CASE-CONTROL STUDY;VIRUS;STAGE (STRATIGRAPHY);IN VITRO;LOGISTIC REGRESSION;POPULATION;APOPTOSIS;ENZYME;IMMUNOHISTOCHEMISTRY;LYMPHOMA;MULTIVARIATE ANALYSIS;BODY MASS INDEX;HYPERPLASIA;IMMUNE SYSTEM;MELANOMA","42;16;15;15;14;9;9;7;6;6;6;5;5;5;5;5;4;4;4;4","BREAST CANCER;PROSTATE;COLORECTAL CANCER;CISPLATIN;PROSTATE CANCER;METASTASIS;NEUTROPENIA;OVARIAN CANCER;ADENOCARCINOMA;CARCINOGENESIS;HEPATITIS C VIRUS;PACLITAXEL;VIRAL DISEASE;CELL CYCLE;CYTOTOXIC T CELL;DOXORUBICIN;FLUOROURACIL;GEMCITABINE;GENE EXPRESSION;UNIVARIATE ANALYSIS","9;8;7;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","OXALIPLATIN;EPIRUBICIN;ANTHRACYCLINE;CTL*;GEFITINIB;HERPESVIRIDAE;IFOSFAMIDE;PROSTATECTOMY;VINORELBINE;ALTERNATIVE SPLICING;ANAPLASTIC THYROID CANCER;ANTIRETROVIRAL THERAPY;CARBOPLATIN;CARDIOLIPIN;CARNITINE O-PALMITOYLTRANSFERASE;CARNITINE PALMITOYLTRANSFERASE I;CHROMOPHOBE CELL;CLADE;CLOSTRIDIUM DIFFICILE COLITIS;COENZYME A;COLONOSCOPY;CUTANEOUS T-CELL LYMPHOMA;CYCLIN D1;CYCLIN-DEPENDENT KINASE 2;CYTOMEGALOVIRUS INFECTION;DEOXYCOFORMYCIN;DISTANT METASTASIS;DYSPLASTIC NEVUS;ENOS;FEBRILE NEUTROPENIA;FILGRASTIM;FOCUSED ASSESSMENT WITH SONOGRAPHY FOR TRAUMA;FOLINIC ACID;GENE EXPRESSION PROFILING;GENETICALLY MODIFIED MOUSE;HELICASE;HEXOKINASE;HORMONAL THERAPY;HSP70;HSP90;INTRAEPITHELIAL NEOPLASIA;IRINOTECAN;KAPOSI'S SARCOMA;LACTACYSTIN;LEUKAPHERESIS;LIPOTOXICITY;MALONYL-COA;MAMMARY GLAND;METASTATIC LESION;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MOLECULAR EPIDEMIOLOGY;MUCINOUS CARCINOMA;NEOPLASTIC TRANSFORMATION;NETRIN;NEUROENDOCRINE DIFFERENTIATION;OVARIAN CARCINOMA;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PAX8;PENTOSE PHOSPHATE PATHWAY;PENTOSTATIN;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA;POINT MUTATION;PROTEIN MASS SPECTROMETRY;RANKL;REPORTER GENE;RNA SPLICING;SENTINEL NODE;SIDA;SYSTEMIC THERAPY;THREONINE;THYMIDYLATE SYNTHASE;THYROID NEOPLASM;VARDENAFIL;ZEAXANTHIN","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;PROSTATIC NEOPLASMS;LIVER NEOPLASMS;AGED, 80 AND OVER;CASE-CONTROL STUDIES;RISK FACTORS;CARCINOMA, SQUAMOUS CELL;COLORECTAL NEOPLASMS;DEOXYCYTIDINE;MELANOMA;OVARIAN NEOPLASMS;CARCINOMA;FLUOROURACIL","80;53;47;42;41;37;29;28;19;17;14;14;14;13;13;13;12;12;11;11","THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMMUNOBIOLOGY OF DENDRITIC CELLS;LYMPHOID NEOPLASMS;MELANOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANESTHESIA AND SEDATION MANAGEMENT;BIOLOGICAL EFFECTS OF ELECTROMAGNETIC FIELDS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CANCER THERAPY;BREAST CANCER;EPIRUBICIN;HEPATITIS C;KAPOSI'S SARCOMA;METASTATIC COLORECTAL CANCER;UNIVARIATE ANALYSIS;APOPTOSIS;CANCER;CHAPERONE (CLINICAL);CLINICAL ENDPOINT;CONSUMPTION (SOCIOLOGY);CT IMAGING;CTL*;DACARBAZINE;ETIOLOGY;FOLATE;HEALTHY EATING INDEX;HEPATITIS C VIRUS;HIV","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","PROSTATE CANCER;OVARIAN CANCER;SOUTHERN ITALY;BENIGN PROSTATIC;BREAST CANCER;CANCER CELLS;CELL CARCINOMA;LUNG CANCER;PHASE II;PROSTATIC HYPERPLASIA;VIRUS INFECTION;CASE-CONTROL STUDY;CASECONTROL STUDY;DIETARY FOLATE;EPITHELIAL OVARIAN;FARNESYL TRANSFERASE;FLUOROURACIL IV;FOLINIC ACID;HIGH-DOSE FOLINIC;II TRIAL;IV BOLUS;KAPOSI SARCOMA;MOUSE MAMMARY;NONHODGKIN LYMPHOMA;PILOT STUDY;RENAL CELL;SOFT TISSUE;STEM CELL;TISSUE SARCOMAS;TRANSFERASE INHIBITOR","6;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;CELL LINES;EXPRESSION VECTORS;REPORTER GENE;CANCER CELLS;COLORECTAL CANCERS;COLON CANCER;FRUCHART J-C;ORLANDO CATALANO;BIOL CHEM;CATALANO MD;CHEM -ABSTRACT;INSTITUTO PASCALE;PUBMED GOOGLE;RADIOLOGY INSTITUTO;SONOGRAPHIC FINDINGS;BASELINE SONOGRAPHIC;CACO CELLS;CONFIDENCE INTERVAL;DOMINANT NEGATIVE;GROWTH INHIBITION;HDS CELLS;MED -CROSSREF;NAT MED;PASCALE NAPLES;RANGE WEEKS;SHEAR STRESS;SPIEGELMAN BM;SPORADIC COLORECTAL","34;28;13;11;11;8;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5",32,0.34,3,10.75,1,45,1,1,1,3.33,1,7,1,1,1,7,1,19,7.5,4,11,0,0,0,1,1,1,11.12,1,46,0,0,0,0,0,0,8.25,4,18,2,2,2,1,1,1,1,1,1,2.5,1,4,6.25,2,16,2,2,2,0,0,0,0.25,0,1,41.25,11,104,41.5,12,104
"IRCCS_PASCALE",2006,125,9.536,3.12,0.320512820512821,0.336,0.36,0.08,0.4,2,65,22,22,8,0.52,0.18,0.18,0.06,53.99,1.05704571441363,0.432,0.832,NA,0.455160038002599,0.390350877192982,0.40079079798706,0.415458937198068,"SILVIA FRANCESCHI;RENATO TALAMINI;CARLO LA VECCHIA;EVA NEGRI;LUIGINO DAL MASO;MICHELE CARAGLIA;LUIGI BUONAGURO;ALFREDO BUDILLON;MAURIZIO MONTELLA;ANTONIO PINTO;CRISTINA BOSETTI;VALERIO RAMAZZOTTI;GERARDO BOTTI;MARIA NAPOLITANO;GAETANO ROCCO;CORRADO CARACÒ;PAOLO DELRIO;MARIA LINA TORNESELLO;RENATO FRANCO;GIUSEPPE CASTELLO","18;18;17;14;12;11;10;10;10;9;8;7;7;7;6;6;6;6;6;6","LUIGI BUONAGURO;GAETANO ROCCO;SILVIA FRANCESCHI;RENATO TALAMINI;CARLO LA VECCHIA;EVA NEGRI;ALFREDO BUDILLON;MICHELE CARAGLIA;LUIGINO DAL MASO;ANTONIO PINTO;MAURIZIO MONTELLA;MARIA LINA TORNESELLO;CRISTINA BOSETTI;ALESSANDRO BRUNELLI;VALERIO RAMAZZOTTI;MARIA NAPOLITANO;ATTILIO GIACOSA;GIAMPAOLO TORTORA;CORRADO CARACÒ;MAURIZIO MONTELLA","2.58;2.14;1.93;1.93;1.82;1.55;1.36;1.26;1.24;1.16;1.09;0.88;0.87;0.83;0.75;0.74;0.66;0.65;0.65;0.64","MICHELE CARAGLIA;LUIGI BUONAGURO;ALFREDO BUDILLON;MAURIZIO MONTELLA;ANTONIO PINTO;GERARDO BOTTI;MARIA NAPOLITANO;GAETANO ROCCO;CORRADO CARACÒ;PAOLO DELRIO;MARIA LINA TORNESELLO;RENATO FRANCO;GIUSEPPE CASTELLO;MAURIZIO MONTELLA;NICOLA NORMANNO;STEFANO GREGGI;ANNA CRISPO;ANTONIO AVALLONE;ROSARIO VINCENZO IAFFAIOLI;GIOVANNI D’ARENA","11;10;10;10;9;7;7;6;6;6;6;6;6;6;5;5;5;5;5;4","LUIGI BUONAGURO;GAETANO ROCCO;ALFREDO BUDILLON;MICHELE CARAGLIA;ANTONIO PINTO;MAURIZIO MONTELLA;MARIA LINA TORNESELLO;MARIA NAPOLITANO;CORRADO CARACÒ;MAURIZIO MONTELLA;GERARDO BOTTI;RENATO FRANCO;PAOLO DELRIO;FRANCESCO IZZO;ROSARIO VINCENZO IAFFAIOLI;ANTONIO AVALLONE;ANNA CRISPO;NICOLA MOZZILLO;FRANCESCA BRUZZESE;GIANPAOLO MARCACCI","2.58;2.14;1.36;1.26;1.16;1.09;0.88;0.74;0.65;0.64;0.61;0.59;0.57;0.54;0.52;0.51;0.51;0.51;0.5;0.5","RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;ALFREDO FUSCO;MAURIZIO MONTELLA;GENNARO CHIAPPETTA;LUIGINO DAL MASO;GIANCARLO TRONCONE;MARIA NAPOLITANO;MASSIMO SANTORO;CARLO M. CROCE;PIERLORENZO PALLANTE;ROSA VISONE;EVA NEGRI;ANDREA CIARMIELLO;ANGELO FERRARO;CAIGANG LIU;MANUELA FERRACIN;MARIA TERESA BERLINGIERI;MASSIMO NEGRINI","1097;1097;1083;1035;905;886;863;843;834;789;770;770;770;766;526;524;524;524;524;524","MAURIZIO MONTELLA;GENNARO CHIAPPETTA;MARIA NAPOLITANO;ANDREA CIARMIELLO;SECONDO LASTORIA;CLAUDIO ARRA;STEFANO GREGGI;ANNA CRISPO;NICOLA NORMANNO;LUIGI BUONAGURO;GERARDO BOTTI;ANTONIO AVALLONE;FRANCESCO IZZO;GAETANO ROCCO;GIUSEPPE PIROZZI;GIUSEPPE LUCIO CASCINI;ALFREDO BUDILLON;MARCO MONTELLA;FRANCO M. BUONAGURO;CESARE GUIDA","905;886;606;526;504;422;359;340;333;321;318;305;289;289;276;258;247;244;242;237","MAURIZIO MONTELLA;ALFREDO BUDILLON;LUIGI BUONAGURO;MICHELE CARAGLIA;ANTONIO PINTO;GAETANO ROCCO;GERARDO BOTTI;ANNA CRISPO;GIUSEPPE CASTELLO;MARIA LINA TORNESELLO;NICOLA NORMANNO;RENATO FRANCO;ROSARIO VINCENZO IAFFAIOLI;ESTER SIMEONE;STEFANO GREGGI;A. CHIARA;ANTONIO AVALLONE;CLAUDIO ARRA;FRANCESCO IZZO;GENNARO CHIAPPETTA","16;10;10;9;8;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHILOSOPHY;PHYSICS;SOCIOLOGY;MATHEMATICS;PSYCHOLOGY;ART;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE","106;52;23;8;4;4;4;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;BIOCHEMISTRY;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;CANCER RESEARCH;GENETICS;RADIOLOGY;IMMUNOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;UROLOGY;GENERAL SURGERY;GYNECOLOGY;PALEONTOLOGY;VIROLOGY;BOTANY;STEREOCHEMISTRY","93;37;35;30;29;25;23;17;12;11;10;9;8;8;7;7;7;6;5;5","CANCER;CHEMOTHERAPY;GENE;ODDS RATIO;CONFIDENCE INTERVAL;CASE-CONTROL STUDY;LYMPHOMA;RECEPTOR;APOPTOSIS;CARCINOMA;ENZYME;REGIMEN;STAGE (STRATIGRAPHY);TOXICITY;DISEASE;IMMUNOHISTOCHEMISTRY;MELANOMA;RADIATION THERAPY;ANTIBODY;BODY MASS INDEX;CELL GROWTH;CONFOUNDING;FAMILY HISTORY;IN VITRO;RECTUM;SIGNAL TRANSDUCTION;THYROID","63;20;20;15;12;11;10;10;9;8;8;8;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5","COLORECTAL CANCER;BREAST CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;NEUTROPENIA;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;FLUOROURACIL;PROSTATE;RITUXIMAB;THYROID CARCINOMA;GEMCITABINE;GENE EXPRESSION;LYMPHADENECTOMY;MAPK/ERK PATHWAY;PROSTATE CANCER;TRANSCRIPTION FACTOR;TYROSINE-KINASE INHIBITOR;VASCULAR ENDOTHELIAL GROWTH FACTOR;AUTOCRINE SIGNALLING;CARCINOGENESIS;CERVICAL CANCER;CHEMOKINE;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR;HAZARD RATIO;MUCOSITIS;NON-HODGKIN'S LYMPHOMA;PROGRAMMED CELL DEATH;PROTEIN KINASE B","19;12;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","OXALIPLATIN;GEFITINIB;CHEMOKINE RECEPTOR;FOLINIC ACID;NEOADJUVANT THERAPY;PAPILLARY THYROID CANCER;CERVICAL CARCINOMA;CXCR4;EGFR INHIBITORS;FARNESYLTRANSFERASE;FEBRILE NEUTROPENIA;GENETICALLY MODIFIED MOUSE;HISTONE DEACETYLASE;IFOSFAMIDE;IRINOTECAN;LNCAP;MARGINAL ZONE;OSTEOCALCIN;OVARIAN CARCINOMA;PROMOTER;SENTINEL LYMPH NODE;SENTINEL NODE","6;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;ADENOCARCINOMA;;BREAST NEOPLASMS;RECTAL NEOPLASMS;CELL PROLIFERATION;ANIMALS;MELANOMA;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;CELL LINE, TUMOR;CASE-CONTROL STUDIES;NEOPLASMS","95;62;57;54;45;37;31;31;25;23;23;21;20;18;18;17;17;17;16;16","LYMPHOID NEOPLASMS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;COLORECTAL CANCER RESEARCH AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MELANOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;RENAL CELL CARCINOMA","8;6;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","REGIMEN;MELANOMA;BREAST CANCER;CANCER;LYMPHADENECTOMY;OVARIAN CANCER;ZOLEDRONIC ACID;CANCER INCIDENCE;CANCER RISK;ETIOLOGY;FOLINIC ACID;HEPATOCELLULAR CARCINOMA;MANTLE CELL LYMPHOMA;MUCOSITIS;NEOADJUVANT THERAPY;RENAL CELL CARCINOMA;TRANSCRIPTION (LINGUISTICS);ANAL CANCER;ANTIGEN PRESENTATION;AUTOLOGOUS STEM-CELL TRANSPLANTATION","8;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","BREAST CANCER;CANCER CELLS;CANCER PATIENTS;GROWTH FACTOR;PROSTATE CANCER;RECTAL CANCER;ADVANCED RECTAL;COLORECTAL CANCER;INHIBITOR GEFITINIB;KINASE INHIBITOR;LOCALLY ADVANCED;OVARIAN CANCER;PHASE II;RENAL CELL;TYROSINE KINASE;ZOLEDRONIC ACID;CANCER RISK;CASECONTROL STUDY;CELL CANCER;EGFR TYROSINE;ENDOTHELIAL GROWTH;HEPATOCELLULAR CARCINOMA;II STUDY;NON-HODGKINS LYMPHOMA;VASCULAR ENDOTHELIAL;ACID INFUSION;AGGRESSIVE NON-HODGKINS;ANTITUMOR ACTIVITY;BENIGN PROSTATIC;BONE METASTASES","6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","PUBMED SCOPUS;PTB DOMAINS;CELL LINES;CROSSREF PUBMED;CELL CYCLE;COLORECTAL CANCER;UNIPORTAL VATS;CANCER RISK;PROTEIN-PROTEIN INTERACTION;CANCER PATIENTS;BREAST CANCER;CONFIDENCE INTERVAL;PTB DOMAIN;DOMINANT NEGATIVE;LOGISTIC REGRESSION;ODDS RATIOS;PERICARDIAL WINDOW;PHOSPHOTYROSINE BINDING;SURG -ABSTRACT;GROWTH FACTOR;INTERACTION DOMAINS;OVARIAN CANCER;SINGLE INFUSION;BINDING PTB;CIRCULATING LEVELS;INTERVAL CI;OVARIAN CYSTS;PROGRESSION-FREE SURVIVAL;THORAC SURG;BIOL -CROSSREF","33;27;22;19;15;15;12;11;11;10;9;9;9;8;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;5",28,0.22,5.125,25.25,5,132,5.67,1,14,2.5,2,3,2,2,2,2.5,2,3,6.5,5,8,0,0,0,3,3,3,32.5,5,186,2,2,2,1,1,1,31.75,2,109,2,1,3,2,2,2,3,3,3,7,7,7,27.75,2,95,2.5,1,4,0.12,0,1,0,0,0,61.75,15,132,61.88,15,133
"IRCCS_PASCALE",2007,116,9.56896551724138,2.45689655172414,0.407017543859649,0.293103448275862,0.224137931034483,0.0603448275862069,0.301724137931034,1,47,27,28,12,0.41,0.23,0.24,0.1,45.15,0.855437310035232,0.396551724137931,0.844827586206897,NA,0.446978362366997,0.363162118780096,0.466060606060606,0.349462365591398,"SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;LUIGINO DAL MASO;MICHELE CARAGLIA;ALFREDO BUDILLON;GERARDO BOTTI;MAURIZIO MONTELLA;EVA NEGRI;LUIGI BUONAGURO;VALERIO RAMAZZOTTI;ANTONIO PINTO;CRISTINA BOSETTI;MAURIZIO MONTELLA;GAETANO ROCCO;ANTONELLA ZUCCHETTO;CLAUDIO PELUCCHI;ALESSANDRA TAVANI;GIOVANNI D’ARENA;ALFREDO FUSCO","17;16;16;12;12;10;9;9;9;8;7;6;6;6;5;5;5;5;4;4","SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;GAETANO ROCCO;LUIGI BUONAGURO;LUIGINO DAL MASO;MICHELE CARAGLIA;GERARDO BOTTI;MAURIZIO MONTELLA;ORLANDO CATALANO;EVA NEGRI;ALFREDO BUDILLON;VALERIO RAMAZZOTTI;CRISTINA BOSETTI;MARIA LINA TORNESELLO;MAURIZIO MONTELLA;ANTONIO PINTO;FRANCO FULCINITI;SISTO PERDONÀ;RICCARDO AUTORINO","1.74;1.64;1.64;1.53;1.32;1.21;1.18;1.09;0.94;0.92;0.89;0.84;0.71;0.66;0.66;0.62;0.58;0.58;0.55;0.55","MICHELE CARAGLIA;ALFREDO BUDILLON;GERARDO BOTTI;MAURIZIO MONTELLA;LUIGI BUONAGURO;ANTONIO PINTO;MAURIZIO MONTELLA;GAETANO ROCCO;GIOVANNI D’ARENA;CLAUDIO ARRA;SISTO PERDONÀ;LUIGI ALOJ;PAOLO DELRIO;RICCARDO AUTORINO;GIUSEPPE DI LORENZO;ORLANDO CATALANO;MARIA LINA TORNESELLO;FRANCO IONNA;FRANCO FULCINITI;SECONDO LASTORIA","12;10;9;9;8;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4","GAETANO ROCCO;LUIGI BUONAGURO;MICHELE CARAGLIA;GERARDO BOTTI;MAURIZIO MONTELLA;ORLANDO CATALANO;ALFREDO BUDILLON;MARIA LINA TORNESELLO;MAURIZIO MONTELLA;ANTONIO PINTO;FRANCO FULCINITI;SISTO PERDONÀ;RICCARDO AUTORINO;GIUSEPPE DI LORENZO;LUIGI ALOJ;PAOLO MUTO;GIOVANNI DI MINNO;GIOVANNI PAGANO;SECONDO LASTORIA;GUGLIELMO NASTI","1.53;1.32;1.18;1.09;0.94;0.92;0.84;0.66;0.62;0.58;0.58;0.55;0.55;0.55;0.5;0.5;0.5;0.44;0.44;0.44","GIUSEPPE PIROZZI;SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;MAURIZIO MONTELLA;ANTONIO LA CAVA;CLAUDIO PROCACCINI;GAETANO CALÌ;GIUSEPPE MATARESE;SERAFINO ZAPPACOSTA;SILVIA FONTANA;VERONICA DE ROSA;ANTONIO PINTO;MICHELE CARAGLIA;LUIGINO DAL MASO;ALFREDO DE ROSA;ANTONIO GRAZIANO;G LAINO;GIANPAOLO PAPACCIO;MAURILIO SAMPAOLESI","1103;816;760;760;720;608;608;608;608;608;608;608;516;513;497;495;495;495;495;495","GIUSEPPE PIROZZI;MAURIZIO MONTELLA;ANTONIO PINTO;MICHELE CARAGLIA;ALFREDO BUDILLON;LUIGI BUONAGURO;GIOVANNI D’ARENA;GIUSEPPE D’AIUTO;A. COSTA;ANDREA DECENSI;B. BONANNI;F. LOVISON;G GUCCIARDO;GIULIA VIALE;MARCO ROSSELLI DEL TURCO;MARIA ANTONIETTA PIZZICHETTA;MARIA GRAZIA MURACA;NICOLE ROTMENSZ;P. OLIVIERO;PATRICK MAISONNEUVE","1103;720;503;498;349;327;292;280;227;227;227;227;227;227;227;227;227;227;227;227","MAURIZIO MONTELLA;MICHELE CARAGLIA;ALFREDO BUDILLON;GERARDO BOTTI;LUIGI BUONAGURO;ANTONIO PINTO;GAETANO ROCCO;CLAUDIO ARRA;GIOVANNI D’ARENA;LUIGI ALOJ;ORLANDO CATALANO;SISTO PERDONÀ;PAOLO DELRIO;ANNA CRISPO;ANTONELLO LA ROCCA;FRANCESCO IZZO;FRANCO IONNA;GIUSEPPE PIROZZI;MARIA LINA TORNESELLO;MARIO MONACO","15;11;10;7;7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;MATERIALS SCIENCE;POLITICAL SCIENCE","94;45;14;6;6;4;3;3;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CANCER RESEARCH;PATHOLOGY;GENETICS;ONCOLOGY;BIOCHEMISTRY;CELL BIOLOGY;GASTROENTEROLOGY;RADIOLOGY;IMMUNOLOGY;ENDOCRINOLOGY;GYNECOLOGY;ENVIRONMENTAL HEALTH;DEMOGRAPHY;MOLECULAR BIOLOGY;PHARMACOLOGY;ECOLOGY;UROLOGY;ARTIFICIAL INTELLIGENCE;PALEONTOLOGY;VIROLOGY","69;27;25;24;22;22;20;16;15;15;13;11;9;8;6;6;6;5;5;4;4;4","CANCER;GENE;CHEMOTHERAPY;ODDS RATIO;CONFIDENCE INTERVAL;IMMUNOHISTOCHEMISTRY;RECEPTOR;BODY MASS INDEX;ENZYME;RADIATION THERAPY;CASE-CONTROL STUDY;LYMPHOMA;SIGNAL TRANSDUCTION;APOPTOSIS;CARCINOMA;CONFOUNDING;LOGISTIC REGRESSION;RENAL CELL CARCINOMA;STEM CELL;CYTOLOGY;DIFFERENTIAL DIAGNOSIS;HEPATOCELLULAR CARCINOMA;IN VITRO;STROMAL CELL","40;20;18;12;10;9;9;7;7;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;METASTASIS;PROSTATE;PROSTATE CANCER;ADENOCARCINOMA;CARCINOGENESIS;CD34;CHRONIC LYMPHOCYTIC LEUKEMIA;CYTOPATHOLOGY;MAPK/ERK PATHWAY;NEUTROPENIA;OVARIAN CANCER;PHENOTYPE;RITUXIMAB;TRANSCRIPTION FACTOR;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BORTEZOMIB;CELL CYCLE;CHOLECYSTOKININ;CYCLOPHOSPHAMIDE;DNA DAMAGE;ENDOMETRIAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;EPITOPE;GENE EXPRESSION;GENOTYPE;GERM CELL;GLUTATHIONE;HEAD AND NECK CANCER;IMMUNOGENICITY;LARYNGEAL NEOPLASM;MUTATION;OBSTRUCTED DEFECATION;OVERWEIGHT;PHASES OF CLINICAL RESEARCH;PHYLOGENETICS;PROGRAMMED CELL DEATH;PROTEIN KINASE A;PROTEIN KINASE B;RNA;THYROID CANCER;THYROID CARCINOMA;VASCULAR ENDOTHELIAL GROWTH FACTOR;WAIST;WESTERN BLOT","10;6;5;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CD38;BREAST CARCINOMA;GEFITINIB;METASTATIC BREAST CANCER;WAIST–HIP RATIO;ADENOMATOUS POLYPOSIS COLI;ADULT STEM CELL;ALTERNATIVE SPLICING;ALVEOLAR RHABDOMYOSARCOMA;ANAL VERGE;ANDROGEN RECEPTOR;ANTHRACYCLINE;ATAXIA-TELANGIECTASIA;BONE METASTASIS;CANNABINOID RECEPTOR;CAPECITABINE;CASPASE 3;CELL CYCLE CHECKPOINT;CETUXIMAB;CHEMOKINE RECEPTOR;CHOLECYSTOKININ RECEPTOR;CLADE;COLON CARCINOMA;CREB;CYCLIN-DEPENDENT KINASE 1;CYSTECTOMY;DNA MICROARRAY;DNA VACCINATION;EGFR INHIBITORS;EMBRYONAL CARCINOMA;ERLOTINIB;EXPRESSION VECTOR;FAMILIAL ADENOMATOUS POLYPOSIS;FARNESYLTRANSFERASE;FOLINIC ACID;FRAMESHIFT MUTATION;GENE EXPRESSION PROFILING;GENE SIGNATURE;GENTAMICIN PROTECTION ASSAY;GLUTATHIONE DISULFIDE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HISTONE DEACETYLASE;HIV VACCINE;HMGA2;HOMEOTIC GENE;HOX GENE;IL-2 RECEPTOR;IMMATURE TERATOMA;IRINOTECAN;LARGE CELL;LARYNGOSCOPES;LUCIFERASE;MARGINAL ZONE;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MISSENSE MUTATION;MITOGEN-ACTIVATED PROTEIN KINASE KINASE;MOLECULAR EPIDEMIOLOGY;MOLECULAR MEDICINE;MUCINOUS CARCINOMA;NEOINTIMAL HYPERPLASIA;NEOPLASTIC TRANSFORMATION;NEUROENDOCRINE DIFFERENTIATION;ONCOGENE;OSTEOCALCIN;P-GLYCOPROTEIN;PITTSBURGH SLEEP QUALITY INDEX;PLACENTA;POLYAMINE OXIDASE;POLYUNSATURATED FAT;PROMOTER;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;RADIOIMMUNOTHERAPY;REPORTER GENE;RNA INTERFERENCE;RNA SPLICING;SH3 DOMAIN;SINGLE-STRAND CONFORMATION POLYMORPHISM;SOMATOSTATIN RECEPTOR 2;STAT;TAMOXIFEN;THYMIDYLATE SYNTHASE;TOTAL MESORECTAL EXCISION;TRANSORAL LASER MICROSURGERY;TRASTUZUMAB;UBIQUITIN LIGASE;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;VINCRISTINE;VINORELBINE","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;;CARCINOMA, SQUAMOUS CELL;BREAST NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;ANTINEOPLASTIC AGENTS;LIVER NEOPLASMS;RNA, MESSENGER;CELL PROLIFERATION;PROSTATIC NEOPLASMS;CARCINOMA, HEPATOCELLULAR;CASE-CONTROL STUDIES;KIDNEY NEOPLASMS","86;50;48;45;42;32;30;23;22;19;19;19;18;18;18;17;17;16;16;16","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;ETIOLOGY AND MANAGEMENT OF PERITONEAL ADHESIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;ROLE OF STAT3 IN CANCER INFLAMMATION AND IMMUNITY;TESTICULAR GERM CELL TUMORS AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","BREAST CANCER;CANCER INCIDENCE;CANCER RISK;MANTLE CELL LYMPHOMA;CANCER;CANCER THERAPY;CYTOPATHOLOGY;HEPATOCELLULAR CARCINOMA;HIV;TREATMENT;ZOLEDRONIC ACID;;APPROPRIATENESS CRITERIA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BONE PAIN;BREAST CARCINOMA;CANCER TREATMENT;CD30+ LYMPHOPROLIFERATIVE DISORDERS;CONCOMITANT;DIET QUALITY","5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER CELLS;CASE-CONTROL STUDY;PROSTATE CANCER;RENAL CELL;CANCER RISK;CELL CARCINOMA;CONTRAST-ENHANCED SONOGRAPHY;PHASE II;RISK FACTORS;ZOLEDRONIC ACID;ADVANCED STAGE;BODY MASS;CASECONTROL STUDY;CELL CANCER;CELL GROWTH;CHRONIC LYMPHOCYTIC;CLL CELLS;ENDOMETRIAL CANCER;FINE NEEDLE;FIRST-LINE TREATMENT;GERM CELL;HEPATOCELLULAR CARCINOMA;II STUDY;LIVER RESECTION;LYMPHOCYTIC LEUKEMIA;MASS INDEX;MIGRATORY POTENTIAL;NON-HODGKIN LYMPHOMA;OBSTRUCTED DEFECATION","4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CHEST WALL;BREAST CANCER;PUBMED SCOPUS;RR CI;FRA- PROTEIN;ZAP CD;CANCER PATIENTS;CONFIDENCE INTERVAL;ODDS RATIO;SURG -ABSTRACT;BODY MASS;CYCLE ARREST;ENDOMETRIAL CANCER;ENERGY INTAKE;MEDITERRANEAN DIET;TREG CELLS;BAX PROTEIN;CANCER CELL;CD PATIENTS;CELL GROWTH;CLINICAL OUTCOME;CONFIDENCE INTERVALS;CONSECUTIVE PATIENTS;HEPATOCELLULAR CARCINOMA;LUNG RESECTION;MAJOR LUNG;MASS INDEX;MELANOMA CELLS;OBSERVED COSTS;ODDS RATIOS","16;9;9;9;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",30,0.26,3,3.4,1,15,0,0,0,1,1,1,0,0,0,1,1,1,4.18,1,14,0,0,0,1.33,1,3,3.6,1,15,0,0,0,1,1,1,1.67,1,3,0,0,0,1.33,1,2,0,0,0,0,0,0,1.67,1,3,0,0,0,0.05,0,1,0.25,0,2,50.2,7,201,50.5,7,201
"IRCCS_PASCALE",2008,92,10.4565217391304,2.65217391304348,0.377049180327869,0.326086956521739,0.260869565217391,0.0760869565217391,0.347826086956522,2,48,12,12,12,0.52,0.13,0.13,0.13,50.33,0.91715639225633,0.41304347826087,0.826086956521739,NA,0.479419431173921,0.452851496329757,0.349726775956284,0.288888888888889,"LUIGI BUONAGURO;CARLO LA VECCHIA;GERARDO BOTTI;RENATO TALAMINI;SILVIA FRANCESCHI;EVA NEGRI;MAURIZIO MONTELLA;MARIA LINA TORNESELLO;MICHELE CARAGLIA;LUIGINO DAL MASO;ANTONIO PINTO;ANTONELLA ZUCCHETTO;LUIGI ALOJ;ANNA CRISPO;CLAUDIO ARRA;GIOVANNI SCAMBIA;LUCIANO PEZZULLO;GENNARO CHIAPPETTA;ALESSANDRO MORABITO;CRISTINA BOSETTI","11;11;10;10;9;9;8;7;7;6;6;5;5;5;4;4;4;4;4;4","LUIGI BUONAGURO;FRANCO M. BUONAGURO;GAETANO ROCCO;MICHELE CARAGLIA;CARLO LA VECCHIA;RENATO TALAMINI;GERARDO BOTTI;EVA NEGRI;SILVIA FRANCESCHI;ANTONIO PINTO;MARIA LINA TORNESELLO;MAURIZIO MONTELLA;ALFREDO BUDILLON;LUIGINO DAL MASO;RENATO FRANCO;ANNA CRISPO;LUIGI ALOJ;ANTONELLA ZUCCHETTO;GIOVANNI CONZO;PAOLO DELRIO","1.46;1.41;1.27;1.23;1.15;1.05;0.98;0.94;0.92;0.86;0.85;0.82;0.76;0.67;0.67;0.54;0.52;0.52;0.5;0.5","LUIGI BUONAGURO;GERARDO BOTTI;MAURIZIO MONTELLA;MARIA LINA TORNESELLO;MICHELE CARAGLIA;ANTONIO PINTO;LUIGI ALOJ;ANNA CRISPO;CLAUDIO ARRA;LUCIANO PEZZULLO;GENNARO CHIAPPETTA;ALESSANDRO MORABITO;RENATO FRANCO;FRANCO M. BUONAGURO;GAETANO ROCCO;NICOLA NORMANNO;ALFREDO BUDILLON;MARIA GRIMALDI;FERDINANDO FRIGERI;MAURIZIO MONTELLA","11;10;8;7;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","LUIGI BUONAGURO;FRANCO M. BUONAGURO;GAETANO ROCCO;MICHELE CARAGLIA;GERARDO BOTTI;ANTONIO PINTO;MARIA LINA TORNESELLO;MAURIZIO MONTELLA;ALFREDO BUDILLON;RENATO FRANCO;ANNA CRISPO;LUIGI ALOJ;PAOLO DELRIO;AMELIA D’ALESSIO;NICOLA NORMANNO;CLAUDIO ARRA;ALESSANDRO MORABITO;FERDINANDO FRIGERI;ALFREDO SIANI;MONICA MARRA","1.46;1.41;1.27;1.23;0.98;0.86;0.85;0.82;0.76;0.67;0.54;0.52;0.5;0.5;0.49;0.46;0.4;0.36;0.33;0.33","GIOVANNI SCAMBIA;DIONYSSIOS KATSAROS;STEFANO GREGGI;ANDREA ALBERTO LISSONI;C. DELLA CROCE;COSTANTINO MANGIONI;DIANA GIANNARELLI;E CAMPAGNUTTA;F. MANESCHI;FRANCESCO RASPAGLIESI;G GAROZZO;GENNARO CORMIO;GIORGIA MANGILI;M. AMOROSO;MASSIMO PIERGIUSEPPE FRANCHI;MAURO MELPIGNANO;MAURO SIGNORELLI;NICOLA RAGNI;NICOLETTA DONADELLO;PIERLUIGI BENEDETTI PANICI","1760;1720;1488;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439","STEFANO GREGGI;GENNARO CHIAPPETTA;MAURIZIO MONTELLA;GERARDO BOTTI;LUIGI BUONAGURO;SANDRO PIGNATA;ANDREA VECCHIONE;EMILIA VUTTARIELLO;MARIA LINA TORNESELLO;ANNA CRISPO;RENATO FRANCO;SISTO PERDONÀ;LUCIANO PEZZULLO;CLAUDIO ARRA;FRANCO M. BUONAGURO;ANTÔNIO BARBIERI;LUIGI ALOJ;ENRICO LEONARDI;GIUSEPPE CASTELLO;MARCO MONTELLA","1488;546;544;457;343;281;278;262;252;249;209;201;180;120;103;93;90;85;85;71","LUIGI BUONAGURO;MAURIZIO MONTELLA;GERARDO BOTTI;MARIA LINA TORNESELLO;MICHELE CARAGLIA;ANNA CRISPO;ANTONIO PINTO;LUIGI ALOJ;ALESSANDRO MORABITO;CLAUDIO ARRA;FRANCO M. BUONAGURO;GENNARO CHIAPPETTA;LUCIANO PEZZULLO;RENATO FRANCO;ALFREDO BUDILLON;FERDINANDO FRIGERI;GAETANO ROCCO;MARIA GRIMALDI;NICOLA NORMANNO;A. DE MATTEIS","11;11;10;7;7;5;5;5;4;4;4;4;4;4;3;3;3;3;3;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;ECONOMICS","78;43;12;6;5;5;4;3;3;2;2;2;1","INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;BIOCHEMISTRY;CANCER RESEARCH;GENETICS;SURGERY;IMMUNOLOGY;GYNECOLOGY;GASTROENTEROLOGY;VIROLOGY;PALEONTOLOGY;RADIOLOGY;CELL BIOLOGY;MOLECULAR BIOLOGY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;ORGANIC CHEMISTRY;UROLOGY","60;28;26;21;21;21;16;14;12;9;9;7;7;6;6;5;5;4;4;4;4","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;ODDS RATIO;CASE-CONTROL STUDY;IMMUNOHISTOCHEMISTRY;THYROID;IN VITRO;REGIMEN;SIGNAL TRANSDUCTION;VIRUS;ANTIBODY;IN VIVO;LOGISTIC REGRESSION;LYMPHOMA;POPULATION;APOPTOSIS;CARCINOMA;IMMUNE SYSTEM;KINASE;MALIGNANCY;RENAL CELL CARCINOMA;STAGE (STRATIGRAPHY)","47;21;12;10;10;9;8;8;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;GENE EXPRESSION;METASTASIS;THYROID CANCER;ENDOMETRIAL CANCER;MONOCLONAL ANTIBODY;OVARIAN CANCER;ADENOCARCINOMA;BEVACIZUMAB;CARCINOGENESIS;CELL CYCLE;GEMCITABINE;GENOTYPE;PRENYLATION;RITUXIMAB;ATP SYNTHASE;BIODISTRIBUTION;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CHROMOSOME;COLORECTAL SURGERY;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;ETOPOSIDE;FINE-NEEDLE ASPIRATION;HEAD AND NECK CANCER;MALT LYMPHOMA;MAPK/ERK PATHWAY;PACLITAXEL;PERIPHERAL BLOOD MONONUCLEAR CELL;PROSTATE CANCER;PROTEIN KINASE A;RECOMBINANT DNA;THYROID CARCINOMA;TOLERABILITY;TRANSCRIPTION FACTOR;TYROSINE KINASE","15;7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANAPLASTIC THYROID CANCER;BREAST CARCINOMA;DNA MICROARRAY;DUCTAL CARCINOMA;ESTROGEN RECEPTOR;FARNESYL PYROPHOSPHATE;FARNESYLTRANSFERASE;FLUORESCENCE IN SITU HYBRIDIZATION;GEFITINIB;HORMONE RECEPTOR;LYMPHOVASCULAR INVASION;METASTATIC BREAST CANCER;MUCOSA-ASSOCIATED LYMPHOID TISSUE;OXALIPLATIN;TAXANE;ADENOMATOUS POLYPOSIS COLI;AMPHIPHILE;ANTHOCYANIDINS;ANTI-APOPTOTIC RAS SIGNALLING CASCADE;AROMATASE;ATROPHIC GASTRITIS;BRONCHOPLEURAL FISTULA;BRONCHUS;CAPECITABINE;CARBOPLATIN;CARMUSTINE;CATENIN;CENTROSOME;CERVICAL INTRAEPITHELIAL NEOPLASIA;CETUXIMAB;CHIMERIC GENE;CHOLECYSTOKININ RECEPTOR;CHRONIC GASTRITIS;CXCR4;CYSTADENOCARCINOMA;CYSTECTOMY;DNA FRAGMENTATION;ELISPOT;FAMILIAL ADENOMATOUS POLYPOSIS;FARNESYL DIPHOSPHATE SYNTHASE;FLAVONOLS;FUSION PROTEIN;GENE EXPRESSION PROFILING;GENETICALLY MODIFIED MOUSE;GERMINAL CENTER;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;GONADOTROPIN-RELEASING HORMONE;HIV ANTIGENS;HMGA2;HORMONE THERAPY;HPV INFECTION;IFOSFAMIDE;IMMUNOGEN;IN SITU HYBRIDIZATION;INVASIVE DUCTAL CARCINOMA;IRINOTECAN;ISOPENTENYL PYROPHOSPHATE;MAMMARY GLAND;MAMMARY TUMOR;MARGINAL ZONE;MASTECTOMY;MEDULLARY THYROID CANCER;MEVALONATE PATHWAY;MICROARRAY;MOLECULAR EPIDEMIOLOGY;MOLECULAR EVOLUTION;MOLECULAR MEDICINE;MONOCLONAL;NEOPLASTIC TRANSFORMATION;NEUROENDOCRINE DIFFERENTIATION;NORTHERN BLOT;ONCOGENE;ONCOLYTIC ADENOVIRUS;OVARIAN CARCINOMA;PLASTID;POLY ADP RIBOSE POLYMERASE;PRIMARY TUMOR;PROSTATE-SPECIFIC ANTIGEN;RADIOIMMUNOTHERAPY;RECEPTOR PROTEIN-TYROSINE KINASES;TRANSACTIVATION;TRASTUZUMAB;TROPOMYOSIN RECEPTOR KINASE B;ZEAXANTHIN","2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;BREAST NEOPLASMS;ITALY;ADULT;AGED;MALE;THYROID NEOPLASMS;ANTINEOPLASTIC AGENTS;;ENDOMETRIAL NEOPLASMS;OVARIAN NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA;LUNG NEOPLASMS;ANIMALS;CARCINOMA, RENAL CELL;CASE-CONTROL STUDIES;RISK FACTORS","70;43;40;34;33;30;28;27;22;20;18;18;17;16;14;13;12;12;12;12","HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;LYMPHOID NEOPLASMS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;IMMUNOBIOLOGY OF DENDRITIC CELLS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;TESTICULAR GERM CELL TUMORS AND TREATMENT;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BIOLOGICAL AGENTS FOR BIOTERRORISM;BIOLOGICAL PROPERTIES OF GARLIC AND ITS COMPOUNDS;BIOLOGICAL ROLE OF CAVEOLAE IN CELLULAR PROCESSES;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CANCER STEM CELLS AND TUMOR METASTASIS","6;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","BREAST CANCER;REGIMEN;HER2;HIV;TREATMENT;CANCER RISK;HIV INFECTION;HPV VACCINATION;MANTLE CELL LYMPHOMA;RENAL CELL CARCINOMA;THYROID NODULES;ANAPLASTIC THYROID CANCER;BIODISTRIBUTION;BREAST CARCINOMA;CANCER INCIDENCE;CHEMOTHERAPY REGIMEN;COLORECTAL SURGERY;ENDOMETRIAL CARCINOMA;FARNESYL PYROPHOSPHATE;FARNESYLTRANSFERASE INHIBITOR","7;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER RISK;BREAST CANCER;CANCER PATIENTS;CASECONTROL STUDY;CELL CANCER;COLORECTAL CANCER;ENDOMETRIAL CANCER;HUMAN IMMUNODEFICIENCY;HUMAN PAPILLOMAVIRUS;III TRIAL;ITALIAN ASSOCIATION;OVARIAN CANCER;PHASE III;PRELIMINARY RESULTS;RENAL CELL;SITU HYBRIDIZATION;ANNUAL MEETING;BLOOD MONONUCLEAR;BONE METASTASES;BREAST CANCERS;CASE-CONTROL STUDY;CELL CULTURES;CULTURES AICC;DELIVERY STRATEGIES;DRUG DELIVERY;DUCTAL HISTOTYPE;HEPATOCELLULAR CARCINOMA;HODGKIN LYMPHOMA;HPV VARIANTS;IMMUNODEFICIENCY VIRUS","8;7;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;SALOMON DS;MAMMARY EPITHELIAL;BREAST CANCER;DS CRIPTO-;MOUSE MAMMARY;LISANTI MP;PUBMED GOOGLE;MAMMARY GLAND;BIOL -CROSSREF;BIOL CHEM;DE LUCA;EPITHELIAL CELLS;GROWTH FACTOR;SIGNALING PATHWAYS;CELL BIOL;CHEM -CROSSREF;EPH CR-CAV-;MONOCLONAL ANTIBODY;OVARIAN CANCER;CANCER RISK;EBERT AD;ACTIVATES NODAL-;ADKINS HB;CAV- EXPRESSION;CELLSMOL CELL;CR-CAV- CELLS;CRIPTO- ACTIVATES;ENDOMETRIAL CANCER","62;54;32;26;18;13;13;12;12;11;10;9;9;9;9;9;8;8;8;8;8;7;7;6;6;6;6;6;6;6",21,0.23,6,4.38,1,8,0,0,0,1,1,1,0,0,0,1.5,1,3,6,5,7,1,1,1,1.5,1,2,5.25,1,10,0,0,0,1,1,1,2,2,2,0,0,0,1,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0.25,0,2,0.12,0,1,97.75,16,437,98.12,16,437
"IRCCS_PASCALE",2009,112,9.6875,2.65178571428571,0.377104377104377,0.294642857142857,0.348214285714286,0.419642857142857,0.508928571428571,3,51,24,9,16,0.46,0.21,0.08,0.14,46.63,1.00814373045136,0.348214285714286,0.848214285714286,NA,0.521286842900046,0.48,0.446894689468947,0.474310776942356,"LUIGI BUONAGURO;GAETANO ROCCO;ANTONIO PINTO;MARIA LINA TORNESELLO;CARLO LA VECCHIA;RENATO TALAMINI;GERARDO BOTTI;LUIGINO DAL MASO;SILVIA FRANCESCHI;FILIPPO RUSSO;FERDINANDO FRIGERI;GAETANO CORAZZELLI;GIANPAOLO MARCACCI;EVA NEGRI;CRISTINA BECCHIMANZI;MANUELA ARCAMONE;GENNARO CHIAPPETTA;RENATO FRANCO;MAURIZIO MONTELLA;GAETANA CAPOBIANCO","19;12;10;10;9;9;8;8;8;7;6;6;6;6;5;5;5;5;5;5","GAETANO ROCCO;LUIGI BUONAGURO;MARIA LINA TORNESELLO;FRANCESCO CAPONIGRO;FRANCO M. BUONAGURO;FABIO AYALA;ORLANDO CATALANO;LUIGINO DAL MASO;GERARDO BOTTI;ANTONIO PINTO;CARLO LA VECCHIA;RENATO TALAMINI;SILVIA FRANCESCHI;FLAVIO FAZIOLI;MASSIMO DI MAÏO;FRANCO M. BUONAGURO;ALFREDO BUDILLON;FILIPPO RUSSO;EVA NEGRI;ROSANNA ACCARDO","3.04;2.67;1.53;1.33;1;1;1;0.93;0.9;0.87;0.86;0.84;0.78;0.75;0.67;0.66;0.62;0.61;0.6;0.56","LUIGI BUONAGURO;GAETANO ROCCO;ANTONIO PINTO;MARIA LINA TORNESELLO;CARLO LA VECCHIA;GERARDO BOTTI;FILIPPO RUSSO;FERDINANDO FRIGERI;GAETANO CORAZZELLI;GIANPAOLO MARCACCI;CRISTINA BECCHIMANZI;MANUELA ARCAMONE;GENNARO CHIAPPETTA;RENATO FRANCO;MAURIZIO MONTELLA;GAETANA CAPOBIANCO;NICOLA NORMANNO;MASSIMO DI MAÏO;PAOLO A. ASCIERTO;SIMONA LOSITO","19;12;10;10;9;8;7;6;6;6;5;5;5;5;5;5;4;4;4;4","GAETANO ROCCO;LUIGI BUONAGURO;MARIA LINA TORNESELLO;FRANCESCO CAPONIGRO;FRANCO M. BUONAGURO;FABIO AYALA;ORLANDO CATALANO;GERARDO BOTTI;ANTONIO PINTO;CARLO LA VECCHIA;FLAVIO FAZIOLI;MASSIMO DI MAÏO;FRANCO M. BUONAGURO;ALFREDO BUDILLON;FILIPPO RUSSO;ROSANNA ACCARDO;ELENA DI GENNARO;SIMONA LOSITO;GIANPAOLO MARCACCI;RENATO FRANCO","3.04;2.67;1.53;1.33;1;1;1;0.9;0.87;0.86;0.75;0.67;0.66;0.62;0.61;0.56;0.55;0.53;0.52;0.51","GAETANO ROCCO;ALESSANDRO BRUNELLI;GONZÁLO VARELA;MARK K. FERGUSON;ANNE CHARLOUX;C. FAIVRE‐FINN;CHRIS T. BOLLIGER;DIRK DE RUYSSCHER;ENRICO CLINI;L GOLDMAN;MARC LICKER;R. HUBER;SCULIER JP;THIDA WIN;GAETANO CORAZZELLI;ALBA A. BRANDES;ALBERTO FABBRI;ANDRÉS JM FERRERI;ATTILIO GUARINI;CATERINA STELITANO","1042;930;882;827;806;806;806;806;806;806;806;806;806;806;708;624;624;624;624;624","GAETANO ROCCO;GAETANO CORAZZELLI;LUIGI BUONAGURO;GIUSEPPE PIROZZI;STEFANIA SCALA;MAURIZIO MONTELLA;GERARDO BOTTI;GIANNI BRUNI;GENNARO CHIAPPETTA;ANTONIO PINTO;SUSAN COSTANTINI;RENATO FRANCO;LUIGI ALOJ;RAFFAELE DI FRANCIA;SISTO PERDONÀ;ROSARIA DE FILIPPI;CLAUDIO ARRA;MARIA LINA TORNESELLO;ALFREDO BUDILLON;ANNA CRISPO","1042;639;393;355;353;352;217;213;204;194;166;156;149;146;140;134;133;127;117;113","LUIGI BUONAGURO;GAETANO ROCCO;MARIA LINA TORNESELLO;MAURIZIO MONTELLA;ANTONIO PINTO;GERARDO BOTTI;FILIPPO RUSSO;FERDINANDO FRIGERI;GENNARO CHIAPPETTA;GAETANO CORAZZELLI;GIANPAOLO MARCACCI;RENATO FRANCO;ALFREDO BUDILLON;ANTONELLO LA ROCCA;CRISTINA BECCHIMANZI;FRANCO M. BUONAGURO;GAETANA CAPOBIANCO;MANUELA ARCAMONE;ROSANNA ACCARDO;PAOLO A. ASCIERTO","19;12;10;9;9;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PHILOSOPHY;ENGINEERING;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;ECONOMICS;MATHEMATICS","97;52;11;10;9;5;3;3;3;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;GENETICS;SURGERY;ONCOLOGY;BIOCHEMISTRY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;CELL BIOLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;VIROLOGY;GYNECOLOGY;RADIOLOGY;PHARMACOLOGY;ASTROBIOLOGY;GENERAL SURGERY;OBSTETRICS;OPTICS","65;28;28;28;26;20;20;19;14;13;9;9;8;7;7;5;4;4;4;4","CANCER;GENE;CHEMOTHERAPY;LYMPHOMA;ODDS RATIO;ANTIBODY;CELL;CELL CULTURE;DISEASE;IMMUNOHISTOCHEMISTRY;IN VITRO;MELANOMA;VIRUS;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;LOGISTIC REGRESSION;SIGNAL TRANSDUCTION;CARCINOMA;CELL GROWTH;INCIDENCE (GEOMETRY);LUNG;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REFRACTORY (PLANETARY SCIENCE);REGIMEN","46;30;16;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","CELL CYCLE;BREAST CANCER;COLORECTAL CANCER;CARCINOGENESIS;PROSTATE CANCER;GENE EXPRESSION;NEUTROPENIA;PERIPHERAL BLOOD MONONUCLEAR CELL;PNEUMONECTOMY;CANCER CELL;CYTARABINE;DOWNREGULATION AND UPREGULATION;ENDOMETRIAL CANCER;EX VIVO;FLUOROURACIL;GEMCITABINE;GENOTYPE;MONOCLONAL ANTIBODY;PROSTATE;PROTEIN KINASE B;RITUXIMAB;SURVIVIN","12;11;11;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CYCLIN D1;OXALIPLATIN;BRONCHOPLEURAL FISTULA;CAPECITABINE;FOLINIC ACID;GERMINAL CENTER;GLYCEMIC INDEX;HISTONE DEACETYLASE;INDUCED PLURIPOTENT STEM CELL;MASTECTOMY;MICROARRAY;POLYMORPHISM (COMPUTER SCIENCE);REED–STERNBERG CELL;TRASTUZUMAB;ABDOMINAL OBESITY;ADENOVIRIDAE;AGROBACTERIUM;AIDS VACCINES;ALLELE FREQUENCY;ANAPLASTIC THYROID CANCER;ARGININE DEIMINASE;ATP-BINDING CASSETTE TRANSPORTER;AURORA INHIBITOR;BETA-CATENIN;BIOMARKER DISCOVERY;BREAST CARCINOMA;CARMUSTINE;CASPASE;CATENIN;CD90;CDKN2B;CERVICAL INTRAEPITHELIAL NEOPLASIA;CETUXIMAB;CHEMOKINE RECEPTOR;CHROMOSOMAL FRAGILE SITE;CIRCULATING TUMOR CELL;CITRULLINE;COLOANAL ANASTOMOSIS;CTGF;CXCR4;CYCLIN-DEPENDENT KINASE 1;CYSTECTOMY;CYTOKINESIS;ELISPOT;EMBRYONAL CARCINOMA;EPITHELIAL OVARIAN CANCER;ERBB3;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;FOLD CHANGE;FOLLICLE-STIMULATING HORMONE;GEFITINIB;GENE DELIVERY;GENE EXPRESSION PROFILING;GENE SIGNATURE;GERMLINE MUTATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HIV VACCINE;HOX GENE;HUMAN BREAST;IFOSFAMIDE;IMMUNOGEN;IRINOTECAN;KAPOSI'S SARCOMA;KRAS;LENTIVIRUS;LOWER URINARY TRACT SYMPTOMS;MAMMOGRAPHY;MEDULLARY CARCINOMA;METASTATIC BREAST CANCER;MICROARRAY ANALYSIS TECHNIQUES;MULTICENTER TRIAL;NETRIN;NODULAR SCLEROSIS;NUCLEAR PROTEIN;ONCOGENE;PAX5;PENTAGASTRIN;PLASTID;PLEURAL DISEASE;POLYCYSTIC OVARY;PROANTHOCYANIDIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETINOBLASTOMA PROTEIN;RNA EXTRACTION;SEROPREVALENCE;SIDE POPULATION;SINGLE-NUCLEOTIDE POLYMORPHISM;SYSTEMIC THERAPY;TAMOXIFEN;TAQMAN;THYMIDYLATE SYNTHASE;TRANSURETHRAL RESECTION OF THE PROSTATE;TUMOR SUPPRESSOR GENE;VINCRISTINE;VINORELBINE;WWOX","3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MIDDLE AGED;FEMALE;;MALE;ADULT;AGED;ITALY;BREAST NEOPLASMS;ANTINEOPLASTIC AGENTS;NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CELL LINE, TUMOR;LUNG NEOPLASMS;DEOXYCYTIDINE;MELANOMA;ANTIMETABOLITES, ANTINEOPLASTIC;PNEUMONECTOMY;PROSTATIC NEOPLASMS;GENE EXPRESSION REGULATION, NEOPLASTIC","74;40;37;34;34;31;29;28;21;20;20;16;16;16;15;14;13;13;13;11","LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;CANCER STEM CELLS AND TUMOR METASTASIS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;GENE THERAPY TECHNIQUES AND APPLICATIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;GYNECOLOGIC ONCOLOGY;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MELANOMA;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;MICROSURGICAL RECONSTRUCTION TECHNIQUES;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MULTIPOTENT MESENCHYMAL STEM CELLS;ROLE OF HISTONE DEACETYLASES IN CELLULAR REGULATION;ROLE OF LONG NONCODING RNAS IN CANCER AND DEVELOPMENT;SALIVARY GLAND TUMORS AND CARCINOMAS","8;6;5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER THERAPY;HIV;REFRACTORY (PLANETARY SCIENCE);REGIMEN;BRONCHOPLEURAL FISTULA;CANCER;CANCER INCIDENCE;CANCER RISK;CANCER SUSCEPTIBILITY;CHRISTIAN MINISTRY;MELANOMA;SURVIVIN;B-CELL RECEPTOR SIGNALING;BIOMARKER ANALYSIS;BREAST CANCER SCREENING;CANCER IMAGING;CARDIOTHORACIC SURGERY;CARDIOTOXICITY;CHEMOTHERAPY REGIMEN","4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","BREAST CANCER;CANCER CELLS;CANCER PATIENTS;CELL CARCINOMA;CANCER RISK;CHEST WALL;COLORECTAL CANCER;ENDOMETRIAL CANCER;HEPATOCELLULAR CARCINOMA;HODGKINS LYMPHOMA;II STUDY;OVARIAN CANCER;PHASE II;RENAL CELL;B-CELL LYMPHOMA;CELL CYCLE;COMBINED BLOCKADE;CYCLE REGULATORY;DOXORUBICIN MYOCET;FINENEEDLE CYTOLOGY;GLYCEMIC LOAD;HIGH-DOSE METHOTREXATE;HIV- GLYCOPROTEINS;INDUCTION TREATMENT;INTEGRATED ONCOLOGY;ITALIAN MINISTRY;LUNG CANCER;LUNG RESECTION;LYMPHOMA CHL;ONCOLOGY PROGRAM","8;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;OTX EXPRESSION;CD CD;OTX CELLS;BREAST CANCER;CHEST WALL;LATISSIMUS DORSI;PHRENIC NERVE;SURG -ABSTRACT;V-Y LATISSIMUS;THORAC SURG;CANCER CELLS;SURG -CROSSREF;CELL CYCLE;CELL LINES;MONONUCLEAR CELLS;MULTIPLE MYELOMA;PUBMED GOOGLE;ADIPOCYTE DIFFERENTIATION;EXTENDED V-Y;LEFT ATRIUM;OTX GENE;PULMONARY VEINS;ANTERIOR CHEST;ANTI-CD DAKO;CARDIOTHORAC SURG;CLINICAL TRIALS;LYMPH NODES;LYMPHOID TISSUES","39;28;21;19;19;16;16;13;11;11;11;10;9;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6",22,0.2,3,4.67,1,15,2,2,2,0,0,0,0,0,0,1,1,1,1.67,1,2,0,0,0,2,2,2,5.5,1,17,0,0,0,1,1,1,12,12,12,0,0,0,1,1,1,1,1,1,2,2,2,8,8,8,1,1,1,0.17,0,1,0.33,0,1,106.67,23,342,107.17,23,343
"IRCCS_PASCALE",2010,122,10.0491803278689,3.51639344262295,0.284382284382284,0.336065573770492,0.385245901639344,0.204918032786885,0.385245901639344,6,46,38,15,16,0.38,0.31,0.12,0.13,37.47,0.829093183130025,0.336065573770492,0.778688524590164,NA,0.502092060853913,0.407407407407407,0.425287356321839,0.486342438374417,"LUIGI BUONAGURO;CLAUDIO ARRA;RENATO FRANCO;GAETANO ROCCO;GERARDO BOTTI;GIUSEPPE CASTELLO;ALFREDO BUDILLON;STEFANIA SCALA;MARIA LINA TORNESELLO;CARLO LA VECCHIA;RENATO TALAMINI;ANTONIO PINTO;GENNARO CHIAPPETTA;EVA NEGRI;SISTO PERDONÀ;ROSA CALEMMA;ANTONELLA PETRILLO;SILVIA FRANCESCHI;ELENA DI GENNARO;ANNA CRISPO","17;11;11;9;9;9;8;7;7;7;7;6;6;6;5;5;5;5;5;5","LUIGI BUONAGURO;GAETANO ROCCO;RENATO FRANCO;FRANCO M. BUONAGURO;GENNARO CHIAPPETTA;CLAUDIO ARRA;FRANCO M. BUONAGURO;MARIA LINA TORNESELLO;GERARDO BOTTI;CARLO LA VECCHIA;MASSIMO DI MAÏO;NICOLA NORMANNO;GIUSEPPE CASTELLO;RENATO TALAMINI;ORLANDO CATALANO;ALFREDO BUDILLON;EVA NEGRI;SISTO PERDONÀ;MAURIZIO MONTELLA;ANTONELLA DE LUCA","4.17;2.22;1.82;1.16;1.11;1;1;1;0.97;0.87;0.8;0.78;0.77;0.76;0.73;0.68;0.67;0.66;0.66;0.61","LUIGI BUONAGURO;CLAUDIO ARRA;RENATO FRANCO;GAETANO ROCCO;GERARDO BOTTI;GIUSEPPE CASTELLO;ALFREDO BUDILLON;STEFANIA SCALA;MARIA LINA TORNESELLO;ANTONIO PINTO;GENNARO CHIAPPETTA;SISTO PERDONÀ;ROSA CALEMMA;ANTONELLA PETRILLO;ELENA DI GENNARO;ANNA CRISPO;MARIA NAPOLITANO;MICHELE CARAGLIA;MAURIZIO MONTELLA;CRESCENZO D’ALTERIO","17;11;11;9;9;9;8;7;7;6;6;5;5;5;5;5;5;5;5;4","LUIGI BUONAGURO;GAETANO ROCCO;RENATO FRANCO;FRANCO M. BUONAGURO;GENNARO CHIAPPETTA;CLAUDIO ARRA;FRANCO M. BUONAGURO;MARIA LINA TORNESELLO;GERARDO BOTTI;MASSIMO DI MAÏO;NICOLA NORMANNO;GIUSEPPE CASTELLO;ORLANDO CATALANO;ALFREDO BUDILLON;SISTO PERDONÀ;MAURIZIO MONTELLA;ANTONELLA DE LUCA;FLAVIO FAZIOLI;STEFANIA SCALA;ANTONIO PINTO","4.17;2.22;1.82;1.16;1.11;1;1;1;0.97;0.8;0.78;0.77;0.73;0.68;0.66;0.66;0.61;0.6;0.56;0.55","SANDRO PIGNATA;RENATO FRANCO;ALAIN LORTHOLARY;ANDREAS DU BOIS;ANNAMARIA FERRERO;BIRGIT VOLGGER;CHRIS BROWN;CHRISTIAN JACKISCH;ELISABETH AAVALL-LUNDQVIST;FLORENCE JOLY;GUNNAR B. KRISTENSEN;IGNACE VERGOTE;JALID SEHOULI;M. HEYWOOD;NATHALIE LE FUR;P. VASEY;UWE WAGNER;VAL GEBSKI;ÉRIC PUJADE-LAURAINE;CLAUDIO ARRA","761;683;525;525;525;525;525;525;525;525;525;525;525;525;525;525;525;525;525;439","SANDRO PIGNATA;RENATO FRANCO;CLAUDIO ARRA;GAETANO ROCCO;GERARDO BOTTI;SISTO PERDONÀ;MAURIZIO MONTELLA;LUIGI BUONAGURO;STEFANIA SCALA;FRANCESCO IZZO;GENNARO CHIAPPETTA;FRANCESCO FIORE;SECONDO LASTORIA;ALFREDO BUDILLON;ANTÔNIO BARBIERI;GIUSEPPE PIROZZI;NICOLA NORMANNO;ELENA DI GENNARO;FRANCESCA BRUZZESE;ROSA CALEMMA","761;683;439;359;355;355;347;335;308;293;283;224;220;209;208;182;181;179;179;179","LUIGI BUONAGURO;CLAUDIO ARRA;RENATO FRANCO;GAETANO ROCCO;GERARDO BOTTI;ALFREDO BUDILLON;GIUSEPPE CASTELLO;MARIA LINA TORNESELLO;STEFANIA SCALA;MAURIZIO MONTELLA;ANTONIO PINTO;GENNARO CHIAPPETTA;ANNA CRISPO;ANTONELLA PETRILLO;ELENA DI GENNARO;MARIA NAPOLITANO;ROSA CALEMMA;SISTO PERDONÀ;ANTONELLO LA ROCCA;FLAVIO FAZIOLI","16;11;11;9;8;7;7;7;7;7;6;6;5;5;5;5;5;5;4;4","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;PHYSICS;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;PSYCHOLOGY;PHILOSOPHY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY","104;50;16;9;7;6;5;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;GENETICS;PATHOLOGY;SURGERY;BIOCHEMISTRY;GASTROENTEROLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PHARMACOLOGY;RADIOLOGY;VIROLOGY;GYNECOLOGY;UROLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;GENERAL SURGERY;STATISTICS","81;35;33;26;26;25;20;17;14;11;11;11;10;10;9;7;6;6;5;5","CANCER;GENE;CHEMOTHERAPY;RECEPTOR;POPULATION;ADVERSE EFFECT;DISEASE;MELANOMA;SIGNAL TRANSDUCTION;CELL CULTURE;CLINICAL TRIAL;IN VIVO;ODDS RATIO;REGIMEN;CASE-CONTROL STUDY;CELL GROWTH;HEPATOCELLULAR CARCINOMA;LUNG;LUNG CANCER;RESECTION;VEGF RECEPTORS;VIRUS","54;28;14;14;11;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5","COLORECTAL CANCER;BREAST CANCER;CHEMOKINE;ENDOMETRIAL CANCER;GENE EXPRESSION;METASTASIS;GENOTYPE;TOLERABILITY;CANCER CELL;CISPLATIN;CLINICAL ENDPOINT;HISTONE;PROSTATE CANCER;VASCULAR ENDOTHELIAL GROWTH FACTOR;CARCINOGENESIS;GEMCITABINE;MAPK/ERK PATHWAY;MUTATION;NEUTROPENIA;PROGRAMMED CELL DEATH","19;16;7;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","CXCR4;OXALIPLATIN;HISTONE DEACETYLASE;CHEMOKINE RECEPTOR;SENTINEL LYMPH NODE;CAPECITABINE;COLONOSCOPY;DNA METHYLATION;GENOTYPING;KAPOSI'S SARCOMA;LATENT TUBERCULOSIS;LNCAP;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATOSTATIN RECEPTOR 2;TAMOXIFEN;VINORELBINE;ABDOMINOPERINEAL RESECTION;ADIPOKINE;ADJUVANT CHEMOTHERAPY;ALLELE FREQUENCY;AMPHIPHILE;ATHERECTOMY;ATOMOXETINE;AXITINIB;BAG3;BOMBESIN;CANCER VACCINE;CARBOPLATIN;CASPASE;CELL CYCLE CHECKPOINT;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CLADE;COACTIVATOR;CORONAVIRUS DISEASE 2019 (COVID-19);CRYOGLOBULINEMIA;CYP2D6;CYSTECTOMY;DIFFUSING CAPACITY;DUCTAL CARCINOMA;EGFR INHIBITORS;ERBB3;ESTROGEN RECEPTOR;FLUDARABINE;FOLINIC ACID;FUNCTIONAL RESIDUAL CAPACITY;GASTRIC BYPASS;GEFITINIB;GENE DELIVERY;GERMLINE MUTATION;GROWTH FACTOR RECEPTOR INHIBITOR;HIV VACCINE;HLA-C;HOUSEKEEPING GENE;IDIOTYPE;IFOSFAMIDE;IGFBP3;IGHV@;INTERFERON Γ;KRAS;LEPTIN RECEPTOR;LEWIS LUNG CARCINOMA;LYMPHOCYTE SUBSETS;MAMMARY GLAND;MAMMOGRAPHY;MEDULLARY CARCINOMA;METASTATIC BREAST CANCER;MICROMETASTASIS;MOLECULAR MEDICINE;MULTIPOTENT STEM CELL;NEOADJUVANT THERAPY;NOREPINEPHRINE TRANSPORTER;ONCOGENE;OVARIAN TUMOR;PALONOSETRON;PARATHYROID GLAND;PARATHYROID NEOPLASM;PEMETREXED;PENTAGASTRIN;POLY ADP RIBOSE POLYMERASE;PRIMARY TUMOR;PROBAND;PROMOTER;PROPIDIUM IODIDE;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;PTEN;RADIOIMMUNOTHERAPY;RECTAL EXAMINATION;REVERSION;SENTINEL NODE;SIDE POPULATION;SOCS3;SUPAR;TAXANE;THIOTEPA;THYMIDYLATE SYNTHASE;TOLL-LIKE RECEPTOR;TRAMP;UBIQUITIN LIGASE;VANDETANIB;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VIRUS-LIKE PARTICLE","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;;AGED;ADULT;ITALY;MELANOMA;LUNG NEOPLASMS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;COLORECTAL NEOPLASMS;ADENOCARCINOMA;ENDOMETRIAL NEOPLASMS;RECTAL NEOPLASMS;AGED, 80 AND OVER;CARCINOMA, RENAL CELL;CELL LINE, TUMOR","82;50;37;36;34;32;29;21;21;20;19;18;17;17;16;15;15;13;12;12","COLORECTAL CANCER RESEARCH AND TREATMENT;MELANOMA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHOLANGIOCARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMMUNOBIOLOGY OF DENDRITIC CELLS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MICROSURGICAL RECONSTRUCTION TECHNIQUES","5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","REGIMEN;KAPOSI'S SARCOMA;MELANOMA;METASTATIC COLORECTAL CANCER;TOLERABILITY;BREAST CANCER;CANCER;CLINICAL ENDPOINT;TREATMENT;HIV;MANTLE CELL LYMPHOMA;TUMOR ANGIOGENESIS;TUMOR STAGING;VASCULAR ENDOTHELIAL GROWTH FACTOR;VORINOSTAT;ADJUVANT THERAPY;ANGIOGENIC SIGNALING;BREAST MRI;CHEMOKINE RECEPTORS;CONCOMITANT","7;5;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;ENDOMETRIAL CANCER;RECTAL CANCER;CELL LINES;PROSTATE CANCER;CANCER RISK;CASECONTROL STUDY;CUTANEOUS MELANOMA;HDAC INHIBITOR;KAPOSIS SARCOMA;LUNG CARCINOMA;PHASE II;ABSTRACT IIN;AIDS ERA;ANTITUMOR EFFECT;BACILLE CALMETTEGUÉRIN;CANCER CELL;CANCER CELLS;CANCER PATIENTS;CELL CARCINOMA;CIRCULATING ENDOTHELIAL;CLINICAL MANAGEMENT;CLINICAL OUTCOME;CLINICAL TRIAL;ELDERLY PATIENTS;ENDOTHELIAL CELLS;FIRST-LINE TREATMENT;GASTRIC CANCER;GENE TRANSFER","7;6;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CELL LINES;UNIPORTAL VATS;CANCER CELL;CANCER CELLS;LUNG CARCINOMA;LYMPH NODE;RECTAL CANCER;CXCR EXPRESSION;ENDOMETRIAL CANCER;LUNG CANCER;RET MUTATIONS;STATISTICALLY SIGNIFICANT;ADNEXAL MASSES;CANCER PATIENTS;CLINICAL PRACTICE;GENE DELIVERY;GERMLINE RET;GROWTH FACTOR;HMGA PROTEINS;MIDDLE LOBE;NEDD- EXPRESSION;NEDD- OVEREXPRESSION;PERIPHERAL NODULES;PTEN PROTEIN;RENAL CANCER;TUMOR GROWTH;UVEAL MELANOMA;VASCULAR EVENT;ARTERY DISEASE","15;8;8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3",19,0.16,3,6.8,2,15,2,2,2,1.5,1,2,0,0,0,13,13,13,2,2,2,1,1,1,2,2,2,10.6,3,19,0,0,0,0,0,0,3,1,5,0,0,0,1,1,1,0,0,0,1,1,1,2.67,1,4,0,0,0,0.2,0,1,0,0,0,53.2,12,133,53.4,12,133
"IRCCS_PASCALE",2011,134,10.955223880597,3.11194029850746,0.321342925659472,0.313432835820896,0.373134328358209,0.208955223880597,0.470149253731343,3,72,33,12,9,0.54,0.25,0.09,0.07,101.87,2.39490723551351,0.373134328358209,0.865671641791045,NA,0.504592322541,0.40599700149925,0.398613103778097,0.438281901584654,"GERARDO BOTTI;RENATO FRANCO;LUIGI BUONAGURO;CLAUDIO ARRA;GAETANO ROCCO;NICOLA NORMANNO;ANTONIO PINTO;ALFREDO BUDILLON;MARIA LINA TORNESELLO;MASSIMO DI MAÏO;ANTÔNIO BARBIERI;MICHELE CARAGLIA;RENATO TALAMINI;SIMONA LOSITO;LUIGI ALOJ;CARLO LA VECCHIA;MARIA CATERINA TURCO;ANTONELLA DE LUCA;MONICA CANTILE;NICOLA MARTUCCI","14;13;12;10;9;9;8;8;8;7;7;7;7;6;6;6;5;5;5;5","LUIGI BUONAGURO;GAETANO ROCCO;NICOLA NORMANNO;MARIA LINA TORNESELLO;RENATO FRANCO;GERARDO BOTTI;FRANCESCO PERRI;CLAUDIO ARRA;NICOLA MARTUCCI;ALFREDO BUDILLON;RENATO TALAMINI;ANTONIO PINTO;CONO SCAFFA;MASSIMO DI MAÏO;ANTONELLA DE LUCA;CARLO LA VECCHIA;ANTÔNIO BARBIERI;SUSAN COSTANTINI;G MAININI;SIMONA LOSITO","2.51;2.23;1.93;1.4;1.38;1.38;1;0.91;0.81;0.77;0.71;0.71;0.67;0.66;0.65;0.64;0.61;0.6;0.58;0.55","GERARDO BOTTI;RENATO FRANCO;LUIGI BUONAGURO;CLAUDIO ARRA;GAETANO ROCCO;NICOLA NORMANNO;ANTONIO PINTO;ALFREDO BUDILLON;MARIA LINA TORNESELLO;MASSIMO DI MAÏO;ANTÔNIO BARBIERI;SIMONA LOSITO;LUIGI ALOJ;ANTONELLA DE LUCA;MONICA CANTILE;NICOLA MARTUCCI;ROSARIA DE FILIPPI;EMANUELA MORELLI;PAOLO A. ASCIERTO;ELENA DI GENNARO","14;13;12;10;9;9;8;8;8;7;7;6;6;5;5;5;5;5;4;4","LUIGI BUONAGURO;GAETANO ROCCO;NICOLA NORMANNO;MARIA LINA TORNESELLO;RENATO FRANCO;GERARDO BOTTI;FRANCESCO PERRI;CLAUDIO ARRA;NICOLA MARTUCCI;ALFREDO BUDILLON;ANTONIO PINTO;CONO SCAFFA;MASSIMO DI MAÏO;ANTONELLA DE LUCA;ANTÔNIO BARBIERI;SUSAN COSTANTINI;G MAININI;SIMONA LOSITO;LUIGI ALOJ;GIUSEPPINA LIGUORI","2.51;2.23;1.93;1.4;1.38;1.38;1;0.91;0.81;0.77;0.71;0.67;0.66;0.65;0.61;0.6;0.58;0.55;0.54;0.5","PAOLO A. ASCIERTO;ANTONI RIBAS;JOHN M. KIRKWOOD;KEITH T. FLAHERTY;MICHELE MAIO;ALESSANDRO TESTORI;ALEXANDER M.M. EGGERMONT;AXEL HAUSCHILD;B. NELSON;BRIGITTE DRÉNO;CAROLINE ROBERT;CLAUS GARBE;CÉLÈSTE LEBBÉ;DAVID HOGG;DIRK SCHADENDORF;GRANT A. MCARTHUR;JAMES LARKIN;JEANNIE HOU;JEFFREY A. SOSMAN;JIANG LI","7372;7347;7347;7347;7347;7317;7317;7317;7317;7317;7317;7317;7317;7317;7317;7317;7317;7317;7317;7317","PAOLO A. ASCIERTO;ORLANDO CATALANO;SECONDO LASTORIA;RENATO FRANCO;FRANCESCO IZZO;ALFREDO BUDILLON;GERARDO BOTTI;TANIA MOCCIA;LUIGI BUONAGURO;GAETANO ROCCO;CLAUDIO ARRA;GIUSEPPINA LIGUORI;MARIA LINA TORNESELLO;MAURIZIO MONTELLA;NICOLA NORMANNO;CARMINE CARBONE;DAVIDE MELISI;GENNI PARADISO;JAMES L. ABBRUZZESE;PAUL J. CHIAO","7372;1095;662;660;632;532;471;374;351;324;302;286;282;281;265;237;237;237;237;237","RENATO FRANCO;GERARDO BOTTI;LUIGI BUONAGURO;CLAUDIO ARRA;GAETANO ROCCO;NICOLA NORMANNO;ANTONIO PINTO;MARIA LINA TORNESELLO;ALFREDO BUDILLON;MASSIMO DI MAÏO;ANTÔNIO BARBIERI;LUIGI ALOJ;ANTONELLA DE LUCA;ANTONELLO LA ROCCA;NICOLA MARTUCCI;SIMONA LOSITO;EMANUELA MORELLI;FERDINANDO FRIGERI;FRANCESCO IZZO;FRANCESCO VOLZONE","13;13;12;9;9;9;8;8;8;7;6;6;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATERIALS SCIENCE;PHYSICS;PSYCHOLOGY;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;PHILOSOPHY","114;64;25;6;4;4;4;3;3;2;2;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;GENETICS;BIOCHEMISTRY;SURGERY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;PHARMACOLOGY;RADIOLOGY;CELL BIOLOGY;BIOTECHNOLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;ENVIRONMENTAL HEALTH;VIROLOGY;ORGANIC CHEMISTRY;PALEONTOLOGY;GYNECOLOGY","84;42;36;30;25;25;21;18;17;17;17;13;11;11;10;9;9;8;8;7","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;RECEPTOR;IN VIVO;CELL CULTURE;HEPATOCELLULAR CARCINOMA;POPULATION;ADVERSE EFFECT;APOPTOSIS;IMMUNE SYSTEM;IN VITRO;LYMPHOMA;MELANOMA;ODDS RATIO;STAGE (STRATIGRAPHY);CELL GROWTH;LUNG CANCER;TOXICITY","62;24;23;12;12;10;9;9;9;8;8;8;8;7;7;7;7;6;6;6","BREAST CANCER;METASTASIS;COLORECTAL CANCER;CANCER CELL;EPIDERMAL GROWTH FACTOR RECEPTOR;CARDIOTOXICITY;NEUTROPENIA;TOLERABILITY;CELL CYCLE;CHEMOKINE;CYCLOPHOSPHAMIDE;ENDOMETRIAL CANCER;GENE EXPRESSION;GENOTYPE;MUTATION;PROSTATE CANCER;TRANSCRIPTION FACTOR;ALLELE;BEVACIZUMAB;BIODISTRIBUTION;CHOLECYSTOKININ;DOTA;GASTRIN;GEMCITABINE;GENE KNOCKDOWN;HAZARD RATIO;HISTONE;LIVER CANCER;PANCREATIC CANCER;PROGRAMMED CELL DEATH;RITUXIMAB;THYROID CANCER;TRANSFECTION;UNIVARIATE ANALYSIS","15;10;9;6;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","TRASTUZUMAB;KRAS;BAG3;GEFITINIB;HISTONE DEACETYLASE;HOX GENE;CARBOPLATIN;CETUXIMAB;CHEMOKINE RECEPTOR;CHOLECYSTOKININ B RECEPTOR;CHOLECYSTOKININ RECEPTOR;CIRCULATING TUMOR CELL;CXCR4;DNA METHYLATION;ERLOTINIB;FEBRILE NEUTROPENIA;HOMEOBOX;HOMEOTIC GENE;METASTATIC BREAST CANCER;ONCOGENE;POINT MUTATION;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VINCRISTINE","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;ANTINEOPLASTIC AGENTS;ADULT;AGED;MELANOMA;;LIVER NEOPLASMS;ANIMALS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;CARCINOMA, HEPATOCELLULAR;COLORECTAL NEOPLASMS;SKIN NEOPLASMS;BREAST NEOPLASMS;CELL LINE, TUMOR;AGED, 80 AND OVER;CELL PROLIFERATION","101;62;48;47;46;40;38;33;27;24;23;22;22;21;21;20;19;18;17;17","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HER2 SIGNALING IN BREAST CANCER TREATMENT;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MELANOMA;MOLECULAR CHAPERONES IN PROTEIN FOLDING AND DISEASE;ROLE OF HISTONE DEACETYLASES IN CELLULAR REGULATION;CANCER STEM CELLS AND TUMOR METASTASIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;ECONOMIC BURDEN OF CANCER TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY","4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","CANCER;BREAST CANCER;CARDIOTHORACIC SURGERY;CARDIOTOXICITY;TOLERABILITY;MELANOMA;METASTATIC COLORECTAL CANCER;REGIMEN;TUMOR MICROENVIRONMENT;ADJUVANT THERAPY;BAG3;BIODISTRIBUTION;CANCER THERAPY;DOTA;HEPATOCELLULAR CARCINOMA;KRAS MUTATIONS;LAPATINIB;LIVER CANCER;PEPTIDE RECEPTOR RADIONUCLIDE THERAPY;REFRACTORY (PLANETARY SCIENCE)","8;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;HEPATOCELLULAR CARCINOMA;CANCER CELLS;COLORECTAL CANCER;LUNG CANCER;COMPARATIVE STUDY;ELDERLY PATIENTS;III TRIAL;LOCALLY ADVANCED;PANCREATIC CANCER;PHASE III;THORACIC SURGERY;ZOLEDRONIC ACID;ABSTRACT HISTONE;ADJUVANT THERAPY;ADJUVANT TREATMENT;ANTI-CANCER DRUGS;ANTITUMOR ACTIVITY;BCELL LYMPHOMA;CANCER CELL;CANCER RISK;CARCINOMA HCC;CELL LINES;CELL LUNG;CIRCULATING TUMOR;CLINICAL PRACTICE;COLORECTAL CARCINOMA;DEACETYLASE INHIBITORS;ENDOTHELIAL GROWTH;FINAL RESULTS","10;8;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;FONDAZIONE GPASCALE;GPASCALE IRCCS;ISTITUTO NAZIONALE;NAZIONALE TUMORI;STEM CELL;TUMORI FONDAZIONE;UNIT ISTITUTO;CELL TRANSPLANTATION;IRCCS NAPLESSEARCH;TRANSPLANTATION UNIT;CD CD;TURCO MC;MONOCLONAL ANTIBODY;POSITIVE CELLS;CELL LINES;PANCREATIC CANCER;T-CELL LYMPHOMA;MC LEONE;TRITON X-;TUMOR CELLS;BREAST CANCER;GROWTH FACTOR;BAG PROTEIN;CANCER CELLS;CONFIDENCE INTERVAL;GE HEALTHCARE;PETRILLO MD;BRAIN TUMOR","49;41;26;26;26;26;26;26;26;25;24;23;20;19;15;15;14;14;13;12;11;11;10;10;9;9;9;9;9;8",39,0.29,3,19.15,1,178,5.5,3,8,5,1,9,0,0,0,5,1,9,19.22,1,130,0,0,0,3.5,2,5,21.62,1,202,0,0,0,1,1,1,8.67,3,14,0,0,0,3.33,1,7,1,1,1,2.5,2,3,6,2,9,1,1,1,0.31,0,2,0.08,0,1,302.69,28,3188,303.08,28,3191
"IRCCS_PASCALE",2012,195,11.4153846153846,3.48205128205128,0.287187039764359,0.394871794871795,0.333333333333333,0.138461538461538,0.528205128205128,5,100,24,25,24,0.51,0.12,0.13,0.12,29.5,0.706215270968162,0.37948717948718,0.825641025641026,5.93325092707045,0.537689596830111,0.505929487179487,0.482484472049689,0.430075187969925,"PAOLO A. ASCIERTO;RENATO FRANCO;LUIGI BUONAGURO;GERARDO BOTTI;MARIA LINA TORNESELLO;CLAUDIO ARRA;PAOLA QUEIROLO;GAETANO ROCCO;NICOLA NORMANNO;STEFANIA SCALA;NICOLA MOZZILLO;GIUSEPPE PALMIERI;MICHELE MAIO;ALESSANDRO TESTORI;ESTER SIMEONE;GIUSEPPE PALMA;MARIA NAPOLITANO;MASSIMO DI MAÏO;CORRADO CARACÒ;MONICA CANTILE","29;22;19;18;15;13;13;12;11;11;11;9;9;9;9;8;8;7;7;7","GAETANO ROCCO;LUIGI BUONAGURO;PAOLO A. ASCIERTO;GERARDO BOTTI;MARIA LINA TORNESELLO;RENATO FRANCO;FRANCO M. BUONAGURO;NICOLA NORMANNO;PAOLA QUEIROLO;CLAUDIO ARRA;FRANCESCA IACOBELLIS;SERGIO VENANZIO SETOLA;MONICA CANTILE;MARIA NAPOLITANO;ESTER SIMEONE;NICOLA MOZZILLO;STEFANIA SCALA;MASSIMO DI MAÏO;RAFFAELE DI FRANCIA;ANTONGIULIO FAGGIANO","4.7;3.14;2.54;2.52;2.37;2.23;1.13;1.09;1.09;1.08;1.06;0.96;0.94;0.91;0.87;0.86;0.84;0.8;0.77;0.7","PAOLO A. ASCIERTO;RENATO FRANCO;LUIGI BUONAGURO;GERARDO BOTTI;MARIA LINA TORNESELLO;CLAUDIO ARRA;GAETANO ROCCO;NICOLA NORMANNO;STEFANIA SCALA;NICOLA MOZZILLO;GIUSEPPE PALMIERI;ESTER SIMEONE;GIUSEPPE PALMA;MARIA NAPOLITANO;MASSIMO DI MAÏO;CORRADO CARACÒ;MONICA CANTILE;CARLO G. TOCCHETTI;ANTÔNIO BARBIERI;ANTONGIULIO FAGGIANO","29;22;19;18;15;13;12;11;11;11;9;9;8;8;7;7;7;7;7;6","GAETANO ROCCO;LUIGI BUONAGURO;PAOLO A. ASCIERTO;GERARDO BOTTI;MARIA LINA TORNESELLO;RENATO FRANCO;FRANCO M. BUONAGURO;NICOLA NORMANNO;CLAUDIO ARRA;FRANCESCA IACOBELLIS;SERGIO VENANZIO SETOLA;MONICA CANTILE;MARIA NAPOLITANO;ESTER SIMEONE;NICOLA MOZZILLO;STEFANIA SCALA;MASSIMO DI MAÏO;RAFFAELE DI FRANCIA;ANTONGIULIO FAGGIANO;NICOLA MARTUCCI","4.7;3.14;2.54;2.52;2.37;2.23;1.13;1.09;1.08;1.06;0.96;0.94;0.91;0.87;0.86;0.84;0.8;0.77;0.7;0.67","RENATO FRANCO;GERARDO BOTTI;PAOLO A. ASCIERTO;NICOLA MOZZILLO;STEFANIA STAIBANO;GIUSEPPE PALMIERI;MARIA COLOMBINO;ANNAMARIA COLAO;ANTONGIULIO FAGGIANO;CLAUDIO ARRA;CORRADO CARACÒ;OSCAR NAPPI;ESTER FONSATTI;ANTONIO COSSU;AMELIA LISSIA;CARLO LA VECCHIA;CORRADO RUBINO;DANIELA MASSI;MARIA CRISTINA SINI;VINCENZO DE GIORGI","1358;1060;1057;803;635;589;513;494;494;492;471;470;444;439;438;438;438;438;438;438","RENATO FRANCO;GERARDO BOTTI;PAOLO A. ASCIERTO;ANTONGIULIO FAGGIANO;CLAUDIO ARRA;ANTONELLA MANCA;GIUSEPPE PALMIERI;MARIA CRISTINA SINI;MILENA CASULA;LUIGI BUONAGURO;MAURIZIO MONTELLA;NICOLA MOZZILLO;MARIA LINA TORNESELLO;NICOLA NORMANNO;GAETANO ROCCO;GIUSEPPE PALMA;SISTO PERDONÀ;ANTONIO LUCIANO;FRANCESCO IZZO;GABRIELLA AQUINO","923;625;622;494;492;435;435;435;435;382;368;368;312;286;280;259;237;225;222;210","PAOLO A. ASCIERTO;RENATO FRANCO;LUIGI BUONAGURO;GERARDO BOTTI;MARIA LINA TORNESELLO;CLAUDIO ARRA;GAETANO ROCCO;NICOLA NORMANNO;NICOLA MOZZILLO;STEFANIA SCALA;ESTER SIMEONE;GIUSEPPE PALMA;MONICA CANTILE;MARIA NAPOLITANO;ANTÔNIO BARBIERI;CARLO G. TOCCHETTI;ANTONGIULIO FAGGIANO;DOMENICA REA;CORRADO CARACÒ;GABRIELLA AQUINO","28;21;17;17;13;13;12;11;10;10;9;8;7;7;7;7;6;6;6;6","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;ECONOMICS;BUSINESS;ENGINEERING;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;MATERIALS SCIENCE","174;102;29;12;8;4;3;3;2;2;2;2;2;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;CELL BIOLOGY;PALEONTOLOGY;RADIOLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;PHARMACOLOGY;VIROLOGY;BIOINFORMATICS;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;GYNECOLOGY;NUCLEAR MEDICINE","139;72;72;50;48;34;33;29;28;20;16;15;14;12;12;11;9;7;7;7;7","CANCER;GENE;MELANOMA;CHEMOTHERAPY;LUNG CANCER;ADVERSE EFFECT;APOPTOSIS;CONFIDENCE INTERVAL;ANTIBODY;CLINICAL TRIAL;IMMUNOHISTOCHEMISTRY;RECEPTOR;CELL CULTURE;IMMUNE SYSTEM;LYMPHOMA;RADIATION THERAPY;ODDS RATIO;SIGNAL TRANSDUCTION;STAGE (STRATIGRAPHY);ADJUVANT;CELL;DISEASE;IN VITRO;POPULATION;RANDOMIZED CONTROLLED TRIAL;THYROID;VIRUS","111;42;32;22;14;12;12;12;11;11;11;10;9;9;9;9;8;8;8;7;7;7;7;7;7;7;7","BREAST CANCER;COLORECTAL CANCER;IMMUNOTHERAPY;METASTATIC MELANOMA;METASTASIS;MUTATION;ADENOCARCINOMA;CARCINOGENESIS;GENE EXPRESSION;HAZARD RATIO;CELL CYCLE;CERVICAL CANCER;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;FLUOROURACIL;GENOTYPE;PROSTATE CANCER;THYROID CARCINOMA;CANCER CELL;CARDIOTOXICITY;CHEMOKINE","25;24;17;12;11;11;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5","IPILIMUMAB;KRAS;VEMURAFENIB;IRINOTECAN;TRASTUZUMAB;CETUXIMAB;FOLINIC ACID;OXALIPLATIN;PAPILLOMAVIRIDAE;TUMOR SUPPRESSOR GENE;CHEMOKINE RECEPTOR;DNA METHYLATION;ESTROGEN RECEPTOR;GERMLINE MUTATION;V600E;AKT1;ANTHRACYCLINE;BAG3;BOMBESIN;CANCER IMMUNOTHERAPY;CXCR4;GEFITINIB;GENOTYPING;GERMINAL CENTER;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IN SITU HYBRIDIZATION;INTRAEPITHELIAL NEOPLASIA;MAMMOGRAPHY;PCA3;PHARMACOGENETICS;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;PTEN;SANGER SEQUENCING;VINCRISTINE","13;10;10;6;5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;LUNG NEOPLASMS;AGED;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;MELANOMA;ADULT;BREAST NEOPLASMS;NEOPLASMS;ANIMALS;ITALY;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;TREATMENT OUTCOME;ADENOCARCINOMA;PROSTATIC NEOPLASMS","99;85;58;57;48;46;43;29;29;28;26;26;24;23;23;21;20;20;19;18","LYMPHOID NEOPLASMS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MELANOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;CANCER STEM CELLS AND TUMOR METASTASIS;CARDIOTOXICITY OF CANCER TREATMENTS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MOLECULAR RESEARCH ON BREAST CANCER;MTOR SIGNALING IN GROWTH AND DISEASE","10;10;8;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","MELANOMA;CLINICAL ENDPOINT;TUMOR REGRESSION;ADJUVANT THERAPY;BIOMARKER ANALYSIS;BRAF GENE;BREAST CANCER;CANCER IMMUNOTHERAPY;CARDIOTOXICITY;EGFR MUTATIONS;EXPANDED ACCESS;DABRAFENIB;DACARBAZINE;FOLINIC ACID;GRADING (ENGINEERING);HEPATOCELLULAR CARCINOMA;HPV VACCINATION;LAPATINIB;NEUROENDOCRINE TUMORS;PAPILLOMAVIRIDAE","19;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","LUNG CANCER;BREAST CANCER;METASTATIC MELANOMA;COLORECTAL CANCER;CANCER PATIENTS;ACCESS PROGRAMME;CANCER CELLS;EXPANDED ACCESS;HEPATOCELLULAR CARCINOMA;PROGRAMME EAP;ADVANCED MELANOMA;BRAIN METASTASES;CANCER RISK;GASTRIC CANCER;NON-SMALL-CELL LUNG;PATIENTS PTS;PHASE III;SQUAMOUS CELL;THYROID CARCINOMA;CANCER NSCLC;CELL LUNG;GROWTH FACTOR;HODGKIN LYMPHOMA;IDIOPATHIC PULMONARY;ITALIAN NETWORK;LOCALLY ADVANCED;PROSTATE CANCER;PULMONARY FIBROSIS;STAGE III;ACID LV","11;10;10;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","PUBMED SCOPUS;CROSSREF PUBMED;LUNG CANCER;CELL LINES;TURCO MC;BAG EXPRESSION;PANCREATIC CANCER;BRISTOL-MYERS SQUIBB;ADVERSE EVENTS;BAG PROTEIN;TUMOR SUPPRESSOR;RECEIVED HONORARIA;CANCER CELLS;MALT LYMPHOMAS;MC LEONE;PATHOL -ABSTRACT;ADVISORY BOARD;BRAIN METASTASES;MEDIAN MONTHS;PROGRESSION-FREE SURVIVAL;BAG MRNA;BREAST CANCER;GROWTH FACTOR;MC ROSATI;MERCK SHARP;PROTEIN TYROSINE;SHARP DOHME;STAGE IV;TISSUE SAMPLES;DISEASE CONTROL","82;55;33;30;26;23;23;17;15;14;14;13;12;12;12;12;11;11;11;11;10;10;10;10;10;10;10;10;10;9",52,0.27,3,8.2,2,49,2.33,1,5,1.25,1,2,0,0,0,5.5,1,10,4.7,1,16,1,1,1,1,1,1,9.93,2,58,0,0,0,0,0,0,8.8,1,31,1.5,1,2,1,1,1,1,1,1,6,3,9,5.8,1,20,2,2,2,0.07,0,1,0,0,0,52.4,13,150,52.47,13,150
"IRCCS_PASCALE",2013,228,11.4385964912281,4.1359649122807,0.241781548250265,0.464912280701754,0.43421052631579,0.166666666666667,0.473684210526316,10,104,40,22,34,0.46,0.18,0.1,0.15,29.68,0.850605990837674,0.289473684210526,0.767543859649123,6.2281081081081,0.516978205675496,0.456798245614035,0.385377358490566,0.472962680883473,"PAOLO A. ASCIERTO;RENATO FRANCO;GERARDO BOTTI;ESTER SIMEONE;NICOLA MOZZILLO;ANTONELLA PETRILLO;NICOLA NORMANNO;LUIGI BUONAGURO;PAOLA QUEIROLO;GAETANO ROCCO;CORRADO CARACÒ;MONICA CANTILE;PAOLO MUTO;CLAUDIO ARRA;ANTONIO M. GRIMALDI;FABIANA TATANGELO;SIMONA LOSITO;GENNARO CILIBERTO;FRANCESCO IZZO;MASSIMO DI MAÏO","39;25;24;14;14;13;12;12;12;11;11;11;11;11;11;10;10;10;10;9","PAOLO A. ASCIERTO;GAETANO ROCCO;LUIGI BUONAGURO;RENATO FRANCO;GERARDO BOTTI;SIMONA LOSITO;FRANCO M. BUONAGURO;NICOLA MOZZILLO;SUSAN COSTANTINI;MONICA CANTILE;ANTONELLA PETRILLO;PAOLO MUTO;NICOLA NORMANNO;GAETANO CORAZZELLI;ESTER SIMEONE;CLAUDIO ARRA;CEINGE BIOTECNOLOGIE;BONITO;GIUSEPPE PIROZZI;FRANCESCO IZZO","5.34;3.96;3.1;2.36;2.21;1.97;1.68;1.33;1.25;1.24;1.24;1.19;1.12;1.09;1.07;1.06;1;1;0.99;0.98","PAOLO A. ASCIERTO;RENATO FRANCO;GERARDO BOTTI;ESTER SIMEONE;NICOLA MOZZILLO;ANTONELLA PETRILLO;NICOLA NORMANNO;LUIGI BUONAGURO;GAETANO ROCCO;CORRADO CARACÒ;MONICA CANTILE;PAOLO MUTO;CLAUDIO ARRA;ANTONIO M. GRIMALDI;FABIANA TATANGELO;SIMONA LOSITO;GENNARO CILIBERTO;FRANCESCO IZZO;MASSIMO DI MAÏO;SISTO PERDONÀ","39;25;24;14;14;13;12;12;11;11;11;11;11;11;10;10;10;10;9;9","PAOLO A. ASCIERTO;GAETANO ROCCO;LUIGI BUONAGURO;RENATO FRANCO;GERARDO BOTTI;SIMONA LOSITO;FRANCO M. BUONAGURO;NICOLA MOZZILLO;SUSAN COSTANTINI;MONICA CANTILE;ANTONELLA PETRILLO;PAOLO MUTO;NICOLA NORMANNO;GAETANO CORAZZELLI;ESTER SIMEONE;CLAUDIO ARRA;CEINGE BIOTECNOLOGIE;BONITO;GIUSEPPE PIROZZI;FRANCESCO IZZO","5.34;3.96;3.1;2.36;2.21;1.97;1.68;1.33;1.25;1.24;1.24;1.19;1.12;1.09;1.07;1.06;1;1;0.99;0.98","PAOLO A. ASCIERTO;PAOLA QUEIROLO;AXEL HAUSCHILD;GERARDO BOTTI;REINHARD DUMMER;ANGELA ZUBEL;ANNIE ST‐PIERRE;CARLA M.L. VAN HERPEN;CAROLA BERKING;CHRISTIAN U. BLANK;DIRK SCHADENDORF;FAIZ NIAZI;J. THADDEUS BECK;MALTE PETERS;SANJIV S. AGARWALA;SIMON WANDEL;RENATO FRANCO;GAETANO ROCCO;NICOLA NORMANNO;SISTO PERDONÀ","1800;1019;625;624;618;613;613;613;613;613;613;613;613;613;613;613;528;467;444;417","PAOLO A. ASCIERTO;GERARDO BOTTI;RENATO FRANCO;NICOLA NORMANNO;SISTO PERDONÀ;ANTONIO M. GRIMALDI;GENNARO CILIBERTO;GAETANO ROCCO;ESTER SIMEONE;CLAUDIO ARRA;NICOLA MOZZILLO;FRANCESCO IZZO;MAURIZIO MONTELLA;GIUSEPPE PIROZZI;ANTÔNIO BARBIERI;CORRADO CARACÒ;FABIANA TATANGELO;ANTONELLA PETRILLO;ANTONIO LUCIANO;ANTONELLO LA ROCCA","1800;601;511;444;417;401;400;390;381;378;348;327;322;310;289;281;278;251;251;238","PAOLO A. ASCIERTO;RENATO FRANCO;GERARDO BOTTI;ESTER SIMEONE;NICOLA MOZZILLO;ANTONELLA PETRILLO;NICOLA NORMANNO;CORRADO CARACÒ;LUIGI BUONAGURO;PAOLO MUTO;ANTONIO M. GRIMALDI;CLAUDIO ARRA;SIMONA LOSITO;FABIANA TATANGELO;GENNARO CILIBERTO;FRANCESCO IZZO;MONICA CANTILE;PAOLO DELRIO;SISTO PERDONÀ;MAURIZIO MONTELLA","38;23;23;14;14;13;12;11;11;11;11;10;10;10;10;10;10;9;9;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE;PSYCHOLOGY","210;94;24;15;8;5;5;3;3;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;BIOCHEMISTRY;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;RADIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;NUCLEAR MEDICINE;GYNECOLOGY;PHARMACOLOGY;VIROLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;OPTICS;UROLOGY","180;103;89;54;50;38;37;37;24;23;17;16;16;12;11;11;10;9;9;9;9","CANCER;CHEMOTHERAPY;GENE;MELANOMA;LUNG CANCER;ADVERSE EFFECT;CLINICAL TRIAL;IMMUNOHISTOCHEMISTRY;RADIATION THERAPY;POPULATION;RECEPTOR;ANTIBODY;VIRUS;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;COHORT;IN VITRO;HEPATOCELLULAR CARCINOMA;IN VIVO;SIGNAL TRANSDUCTION;STEM CELL","136;46;43;38;22;19;17;16;16;15;15;14;14;13;12;10;10;9;9;8;8;8;8","BREAST CANCER;COLORECTAL CANCER;IMMUNOTHERAPY;METASTASIS;METASTATIC MELANOMA;CLINICAL ENDPOINT;MONOCLONAL ANTIBODY;MUTATION;CISPLATIN;CANCER CELL;EPIDERMAL GROWTH FACTOR RECEPTOR;OVARIAN CANCER;PROSTATE CANCER;BEVACIZUMAB;GEMCITABINE;HEPATITIS C VIRUS;NEUTROPENIA;PROGRESSIVE DISEASE;T CELL;CANCER STEM CELL;CHEMOKINE;CHEMORADIOTHERAPY;MAPK/ERK PATHWAY;PI3K/AKT/MTOR PATHWAY","36;29;20;14;13;11;10;10;9;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6","IPILIMUMAB;KRAS;VEMURAFENIB;CARBOPLATIN;ESTROGEN RECEPTOR;CETUXIMAB;METASTATIC BREAST CANCER;ONCOGENE;OXALIPLATIN;CHEMOKINE RECEPTOR;CXCR4;BONE METASTASIS;CAPECITABINE;ELECTROCHEMOTHERAPY;ERLOTINIB;GERMLINE MUTATION;PTEN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAMOXIFEN;TRASTUZUMAB","18;9;8;6;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MIDDLE AGED;MALE;AGED;LUNG NEOPLASMS;BREAST NEOPLASMS;MELANOMA;ANTINEOPLASTIC AGENTS;ADULT;SKIN NEOPLASMS;LIVER NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;ANTIBODIES, MONOCLONAL;ITALY;ANIMALS;CARCINOMA, NON-SMALL-CELL LUNG;PROSTATIC NEOPLASMS","124;95;85;70;69;61;54;52;51;50;46;39;36;35;31;29;29;28;27;27","MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN LUNG CANCER RESEARCH;MELANOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS;CANCER IMMUNOTHERAPY;CARDIOTOXICITY OF CANCER TREATMENTS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ROLE OF CHEMOKINE RECEPTORS IN CANCER METASTASIS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;IMMUNOBIOLOGY OF DENDRITIC CELLS;SARCOMA RESEARCH AND TREATMENT;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY","13;11;8;6;6;6;6;6;5;5;5;5;4;4;4;4;4;3;3;3","MELANOMA;CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;BREAST CANCER;HEPATOCELLULAR CARCINOMA;CANCER STEM CELLS;CARBOPLATIN;CHEMORADIOTHERAPY;RADIOTHERAPY;SURGICAL ONCOLOGY;ADJUVANT THERAPY;EXPANDED ACCESS;NEOADJUVANT THERAPY;TOLERABILITY;CANCER;CANCER IMAGING;CARDIOTOXICITY;DACARBAZINE;LIVER CANCER;METASTATIC BREAST CANCER","24;11;9;8;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4","BREAST CANCER;LUNG CANCER;COLORECTAL CANCER;HEPATOCELLULAR CARCINOMA;PROSTATE CANCER;CANCER PATIENTS;METASTATIC MELANOMA;OVARIAN CANCER;PHASE III;ACCESS PROGRAMME;ADVANCED MELANOMA;EXPANDED ACCESS;MELANOMA PATIENTS;CELL CARCINOMA;II STUDY;IPILIMUMAB EXPANDED;METASTATIC COLORECTAL;PHASE II;PROGRAMME EAP;CELL LUNG;GROWTH FACTOR;ITALIAN COHORT;NON-SMALL CELL;PATIENTS TREATED;RECTAL CANCER;ADVANCED NON-SMALL;BRAF INHIBITORS;BREAST MRI;CANCER STEM;COMBINATION THERAPY","21;14;9;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3","PUBMED SCOPUS;CHEST WALL;SURG -ABSTRACT;BREAST CANCER;CARDIOVASC SURG;THORAC CARDIOVASC;UNIPORTAL VATS;WALL RESECTION;LUNG CANCER;ANTERIOR CHEST;BIOMIMESISSEMIN THORAC;CD CD;CELL LINES;TITANIUM PLATES;CHONDROSARCOMAJ THORAC;CANCER CELLS;DIMEGLUMINE-ENHANCED MRI;GROWTH FACTOR;ADVANCED MELANOMA;PROSTATE CANCER;SCHOLAR ROCCO;THORAC SURG;ALTHE COMBINATION;ARTIFICIAL ANTERIOR;CANCER PATIENTS;CHEST CAGE;EXTENSIVE DEMOLITION;INSULIN RESISTANCE;LIVER METASTASES;MULTIPLE MATERIALS","61;58;45;43;37;37;28;24;23;20;19;16;15;15;14;13;12;11;10;10;10;10;9;9;9;9;9;9;9;9",67,0.29,3,11.18,2,44,9.75,1,15,1.25,1,2,1,1,1,4,1,12,7.43,1,41,1,1,1,1.33,1,2,11.94,2,49,0,0,0,0,0,0,4.64,1,28,1,1,1,1,1,1,1,1,1,1.5,1,3,4,1,19,1.8,1,5,0.12,0,1,0,0,0,86.71,15,288,86.82,15,289
"IRCCS_PASCALE",2014,252,13.6071428571429,3.71031746031746,0.26951871657754,0.380952380952381,0.376984126984127,0.0873015873015873,0.53968253968254,11,125,58,21,17,0.5,0.23,0.08,0.07,60.31,1.59573540863588,0.376984126984127,0.793650793650794,6.12327506899723,0.541903619253108,0.44239035337974,0.477435897435897,0.574175824175824,"PAOLO A. ASCIERTO;GERARDO BOTTI;GENNARO CILIBERTO;ESTER SIMEONE;GAETANO ROCCO;RENATO FRANCO;NICOLA MOZZILLO;MICHELE MAIO;ANTONELLA PETRILLO;ANTONIO M. GRIMALDI;MASSIMO DI MAÏO;CLAUDIO ARRA;VANNA CHIARION‐SILENI;PAOLA QUEIROLO;MONICA CANTILE;ALESSANDRO TESTORI;MICHELINO DE LAURENTIIS;NICOLA NORMANNO;SUSAN COSTANTINI;ALFREDO FUSCO","49;32;18;17;16;15;15;14;13;13;12;12;12;12;11;11;11;10;10;9","PAOLO A. ASCIERTO;LUIGI BUONAGURO;GERARDO BOTTI;MARCO CASCELLA;ANTONELLA PETRILLO;SUSAN COSTANTINI;GENNARO CILIBERTO;GAETANO ROCCO;GIUSEPPE D’AIUTO;ESTER SIMEONE;MONICA CANTILE;ANGELA DE MONACO;RENATO FRANCO;FILIPPO RUSSO;CLAUDIO ARRA;NICOLA MOZZILLO;ROBERTA FUSCO;E LA;GIUSEPPE CASTELLO;MASSIMO DI MAÏO","6.06;4.21;2.69;2;1.6;1.54;1.5;1.31;1.28;1.24;1.23;1.17;1.16;1.13;1.11;1.06;1.02;1;0.99;0.96","PAOLO A. ASCIERTO;GERARDO BOTTI;GENNARO CILIBERTO;ESTER SIMEONE;GAETANO ROCCO;RENATO FRANCO;NICOLA MOZZILLO;ANTONELLA PETRILLO;ANTONIO M. GRIMALDI;MASSIMO DI MAÏO;CLAUDIO ARRA;MONICA CANTILE;MICHELINO DE LAURENTIIS;NICOLA NORMANNO;SUSAN COSTANTINI;CORRADO CARACÒ;LUIGI BUONAGURO;ALESSANDRO MORABITO;FRANCESCO PERRONE;GIOSUÈ SCOGNAMIGLIO","49;32;18;17;16;15;15;13;13;12;12;11;11;10;10;9;9;9;9;8","PAOLO A. ASCIERTO;LUIGI BUONAGURO;GERARDO BOTTI;MARCO CASCELLA;ANTONELLA PETRILLO;SUSAN COSTANTINI;GENNARO CILIBERTO;GAETANO ROCCO;GIUSEPPE D’AIUTO;ESTER SIMEONE;MONICA CANTILE;ANGELA DE MONACO;RENATO FRANCO;FILIPPO RUSSO;CLAUDIO ARRA;NICOLA MOZZILLO;ROBERTA FUSCO;E LA;GIUSEPPE CASTELLO;MASSIMO DI MAÏO","6.06;4.21;2.69;2;1.6;1.54;1.5;1.31;1.28;1.24;1.23;1.17;1.16;1.13;1.11;1.06;1.02;1;0.99;0.96","PAOLO A. ASCIERTO;MICHELE MAIO;CAROLINE ROBERT;CÉLÈSTE LEBBÉ;DIRK SCHADENDORF;VANNA CHIARION‐SILENI;FRANCESCO COGNETTI;ANA ARANCE;HELEN GOGAS;HENRIK SCHMIDT;GEORGINA V. LONG;CAROLINE DUTRIAUX;VICTORIA ATKINSON;BENJAMIN BRADY;BRIAN J. SHARKEY;CATALIN MIHALCIOIU;CATRIONA M. MCNEIL;CHRISTINE E. HORAK;CORNELIA MAUCH;EWA KALINKA‐WARZOCHA","7687;6508;5964;5961;5905;5818;5297;5244;5200;5029;4956;4934;4934;4931;4931;4931;4931;4931;4931;4931","PAOLO A. ASCIERTO;GAETANO ROCCO;GENNARO CILIBERTO;ESTER SIMEONE;GERARDO BOTTI;NICOLA MOZZILLO;ANTONIO M. GRIMALDI;ANTONIO PINTO;ANTONELLA PETRILLO;CORRADO CARACÒ;MARCO PALLA;MARCELLO CURVIETTO;ASSUNTA ESPOSITO;MASSIMO DI MAÏO;MIRIAM PAONE;FABIO SANDOMENICO;FRANCESCO PERRONE;MARIA CARMELA PICCIRILLO;NICOLA NORMANNO;STEFANO GREGGI","7669;2069;1103;1006;968;797;778;770;710;672;663;655;648;642;636;604;533;462;450;430","PAOLO A. ASCIERTO;GERARDO BOTTI;GENNARO CILIBERTO;GAETANO ROCCO;NICOLA MOZZILLO;ESTER SIMEONE;ANTONELLA PETRILLO;RENATO FRANCO;CLAUDIO ARRA;MASSIMO DI MAÏO;ANTONIO M. GRIMALDI;MICHELINO DE LAURENTIIS;MAURIZIO MONTELLA;CORRADO CARACÒ;LUIGI BUONAGURO;NICOLA NORMANNO;PAOLO DELRIO;ALESSANDRO MORABITO;FRANCESCO PERRONE;MARCELLO CURVIETTO","48;29;18;16;15;15;13;13;12;12;12;11;10;9;9;9;8;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;PSYCHOLOGY;MATERIALS SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;ENGINEERING;PHILOSOPHY;ART;GEOGRAPHY;HISTORY","222;120;30;19;14;8;7;5;5;4;3;2;2;2;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;SURGERY;PATHOLOGY;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;PALEONTOLOGY;PHARMACOLOGY;MOLECULAR BIOLOGY;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;GENERAL SURGERY;OPTICS;DERMATOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;NURSING","184;98;98;57;54;52;43;37;33;33;21;18;17;17;13;12;10;8;8;7;7;7;7","CANCER;MELANOMA;GENE;CHEMOTHERAPY;CLINICAL TRIAL;ADVERSE EFFECT;LUNG CANCER;IMMUNOHISTOCHEMISTRY;RECEPTOR;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;CONFIDENCE INTERVAL;IN VITRO;POPULATION;RADIATION THERAPY;SIGNAL TRANSDUCTION;CELL;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;DISEASE;TOXICITY","142;50;49;38;24;23;21;19;18;16;15;13;13;12;12;12;11;11;10;10;10","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;METASTATIC MELANOMA;CLINICAL ENDPOINT;METASTASIS;MAPK/ERK PATHWAY;MUTATION;PLACEBO;PROSTATE CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;HAZARD RATIO;CANCER CELL;CARCINOGENESIS;DACARBAZINE;DOCETAXEL;GENOTYPE;PHASES OF CLINICAL RESEARCH;PI3K/AKT/MTOR PATHWAY;PROGRESSION-FREE SURVIVAL","33;30;28;19;16;11;10;9;9;9;8;8;7;7;7;7;7;7;7;7","IPILIMUMAB;VEMURAFENIB;KRAS;CETUXIMAB;GENOTYPING;NIVOLUMAB;ADJUVANT CHEMOTHERAPY;MEK INHIBITOR;TRASTUZUMAB;CHEMOKINE RECEPTOR;CXCR4;ELECTROCHEMOTHERAPY;ERLOTINIB;IRINOTECAN;TRAMETINIB;TUMOR-INFILTRATING LYMPHOCYTES;ESTROGEN RECEPTOR;LNCAP;METASTATIC BREAST CANCER;PTEN","20;13;11;6;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3","HUMANS;;FEMALE;MELANOMA;MALE;MIDDLE AGED;AGED;LUNG NEOPLASMS;ADULT;BREAST NEOPLASMS;SKIN NEOPLASMS;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;ITALY;AGED, 80 AND OVER;BIOMARKERS, TUMOR;CELL PROLIFERATION;TREATMENT OUTCOME;ANTIBODIES, MONOCLONAL","143;103;93;82;76;70;64;62;54;49;48;45;38;37;31;29;29;27;27;26","MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;ROLE OF CHEMOKINE RECEPTORS IN CANCER METASTASIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MELANOMA;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;IMMUNOBIOLOGY OF DENDRITIC CELLS;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY","22;15;11;9;8;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3","MELANOMA;CLINICAL ENDPOINT;BIOMARKERS FOR IMMUNOTHERAPY;TUMOR MICROENVIRONMENT;BREAST CANCER;METASTATIC COLORECTAL CANCER;TREATMENT;DACARBAZINE;NON-SMALL CELL LUNG CANCER;PROGRESSION-FREE SURVIVAL;EGFR MUTATIONS;HEPATOCELLULAR CARCINOMA;KRAS MUTATIONS;ADJUVANT CHEMOTHERAPY;BRAF GENE;CANCER IMMUNOEDITING;CHEMOKINE RECEPTORS;CONSENSUS CONFERENCE;EXPANDED ACCESS;FOLFIRI","33;16;12;11;9;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5","BREAST CANCER;LUNG CANCER;PHASE III;ADVANCED MELANOMA;CELL CARCINOMA;CELL LUNG;COLORECTAL CANCER;METASTATIC MELANOMA;PATIENTS PTS;PROSTATE CANCER;HEPATOCELLULAR CARCINOMA;MELANOMA PATIENTS;NON-SMALL CELL;PHASE TRIAL;ADJUVANT CHEMOTHERAPY;CANCER PATIENTS;CELL LINES;CONSENSUS CONFERENCE;EXPANDED ACCESS;III TRIAL;NON-SMALL-CELL LUNG;VERSUS PLACEBO;CANCER CELL;CANCER CELLS;CANCER NSCLC;ERYTHROPOIETIN ALPHA;OVARIAN CANCER;PHASE STUDY;RANDOMISED PHASE;RENAL CELL","22;20;10;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","BREAST CANCER;BRISTOL-MYERS SQUIBB;PUBMED SCOPUS;METASTATIC MELANOMA;RESEARCH FUNDING;CROSSREF PUBMED;CANCER PATIENTS;LUNG CANCER;CANCER CELLS;COLORECTAL CANCER;PROSTATE CANCER;ADVERSE EVENTS;CELL LINES;GROWTH FACTOR;MELANOMA CELLS;PROGRESSION-FREE SURVIVAL;RECEIVED HONORARIA;ADVANCED MELANOMA;ADVISORY BOARD;EXTERNAL QUALITY;METASTATIC COLORECTAL;SURVIVAL OS;ABSTRACT AIM;ADVISORY BOARDS;FACTOR RECEPTOR;QUALITY ASSESSMENT;GENOMIC HEALTH;HR CI;NATIONAL CANCER;PHASE III","30;29;24;23;22;21;20;20;17;17;17;16;16;16;15;15;15;14;14;14;14;14;13;13;13;13;12;11;11;11",94,0.37,1.5,19.83,2,154,4.33,1,14,1.89,1,4,0,0,0,5.06,1,39,7.88,1,34,0,0,0,1.82,1,5,25.92,2,164,0,0,0,1,1,1,10.68,1,89,1,1,1,2,2,2,1.27,1,3,3.75,1,15,7.29,1,59,2.88,1,13,0.12,0,1,0,0,0,257.75,8,2471,257.88,8,2472
"IRCCS_PASCALE",2015,310,11.9967741935484,3.69354838709677,0.270742358078603,0.429032258064516,0.361290322580645,0.303225806451613,0.541935483870968,18,130,78,36,31,0.42,0.25,0.12,0.1,70.81,1.90008876903711,0.396774193548387,0.783870967741935,6.68832236842106,0.570628617266055,0.491614115121427,0.448577460540867,0.488016279770877,"PAOLO A. ASCIERTO;ANTONELLA PETRILLO;GERARDO BOTTI;RENATO FRANCO;GENNARO CILIBERTO;ORLANDO CATALANO;NICOLA NORMANNO;FRANCESCO IZZO;GAETANO ROCCO;CLAUDIO ARRA;MARCO CASCELLA;ALFREDO BUDILLON;ALESSANDRO MORABITO;ESTER SIMEONE;FABIANA TATANGELO;CORRADO CARACÒ;VINCENZA GRANATA;ANTONIO AVALLONE;NICOLA MOZZILLO;ANTONIO PINTO","38;26;21;20;19;17;16;15;14;14;14;13;13;12;11;11;11;11;11;10","MARCO CASCELLA;PAOLO A. ASCIERTO;ANTONELLA PETRILLO;ORLANDO CATALANO;GAETANO ROCCO;NICOLA NORMANNO;ALFREDO BUDILLON;GENNARO CILIBERTO;NICOLA MOZZILLO;GERARDO BOTTI;RENATO FRANCO;ROBERTA FUSCO;LUIGI BUONAGURO;GIOVANNI COLONNA;SUSAN COSTANTINI;FRANCESCO IZZO;MARIA LINA TORNESELLO;ESTER SIMEONE;CLAUDIO ARRA;ALESSANDRO OTTAIANO","10.94;4.17;3.94;3.53;2.83;2.31;2.04;2.02;1.95;1.87;1.65;1.6;1.51;1.44;1.44;1.43;1.36;1.23;1.22;1.19","PAOLO A. ASCIERTO;ANTONELLA PETRILLO;GERARDO BOTTI;RENATO FRANCO;GENNARO CILIBERTO;ORLANDO CATALANO;NICOLA NORMANNO;FRANCESCO IZZO;GAETANO ROCCO;CLAUDIO ARRA;MARCO CASCELLA;ALFREDO BUDILLON;ALESSANDRO MORABITO;ESTER SIMEONE;FABIANA TATANGELO;CORRADO CARACÒ;VINCENZA GRANATA;ANTONIO AVALLONE;NICOLA MOZZILLO;ANTONIO PINTO","38;26;21;20;19;17;16;15;14;14;14;13;13;12;11;11;11;11;11;10","MARCO CASCELLA;PAOLO A. ASCIERTO;ANTONELLA PETRILLO;ORLANDO CATALANO;GAETANO ROCCO;NICOLA NORMANNO;ALFREDO BUDILLON;GENNARO CILIBERTO;NICOLA MOZZILLO;GERARDO BOTTI;RENATO FRANCO;ROBERTA FUSCO;LUIGI BUONAGURO;SUSAN COSTANTINI;FRANCESCO IZZO;MARIA LINA TORNESELLO;ESTER SIMEONE;CLAUDIO ARRA;ALESSANDRO OTTAIANO;FRANCESCO PERRONE","10.94;4.17;3.94;3.53;2.83;2.31;2.04;2.02;1.95;1.87;1.65;1.6;1.51;1.44;1.43;1.36;1.23;1.22;1.19;1.16","PAOLO A. ASCIERTO;F. STEPHEN HODI;JEAN‐JACQUES GROB;MICHELE MAIO;REINHARD DUMMER;JEDD D. WOLCHOK;CHRISTINE E. HORAK;JAMES LARKIN;MARIO SZNOL;ARVIN YANG;CHRISTOPHER D. LAO;KENNETH F. GROSSMANN;DIRK SCHADENDORF;RENÉ GONZÁLEZ;MATTEO S. CARLINO;VANNA CHIARION‐SILENI;MICHAEL SMYLIE;BRIGITTE DRÉNO;MICHAEL A. POSTOW;GEORGINA V. LONG","13250;11389;11206;11062;10354;9961;9876;9859;9834;9823;9823;9823;8961;8930;8840;8555;8496;7616;7500;7411","PAOLO A. ASCIERTO;FABIANA TATANGELO;ALFREDO BUDILLON;ANTONIO AVALLONE;FRANCESCO IZZO;GERARDO BOTTI;RENATO FRANCO;ANTONELLA PETRILLO;CLAUDIO ARRA;ALESSANDRO MORABITO;VINCENZA GRANATA;GENNARO CILIBERTO;NICOLA NORMANNO;DOMENICA REA;ROBERTA FUSCO;ANTÔNIO BARBIERI;CHIARA CIARDIELLO;GIUSEPPE PALMA;FRANCESCO CAPONIGRO;ORLANDO CATALANO","13249;1340;1254;1210;1036;659;650;619;605;488;480;479;472;457;421;408;405;393;370;356","PAOLO A. ASCIERTO;ANTONELLA PETRILLO;GERARDO BOTTI;RENATO FRANCO;GENNARO CILIBERTO;ORLANDO CATALANO;NICOLA NORMANNO;FRANCESCO IZZO;CLAUDIO ARRA;GAETANO ROCCO;MARCO CASCELLA;ALFREDO BUDILLON;ESTER SIMEONE;NICOLA MOZZILLO;SUSAN COSTANTINI;ALESSANDRO MORABITO;ANTONIO AVALLONE;CORRADO CARACÒ;VINCENZA GRANATA;FABIANA TATANGELO","35;26;21;19;18;17;15;15;14;14;14;13;12;11;11;11;11;11;11;11","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;POLITICAL SCIENCE;MATHEMATICS;PSYCHOLOGY;PHILOSOPHY;ENGINEERING;ART;BUSINESS;ECONOMICS;HISTORY;MATERIALS SCIENCE;SOCIOLOGY;GEOGRAPHY;GEOLOGY","272;136;32;19;13;9;8;7;6;5;4;4;4;4;4;4;2;2","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;BIOCHEMISTRY;GENETICS;IMMUNOLOGY;RADIOLOGY;GASTROENTEROLOGY;CELL BIOLOGY;PHARMACOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;PALEONTOLOGY;PSYCHIATRY;BIOINFORMATICS;COMPUTATIONAL BIOLOGY;GENERAL SURGERY;INTENSIVE CARE MEDICINE","214;116;101;69;61;58;58;40;37;33;31;22;18;17;15;15;15;12;12;12;12","CANCER;GENE;CHEMOTHERAPY;MELANOMA;CLINICAL TRIAL;LUNG CANCER;IN VITRO;RECEPTOR;IMMUNOHISTOCHEMISTRY;POPULATION;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;KINASE;ADVERSE EFFECT;CELL;IMMUNE SYSTEM;LYMPHOMA;MAGNETIC RESONANCE IMAGING;STAGE (STRATIGRAPHY);HEPATOCELLULAR CARCINOMA","171;54;53;39;25;22;16;16;15;15;14;14;13;12;12;12;12;12;12;11","COLORECTAL CANCER;BREAST CANCER;IMMUNOTHERAPY;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;METASTASIS;PHASES OF CLINICAL RESEARCH;METASTATIC MELANOMA;MAPK/ERK PATHWAY;PROSTATE CANCER;CANCER CELL;PROGRESSION-FREE SURVIVAL;ADENOCARCINOMA;HAZARD RATIO;CONTRAST-ENHANCED ULTRASOUND;DACARBAZINE;GENOTYPE;MUTATION;CELL CYCLE;CHEMOKINE;LIVER CANCER;OVARIAN CANCER","40;27;27;23;17;15;15;14;12;12;10;10;9;9;8;8;8;8;7;7;7;7","KRAS;IPILIMUMAB;VEMURAFENIB;NIVOLUMAB;CETUXIMAB;ERLOTINIB;MEK INHIBITOR;GEFITINIB;PEMBROLIZUMAB;OXALIPLATIN;ELECTROCHEMOTHERAPY;EPITHELIAL–MESENCHYMAL TRANSITION;GENOTYPING;TRAMETINIB;CAPECITABINE;CARBOPLATIN;CXCR4;ESTROGEN RECEPTOR;INDUCED PLURIPOTENT STEM CELL;IRINOTECAN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SENTINEL LYMPH NODE;TRASTUZUMAB","16;14;12;11;10;9;9;8;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4","HUMANS;;FEMALE;MIDDLE AGED;MALE;AGED;ADULT;MELANOMA;ANTINEOPLASTIC AGENTS;LUNG NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;BIOMARKERS, TUMOR;SKIN NEOPLASMS;COLORECTAL NEOPLASMS;ITALY;AGED, 80 AND OVER;LIVER NEOPLASMS;NEOPLASMS;TREATMENT OUTCOME","178;125;108;90;88;82;69;61;60;60;56;51;40;40;39;37;36;34;34;34","MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;LYMPHOID NEOPLASMS;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;MELANOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;NATURAL KILLER CELLS IN IMMUNITY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;MOLECULAR RESEARCH ON BREAST CANCER;ROLE OF HISTONE DEACETYLASES IN CELLULAR REGULATION;ANESTHESIA AND SEDATION MANAGEMENT;CANCER STEM CELLS AND TUMOR METASTASIS;CANCER SURVIVORSHIP AND QUALITY OF LIFE","18;16;14;13;8;8;6;6;6;5;5;5;5;4;4;4;4;3;3;3","MELANOMA;CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;CANCER;CONTRAST-ENHANCED ULTRASOUND;DACARBAZINE;EGFR MUTATIONS;AFATINIB;BREAST CANCER;CANCER GENOMICS;LIVER CANCER;ADJUVANT THERAPY;BIOMARKER ANALYSIS;BIOMARKERS FOR IMMUNOTHERAPY;BRAF GENE;CANCER IMAGING;DYNAMIC CONTRAST-ENHANCED MRI;KRAS MUTATIONS;MEK INHIBITION","29;23;10;10;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6","COLORECTAL CANCER;BREAST CANCER;CANCER PATIENTS;PATIENTS PTS;PHASE III;LUNG CANCER;CELL CARCINOMA;HEPATOCELLULAR CARCINOMA;PHASE TRIAL;ADVANCED MELANOMA;MELANOMA PATIENTS;PROSTATE CANCER;SQUAMOUS CELL;CANCER CELLS;LOCALLY ADVANCED;PHASE II;RECTAL CANCER;ADVANCED SQUAMOUS;HODGKIN LYMPHOMA;III TRIAL;OVARIAN CANCER;SECOND-LINE TREATMENT;MELANOMA MEL;METASTATIC COLORECTAL;CANCER PROGNOSTIC;CANCER RISK;CANCER SCREENING;CARCINOMA SCC;CASECONTROL STUDY;CELL LYMPHOMA","18;17;15;14;14;13;11;11;11;10;10;9;8;7;7;7;7;6;6;6;6;6;5;5;4;4;4;4;4;4","BREAST CANCER;LUNG CANCER;MEDIAN PFS;ISTITUTO NAZIONALE;CANCER CELLS;PROGRESSION-FREE SURVIVAL;ADVERSE EVENTS;CANCER PATIENTS;CURA DEI;FONDAZIONE PASCALE;LA CURA;LO STUDIO;METASTATIC MELANOMA;HR CI;PRIMARY ENDPOINT;RESPONSE RATE;DIPARTIMENTO DI;DISEASE PROGRESSION;EGFR MUTATION;DEI TUMORI;OVARIAN CANCER;PASCALE NAPLES;PATHOLOGY UNIT;PHASE III;CANCER CELL;CELL LINES;NAPOLI ITALY;PATIENTS PTS;SURVIVAL OS;HEPATOCELLULAR CARCINOMA","33;31;24;21;20;20;18;18;17;17;17;17;17;16;16;16;15;15;15;14;14;14;14;14;13;13;13;13;13;12",131,0.42,1,24.32,1,316,3.69,1,17,3.5,1,10,2,1,3,5.09,1,43,13.83,1,114,1,1,1,2.75,1,8,27.26,1,348,0,0,0,1,1,1,14.97,1,118,0,0,0,1.2,1,2,1.86,1,3,3.69,1,20,11.04,1,78,3.44,1,17,0.18,0,3,0,0,0,277.21,1,3685,277.38,1,3686
"IRCCS_PASCALE",2016,350,14.1714285714286,3.80285714285714,0.262960180315552,0.4,0.354285714285714,0.32,0.58,6,209,72,24,16,0.6,0.21,0.07,0.05,44.24,1.36203070381169,0.44,0.854285714285714,7.19656897784132,0.560953689752048,0.521418966510854,0.445777906304222,0.444912239089184,"PAOLO A. ASCIERTO;GERARDO BOTTI;GENNARO CILIBERTO;SANDRO PIGNATA;NICOLA NORMANNO;GAETANO FACCHINI;MICHELINO DE LAURENTIIS;GAETANO ROCCO;SABRINA CHIARA CECERE;ALESSANDRO MORABITO;FABIANA TATANGELO;ORAZIO CAFFO;FRANCESCO PERRONE;ANNA CRISPO;MARIA CARMELA PICCIRILLO;BRIGITTE DRÉNO;ANTONELLA PETRILLO;FRANCESCO IZZO;FRANCESCA MAINES;UGO DE GIORGI","52;37;27;24;22;22;20;18;17;17;16;16;16;15;15;14;14;14;13;13","PAOLO A. ASCIERTO;GAETANO ROCCO;GERARDO BOTTI;MARCO CASCELLA;GENNARO CILIBERTO;ALESSANDRO MORABITO;ANTONELLA PETRILLO;SANDRO PIGNATA;RENATO FRANCO;NICOLA NORMANNO;FRANCESCO PERRONE;SUSAN COSTANTINI;LUIGI BUONAGURO;ARTURO CUOMO;MICHELINO DE LAURENTIIS;FRANCO M. BUONAGURO;MARIA LINA TORNESELLO;GAETANO FACCHINI;ROBERTA FUSCO;SABRINA CHIARA CECERE","4.6;3.25;3.16;3.05;2.28;2.1;1.79;1.76;1.65;1.6;1.57;1.55;1.52;1.49;1.42;1.41;1.33;1.32;1.32;1.28","PAOLO A. ASCIERTO;GERARDO BOTTI;GENNARO CILIBERTO;SANDRO PIGNATA;NICOLA NORMANNO;GAETANO FACCHINI;MICHELINO DE LAURENTIIS;GAETANO ROCCO;SABRINA CHIARA CECERE;ALESSANDRO MORABITO;FABIANA TATANGELO;FRANCESCO PERRONE;ANNA CRISPO;MARIA CARMELA PICCIRILLO;ANTONELLA PETRILLO;FRANCESCO IZZO;GUGLIELMO NASTI;VINCENZA GRANATA;ALFREDO BUDILLON;GIOSUÈ SCOGNAMIGLIO","52;37;27;24;22;22;20;18;17;17;16;16;15;15;14;14;13;12;12;12","PAOLO A. ASCIERTO;GAETANO ROCCO;GERARDO BOTTI;MARCO CASCELLA;GENNARO CILIBERTO;ALESSANDRO MORABITO;ANTONELLA PETRILLO;SANDRO PIGNATA;RENATO FRANCO;NICOLA NORMANNO;FRANCESCO PERRONE;SUSAN COSTANTINI;LUIGI BUONAGURO;ARTURO CUOMO;MICHELINO DE LAURENTIIS;FRANCO M. BUONAGURO;MARIA LINA TORNESELLO;GAETANO FACCHINI;ROBERTA FUSCO;SABRINA CHIARA CECERE","4.6;3.25;3.16;3.05;2.28;2.1;1.79;1.76;1.65;1.6;1.57;1.55;1.52;1.49;1.42;1.41;1.33;1.32;1.32;1.28","PAOLO A. ASCIERTO;NICOLA NORMANNO;FORTUNATO CIARDIELLO;MICHELE MAIO;J. HAN VAN KRIEKEN;ROBERTO LABIANCA;A. ROTH;AL B. BENSON;ALBERTO BARDELLI;ALBERTO SOBRERO;ALFREDO FALCONE;ANDRÉ D’HOORE;ANDRÉS CERVANTES;AXEL GROTHEY;AZIZ ZAANAN;BRIGETTE MA;C.-H. KÖHNE;CORNELIS J.A. PUNT;DAN ADERKA;DEMETRIS PAPAMICHAEL","6402;3391;3223;2939;2888;2886;2882;2882;2882;2882;2882;2882;2882;2882;2882;2882;2882;2882;2882;2882","PAOLO A. ASCIERTO;NICOLA NORMANNO;GERARDO BOTTI;MARIAELENA CAPONE;ESTER SIMEONE;GENNARO CILIBERTO;MAURIZIO MONTELLA;FABIANA TATANGELO;GAETANO FACCHINI;GAETANO ROCCO;ORLANDO CATALANO;SANDRO PIGNATA;VINCENZO QUAGLIARIELLO;ANTONELLA PETRILLO;ROSARIO VINCENZO IAFFAIOLI;SIMONA LOSITO;STEFANIA SCALA;FRANCESCO IZZO;VINCENZA GRANATA;ALESSANDRO MORABITO","6402;3391;1226;996;973;901;546;518;513;500;457;440;426;404;395;395;383;381;376;373","PAOLO A. ASCIERTO;GERARDO BOTTI;GENNARO CILIBERTO;GAETANO FACCHINI;NICOLA NORMANNO;SANDRO PIGNATA;MAURIZIO MONTELLA;MICHELINO DE LAURENTIIS;GAETANO ROCCO;ALESSANDRO MORABITO;FABIANA TATANGELO;FRANCESCO PERRONE;SABRINA CHIARA CECERE;ANTONELLA PETRILLO;FRANCESCO IZZO;MARIA CARMELA PICCIRILLO;ANNA CRISPO;ALFREDO BUDILLON;VINCENZA GRANATA;GIOSUÈ SCOGNAMIGLIO","52;33;27;22;22;21;20;20;18;16;15;15;15;14;14;14;14;12;11;11","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE;SOCIOLOGY;PSYCHOLOGY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;ART;BUSINESS;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE;GEOLOGY","319;112;41;19;16;13;11;11;8;7;6;6;3;2;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;BIOCHEMISTRY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;PHARMACOLOGY;ENDOCRINOLOGY;CELL BIOLOGY;NURSING;BIOTECHNOLOGY;FAMILY MEDICINE;GYNECOLOGY;NUCLEAR MEDICINE","275;167;97;79;57;48;45;42;34;30;29;24;23;20;18;18;14;14;14;14","CANCER;CHEMOTHERAPY;GENE;MELANOMA;CLINICAL TRIAL;CONFIDENCE INTERVAL;LUNG CANCER;POPULATION;ADVERSE EFFECT;IMMUNE SYSTEM;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;ODDS RATIO;RADIATION THERAPY;RECEPTOR;IN VITRO;MULTIVARIATE ANALYSIS;LOGISTIC REGRESSION;QUALITY OF LIFE (HEALTHCARE);IN VIVO;REGIMEN;STAGE (STRATIGRAPHY)","217;73;49;39;37;34;31;24;21;20;20;20;18;18;17;16;16;15;15;14;14;14","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;PROSTATE CANCER;METASTASIS;DOCETAXEL;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;CISPLATIN;METASTATIC MELANOMA;EPIDERMAL GROWTH FACTOR RECEPTOR;MUTATION;PLACEBO;ADENOCARCINOMA;BEVACIZUMAB;TOLERABILITY;PI3K/AKT/MTOR PATHWAY;TUMOR MICROENVIRONMENT","50;41;33;27;22;19;16;15;13;13;13;12;12;10;10;10;9;9;9;8;8","IPILIMUMAB;KRAS;NIVOLUMAB;VEMURAFENIB;ANDROGEN DEPRIVATION THERAPY;CETUXIMAB;OXALIPLATIN;ANDROGEN RECEPTOR;CANCER IMMUNOTHERAPY;CARBOPLATIN;METASTATIC BREAST CANCER;TRASTUZUMAB;IRINOTECAN;PAZOPANIB;ERLOTINIB;ESTROGEN RECEPTOR;HISTONE DEACETYLASE;PRIMARY TUMOR;TAXANE;CHROMOPHOBE CELL;CRIZOTINIB;CXCR4;EPIRUBICIN;FERTILITY PRESERVATION;GEFITINIB;IMMUNE CHECKPOINT;TRIPLE-NEGATIVE BREAST CANCER","21;15;11;10;9;9;9;8;8;7;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;AGED;MIDDLE AGED;MALE;ADULT;MELANOMA;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;SKIN NEOPLASMS;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;OVARIAN NEOPLASMS;LIVER NEOPLASMS;TREATMENT OUTCOME;CELL PROLIFERATION","171;169;119;90;87;83;72;72;71;70;61;52;51;47;38;34;34;31;30;29","CANCER IMMUNOTHERAPY;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RENAL CELL CARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MOLECULAR RESEARCH ON BREAST CANCER;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CARDIOTOXICITY OF CANCER TREATMENTS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;ECONOMIC BURDEN OF CANCER TREATMENT;GASTRIC CANCER RESEARCH AND TREATMENT;LYMPHOID NEOPLASMS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES","25;18;16;11;10;9;8;7;6;6;6;6;5;5;5;5;5;5;5;5","CLINICAL ENDPOINT;MELANOMA;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;REGIMEN;TUMOR REGRESSION;EGFR MUTATIONS;CANCER IMMUNOTHERAPY;METASTATIC COLORECTAL CANCER;TOLERABILITY;TUMOR MICROENVIRONMENT;CANCER IMMUNOEDITING;CARBOPLATIN;ABIRATERONE ACETATE;CANCER IMAGING;FOLFOX;RADIOTHERAPY;TREATMENT;UNIVARIATE ANALYSIS","27;22;22;15;14;14;14;12;11;9;9;9;8;8;7;7;7;7;7;7","BREAST CANCER;PATIENTS PTS;CANCER PATIENTS;LUNG CANCER;PHASE III;COLORECTAL CANCER;OVARIAN CANCER;PROSTATE CANCER;METASTATIC COLORECTAL;CELL CARCINOMA;POOLED ANALYSIS;ADVANCED MELANOMA;MCRPC PATIENTS;MELANOMA PATIENTS;METASTATIC MELANOMA;CANCER RISK;CASTRATION-RESISTANT PROSTATE;CELL LUNG;HEPATOCELLULAR CARCINOMA;III STUDY;LOCALLY ADVANCED;PATIENTS TREATED;PHASE TRIAL;ADJUVANT CHEMOTHERAPY;CANCER CELLS;CANCER MCRPC;CASECONTROL STUDY;CLINICAL OUTCOMES;CLINICAL TRIALS;ENDOMETRIAL CANCER","29;25;23;20;19;13;12;11;10;9;9;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6","HR CI;BREAST CANCER;CANCER PATIENTS;PROGRESSION-FREE SURVIVAL;RESPONSE RATE;ISTITUTO NAZIONALE;SURVIVAL OS;ADVERSE EVENTS;NIVOLUMAB MGKG;SURVIVAL PFS;MEDIAN PFS;IPILIMUMAB MGKG;LUNG CANCER;OVARIAN CANCER;MD DEPARTMENT;MONTHS NA;MONTHS CI;PATIENTS TREATED;ITALY DEPARTMENT;NAZIONALE TUMORI;MEDIAN AGE;MEDIAN OS;PERFORMANCE STATUS;COLORECTAL CANCER;FREE SURVIVAL;MEDIAN FOLLOW-UP;OBJECTIVE RESPONSE;PROGRESSION FREE;PTS TREATED;CELL LINES","54;46;38;32;30;29;29;28;28;27;26;25;25;25;24;24;23;23;21;21;20;20;19;18;18;18;18;18;18;17",145,0.41,1.5,27,2,318,2.11,1,9,1.1,1,2,1,1,1,8.15,1,84,6.33,1,43,0,0,0,1.88,1,3,31.14,2,375,1,1,1,1,1,1,20.9,1,277,0,0,0,1.67,1,3,1.55,1,6,6.76,1,54,13.83,1,164,5.94,1,53,0.08,0,1,0,0,0,183.22,13,1884,188,13,1884
"IRCCS_PASCALE",2017,392,15.4515306122449,2.91836734693878,0.342657342657343,0.267857142857143,0.23469387755102,0.191326530612245,0.650510204081633,7,221,83,17,27,0.56,0.21,0.04,0.07,47.8,1.62165989625667,0.454081632653061,0.905612244897959,7.44808055380743,0.580230923734022,0.577735260770975,0.471836734693878,0.492090017825312,"PAOLO A. ASCIERTO;MICHELINO DE LAURENTIIS;GERARDO BOTTI;SABRINA ROSSETTI;NICOLA NORMANNO;ANTONIO AVALLONE;SANDRO PIGNATA;ALESSANDRO MORABITO;SABINO DE PLACIDO;GAETANO FACCHINI;GAETANO ROCCO;DIRK SCHADENDORF;JAMES LARKIN;ANNA CRISPO;SUSAN COSTANTINI;FRANCESCO IZZO;FILIPPO MONTEMURRO;GENNARO CILIBERTO;UGO DE GIORGI;REINHARD DUMMER","63;39;35;21;20;19;18;17;17;16;15;15;15;14;14;14;13;13;13;13","PAOLO A. ASCIERTO;GAETANO ROCCO;GERARDO BOTTI;FRANCESCA PENTIMALLI;MICHELINO DE LAURENTIIS;NICOLA NORMANNO;MARCO CASCELLA;LUIGI BUONAGURO;SUSAN COSTANTINI;SABRINA ROSSETTI;ANTONIO AVALLONE;SANDRO PIGNATA;ANTONELLA PETRILLO;ANTONIO GIORDANO;FRANCESCO IZZO;MONICA CANTILE;ANNA CRISPO;ROBERTA FUSCO;ALESSANDRO MORABITO;CLAUDIO ARRA","4.8;4.07;3.34;2.9;2.79;2.37;1.79;1.76;1.56;1.51;1.5;1.46;1.37;1.33;1.29;1.26;1.24;1.22;1.08;1.08","PAOLO A. ASCIERTO;MICHELINO DE LAURENTIIS;GERARDO BOTTI;SABRINA ROSSETTI;NICOLA NORMANNO;ANTONIO AVALLONE;SANDRO PIGNATA;ALESSANDRO MORABITO;GAETANO FACCHINI;GAETANO ROCCO;ANNA CRISPO;SUSAN COSTANTINI;FRANCESCO IZZO;GENNARO CILIBERTO;CLAUDIO ARRA;ANTONELLA PETRILLO;ROBERTA FUSCO;ANTONGIULIO FAGGIANO;MONICA CANTILE;ALFREDO BUDILLON","63;39;35;21;20;19;18;17;16;15;14;14;14;13;12;12;12;10;10;10","PAOLO A. ASCIERTO;GAETANO ROCCO;GERARDO BOTTI;FRANCESCA PENTIMALLI;MICHELINO DE LAURENTIIS;NICOLA NORMANNO;MARCO CASCELLA;LUIGI BUONAGURO;SUSAN COSTANTINI;SABRINA ROSSETTI;ANTONIO AVALLONE;SANDRO PIGNATA;ANTONELLA PETRILLO;FRANCESCO IZZO;MONICA CANTILE;ANNA CRISPO;ROBERTA FUSCO;ALESSANDRO MORABITO;CLAUDIO ARRA;GAETANO FACCHINI","4.8;4.07;3.34;2.9;2.79;2.37;1.79;1.76;1.56;1.51;1.5;1.46;1.37;1.29;1.26;1.24;1.22;1.08;1.08;1.05","PAOLO A. ASCIERTO;PIOTR RUTKOWSKI;MICHELE MAIO;VANNA CHIARION‐SILENI;JAMES LARKIN;CÉLÈSTE LEBBÉ;MICHAEL SMYLIE;GEORGINA V. LONG;RENÉ GONZÁLEZ;IVÁN MÁRQUEZ‐RODAS;C. LANCE COWEY;DIRK SCHADENDORF;REINHARD DUMMER;DAVID HOGG;GRANT A. MCARTHUR;F. STEPHEN HODI;JEAN‐JACQUES GROB;MARGARET K. CALLAHAN;JEFFREY A. SOSMAN;JOHN B.A.G. HAANEN","10068;7543;7374;7278;7256;7239;7185;7144;6816;6686;6653;6114;6002;5392;5219;5162;5161;5059;5037;4993","PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;GERARDO BOTTI;NICOLA NORMANNO;GIOSUÈ SCOGNAMIGLIO;CLAUDIO ARRA;MONICA CANTILE;MAURIZIO DI BONITO;ALESSANDRO MORABITO;MAURIZIO MONTELLA;ANTONELLA PETRILLO;ROBERTA FUSCO;FRANCESCO IZZO;ANTONIO PINTO;SUSAN COSTANTINI;ALFREDO BUDILLON;VINCENZA GRANATA;STEFANIA SCALA;ANTONIO AVALLONE","10068;3421;1094;1089;536;439;427;406;394;378;371;366;364;326;296;296;270;267;264;260","PAOLO A. ASCIERTO;MICHELINO DE LAURENTIIS;GERARDO BOTTI;SABRINA ROSSETTI;NICOLA NORMANNO;ANTONIO AVALLONE;SANDRO PIGNATA;ALESSANDRO MORABITO;GAETANO FACCHINI;GAETANO ROCCO;MAURIZIO MONTELLA;ANNA CRISPO;FRANCESCO IZZO;SUSAN COSTANTINI;CLAUDIO ARRA;ROBERTA FUSCO;ANTONELLA PETRILLO;ALFREDO BUDILLON;MONICA CANTILE;ANTONGIULIO FAGGIANO","62;39;35;21;20;19;18;17;16;15;15;14;14;13;12;12;12;10;10;9","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;SOCIOLOGY;PHILOSOPHY;ECONOMICS;ENGINEERING;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;ART;HISTORY","362;139;44;19;13;8;6;6;5;5;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;RADIOLOGY;CELL BIOLOGY;PHARMACOLOGY;NURSING;UROLOGY;GYNECOLOGY;NUCLEAR MEDICINE;FAMILY MEDICINE;BIOINFORMATICS;COMPUTATIONAL BIOLOGY;ENDOCRINOLOGY","316;216;98;96;68;60;55;51;41;40;36;33;27;18;17;16;15;14;13;11;11;11","CANCER;CHEMOTHERAPY;GENE;MELANOMA;ADVERSE EFFECT;CLINICAL TRIAL;POPULATION;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;COHORT;PROPORTIONAL HAZARDS MODEL;STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;IN VITRO;MULTIVARIATE ANALYSIS;IMMUNE SYSTEM;DISEASE;RETROSPECTIVE COHORT STUDY;RADIATION THERAPY","245;72;46;46;44;38;38;37;35;31;26;22;21;19;18;18;17;16;16;15","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;METASTATIC MELANOMA;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;OVARIAN CANCER;ADENOCARCINOMA;EPIDERMAL GROWTH FACTOR RECEPTOR;PLACEBO;TOLERABILITY;CISPLATIN;UNIVARIATE ANALYSIS;DOCETAXEL;MUTATION;CELL CYCLE;PROGRESSIVE DISEASE","64;56;42;41;25;23;20;18;17;16;15;14;14;13;12;11;10;10;9;9","IPILIMUMAB;NIVOLUMAB;VEMURAFENIB;KRAS;METASTATIC BREAST CANCER;TAMOXIFEN;ANDROGEN DEPRIVATION THERAPY;ERLOTINIB;PEMBROLIZUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANDROGEN RECEPTOR;CETUXIMAB;IRINOTECAN;CANCER IMMUNOTHERAPY;OXALIPLATIN;TAXANE;TRIPLE-NEGATIVE BREAST CANCER;IMMUNE CHECKPOINT;POLY ADP RIBOSE POLYMERASE;AROMATASE;BRCA MUTATION;CRIZOTINIB;ELECTROCHEMOTHERAPY;ESTROGEN RECEPTOR;PAZOPANIB;PD-L1","26;24;18;16;16;11;10;10;10;10;9;9;8;7;7;7;7;6;6;5;5;5;5;5;5;5",";HUMANS;FEMALE;MIDDLE AGED;MALE;MELANOMA;AGED;ADULT;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;LUNG NEOPLASMS;SKIN NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;LIVER NEOPLASMS;BIOMARKERS, TUMOR;CELL PROLIFERATION;TREATMENT OUTCOME;YOUNG ADULT","207;178;121;105;102;102;92;82;63;61;53;53;45;45;44;34;32;32;31;31","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;RENAL CELL CARCINOMA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MELANOMA;MOLECULAR RESEARCH ON BREAST CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER","31;22;22;15;12;10;9;9;9;7;7;6;5;5;5;5;5;5;4;4","CLINICAL ENDPOINT;MELANOMA;PROGRESSION-FREE SURVIVAL;BREAST CANCER;METASTATIC COLORECTAL CANCER;BIOMARKERS FOR IMMUNOTHERAPY;REGIMEN;TOLERABILITY;DISCONTINUATION;CANCER IMMUNOTHERAPY;UNIVARIATE ANALYSIS;METASTATIC BREAST CANCER;REFRACTORY (PLANETARY SCIENCE);FOLFIRI;NEOADJUVANT THERAPY;PD-1 AND PD-L1;TUMOR MICROENVIRONMENT;ABIRATERONE ACETATE;AROMATASE INHIBITOR;EGFR MUTATIONS","42;25;23;17;16;13;13;13;12;11;11;10;10;9;9;9;9;8;8;8","BREAST CANCER;PATIENTS PTS;CELL CARCINOMA;LUNG CANCER;CANCER PATIENTS;COLORECTAL CANCER;METASTATIC COLORECTAL;OVARIAN CANCER;PHASE III;PROSTATE CANCER;PHASE TRIAL;RENAL CELL;CELL LUNG;LOCALLY ADVANCED;METASTATIC BREAST;METASTATIC MELANOMA;METASTATIC RENAL;PATIENTS TREATED;RANDOMIZED PHASE;CANCER NSCLC;SQUAMOUS CELL;ADVANCED BREAST;ADVANCED MELANOMA;CARCINOMA MRCC;CASTRATION-RESISTANT PROSTATE;MELANOMA PATIENTS;METASTATIC CASTRATION-RESISTANT;CANCER MCRC;GROWTH FACTOR;MCRC PATIENTS","46;25;21;21;20;18;16;16;15;12;11;11;10;10;10;10;10;10;10;9;9;8;8;8;8;8;8;7;7;7","BRISTOL-MYERS SQUIBB;RESEARCH FUNDING;BREAST CANCER;PROGRESSION-FREE SURVIVAL;CANCER INSTITUTE;NATIONAL CANCER;PERSONAL FEES;ADVERSE EVENTS;ISTITUTO NAZIONALE;RESPONSE RATE;SURVIVAL OS;HR CI;ADVISORY BOARD;ITALY SEARCH;CLINICAL TRIAL;SURVIVAL PFS;SQUIBB MSD;AVIANO ITALY;CRO AVIANO;INSTITUTE AVIANO;SPEAKERS BUREAU;AVIANO IRCCS;ENTITY RESPONSIBLE;IRCCS NATIONAL;LEGAL ENTITY;CANCER PATIENTS;NAZIONALE TUMORI;MSD NOVARTIS;NOVARTIS ROCHE;CLINICAL PRACTICE","180;71;61;58;50;49;45;41;40;39;38;37;36;36;35;35;34;33;33;33;33;32;32;32;32;31;31;30;30;29",164,0.42,2,33.16,1,387,3,1,12,1.64,1,4,1,1,1,10.74,1,78,5.78,1,24,0,0,0,2,1,4,39.65,1,465,1,1,1,1,1,1,27.36,1,265,1.5,1,2,2,2,2,2.17,1,5,10.39,1,48,19.11,1,170,8.61,1,42,0.09,0,2,0,0,0,164.86,8,1853,164.19,8,1854
"IRCCS_PASCALE",2018,302,17.1456953642384,3.05629139072848,0.327193932827736,0.248344370860927,0.23841059602649,0.129139072847682,0.602649006622517,1,170,69,15,17,0.56,0.23,0.05,0.06,52.49,1.72052015003477,0.456953642384106,0.894039735099338,7.47092360319272,0.504453704199811,0.537928802588997,0.469331793909655,0.531986531986532,"PAOLO A. ASCIERTO;GERARDO BOTTI;MICHELINO DE LAURENTIIS;ANTONIO AVALLONE;SANDRO PIGNATA;MARIO MANDALÁ;ALFREDO BUDILLON;PAOLO DELRIO;DIRK SCHADENDORF;CAROLINE ROBERT;GAETANO FACCHINI;ANTONELLA PETRILLO;ALESSANDRO MORABITO;UGO DE GIORGI;CLAUS GARBE;NICOLA NORMANNO;GEORGINA V. LONG;JAMES LARKIN;GAETANO ROCCO;SALVATORE TAFUTO","53;35;22;18;17;16;15;15;14;14;13;12;12;12;11;11;11;11;10;10","PAOLO A. ASCIERTO;GERARDO BOTTI;NICOLA MAUREA;GAETANO ROCCO;MICHELINO DE LAURENTIIS;ANTONIO AVALLONE;ALFREDO BUDILLON;MARCO CASCELLA;ROBERTA FUSCO;ANTONELLA PETRILLO;SUSAN COSTANTINI;GAETANO FACCHINI;PAOLO DELRIO;SANDRO PIGNATA;MARIA LINA TORNESELLO;FRANCO M. BUONAGURO;MONICA CANTILE;ALESSANDRO MORABITO;LUIGI BUONAGURO;CLAUDIO ARRA","3.27;3;1.46;1.41;1.4;1.34;1.23;1.13;1.08;1.04;1;0.99;0.97;0.95;0.88;0.88;0.86;0.83;0.82;0.81","PAOLO A. ASCIERTO;GERARDO BOTTI;MICHELINO DE LAURENTIIS;ANTONIO AVALLONE;SANDRO PIGNATA;ALFREDO BUDILLON;PAOLO DELRIO;GAETANO FACCHINI;ANTONELLA PETRILLO;ALESSANDRO MORABITO;NICOLA NORMANNO;GAETANO ROCCO;SALVATORE TAFUTO;ROBERTA FUSCO;FABIANA TATANGELO;MONICA CANTILE;CLAUDIO ARRA;SABRINA ROSSETTI;DIANA GIANNARELLI;VINCENZA GRANATA","53;35;22;18;17;15;15;13;12;12;11;10;10;10;9;9;9;9;9;8","PAOLO A. ASCIERTO;GERARDO BOTTI;NICOLA MAUREA;GAETANO ROCCO;MICHELINO DE LAURENTIIS;ANTONIO AVALLONE;ALFREDO BUDILLON;MARCO CASCELLA;ROBERTA FUSCO;ANTONELLA PETRILLO;SUSAN COSTANTINI;GAETANO FACCHINI;PAOLO DELRIO;SANDRO PIGNATA;MARIA LINA TORNESELLO;FRANCO M. BUONAGURO;MONICA CANTILE;ALESSANDRO MORABITO;LUIGI BUONAGURO;CLAUDIO ARRA","3.27;3;1.46;1.41;1.4;1.34;1.23;1.13;1.08;1.04;1;0.99;0.97;0.95;0.88;0.88;0.86;0.83;0.82;0.81","PAOLO A. ASCIERTO;DIRK SCHADENDORF;MICHELE MAIO;MARIO MANDALÁ;CAROLINE ROBERT;RALF GUTZMER;GERARDO BOTTI;PIOTR RUTKOWSKI;VICTORIA ATKINSON;GEORGINA V. LONG;VANNA CHIARION‐SILENI;CAROLINE DUTRIAUX;PAOLO DELRIO;JAMES LARKIN;ANA ARANCE;GENNARO CILIBERTO;FABIANA TATANGELO;HELEN GOGAS;SHAHNEEN SANDHU;ADNAN KHATTAK","7680;3676;3622;3464;3425;3043;2401;2212;2120;2094;1934;1916;1894;1836;1833;1802;1781;1753;1736;1734","PAOLO A. ASCIERTO;GERARDO BOTTI;PAOLO DELRIO;FABIANA TATANGELO;MICHELINO DE LAURENTIIS;SANDRO PIGNATA;ALESSANDRO MORABITO;DOMENICO MALLARDO;GABRIELE MADONNA;ESTER SIMEONE;MARIAELENA CAPONE;SISTO PERDONÀ;CORRADO CARACÒ;ERNESTA CAVALCANTI;ANTONIO M. GRIMALDI;VITO VANELLA;LUCIA FESTINO;MIRIAM PAONE;GAETANO FACCHINI;CLAUDIO ARRA","7680;2383;1894;1781;1673;1201;1013;498;468;444;435;422;372;363;362;362;361;361;351;328","PAOLO A. ASCIERTO;GERARDO BOTTI;MICHELINO DE LAURENTIIS;ANTONIO AVALLONE;SANDRO PIGNATA;ALFREDO BUDILLON;PAOLO DELRIO;GAETANO FACCHINI;ANTONELLA PETRILLO;ALESSANDRO MORABITO;NICOLA NORMANNO;GAETANO ROCCO;SALVATORE TAFUTO;ROBERTA FUSCO;FABIANA TATANGELO;CLAUDIO ARRA;SABRINA ROSSETTI;ALFONSO DE STEFANO;MONICA CANTILE;VINCENZA GRANATA","53;33;22;18;16;15;15;13;12;12;11;10;10;10;9;9;9;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;ART;HISTORY","274;95;36;18;17;5;5;5;3;3;3;3;3;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;GASTROENTEROLOGY;PATHOLOGY;BIOCHEMISTRY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PALEONTOLOGY;PHARMACOLOGY;RADIOLOGY;UROLOGY;GYNECOLOGY;CELL BIOLOGY;NUCLEAR MEDICINE;FAMILY MEDICINE;NURSING;MOLECULAR BIOLOGY","246;153;81;64;55;55;50;37;31;29;19;19;18;18;16;13;13;12;12;11","CANCER;CHEMOTHERAPY;CLINICAL TRIAL;MELANOMA;GENE;ADVERSE EFFECT;POPULATION;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;ALTERNATIVE MEDICINE;COHORT;APOPTOSIS;IMMUNE SYSTEM;DISEASE;RECEPTOR;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);IN VITRO;PROPORTIONAL HAZARDS MODEL;RADIATION THERAPY","194;49;46;39;37;36;29;27;24;22;18;18;17;16;15;15;15;15;13;13;13","BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;COLORECTAL CANCER;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;METASTATIC MELANOMA;PLACEBO;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;DOCETAXEL;METASTASIS;BEVACIZUMAB;TOLERABILITY;OVARIAN CANCER;PROGRESSIVE DISEASE;CANCER CELL;MUTATION;BLADDER CANCER;CISPLATIN;EPIDERMAL GROWTH FACTOR RECEPTOR;THYROID CANCER","50;43;40;36;19;17;16;16;14;14;12;11;10;10;9;9;8;8;7;7;7;7","NIVOLUMAB;METASTATIC BREAST CANCER;VEMURAFENIB;IPILIMUMAB;KRAS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;ANDROGEN DEPRIVATION THERAPY;PEMBROLIZUMAB;ANDROGEN RECEPTOR;ERLOTINIB;ESTROGEN RECEPTOR;OXALIPLATIN;TAMOXIFEN;CARBOPLATIN;CETUXIMAB;IRINOTECAN;AROMATASE;NEOADJUVANT THERAPY;TRIPLE-NEGATIVE BREAST CANCER","20;14;13;10;9;8;8;7;7;6;6;6;6;6;5;5;5;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;MELANOMA;ADULT;SKIN NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;AGED, 80 AND OVER;ITALY;BREAST NEOPLASMS;ANTINEOPLASTIC AGENTS;RETROSPECTIVE STUDIES;KIDNEY NEOPLASMS;TREATMENT OUTCOME;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;PROTO-ONCOGENE PROTEINS B-RAF","156;140;102;85;84;77;73;62;54;49;43;40;38;37;34;30;29;29;28;28","CANCER IMMUNOTHERAPY;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MELANOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;RENAL CELL CARCINOMA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GYNECOLOGIC ONCOLOGY;IMMUNOBIOLOGY OF DENDRITIC CELLS;LYMPHOID NEOPLASMS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SALIVARY GLAND TUMORS AND CARCINOMAS;ADVANCES IN METABOLOMICS RESEARCH","23;16;14;12;11;8;8;7;7;6;6;5;5;4;4;4;4;4;4;3","CLINICAL ENDPOINT;MELANOMA;PROGRESSION-FREE SURVIVAL;BREAST CANCER;TREATMENT;METASTATIC COLORECTAL CANCER;TOLERABILITY;BIOMARKERS FOR IMMUNOTHERAPY;CONCOMITANT;NEOADJUVANT THERAPY;CANCER;DISCONTINUATION;EVEROLIMUS;METASTATIC BREAST CANCER;TRASTUZUMAB;BLADDER CANCER;EGFR MUTATIONS;EXPANDED ACCESS;FOLFIRI;FULVESTRANT","44;28;17;13;12;10;10;8;8;8;7;7;7;7;7;6;6;6;6;6","BREAST CANCER;PHASE III;PATIENTS PTS;CANCER PATIENTS;CELL CARCINOMA;COLORECTAL CANCER;LUNG CANCER;METASTATIC COLORECTAL;METASTATIC BREAST;PHASE II;PROSTATE CANCER;LOCALLY ADVANCED;METASTATIC MELANOMA;OVARIAN CANCER;PHASE TRIAL;ADVANCED BREAST;III STUDY;ADVANCED MELANOMA;VERSUS PLACEBO;CANCER ABC;EPIDERMAL GROWTH;GROWTH FACTOR;ONCOLOGYEUROPEAN SOCIETY;PATIENTS TREATED;RANDOMISED PHASE;RANDOMIZED PHASE;RECTAL CANCER;RENAL CELL;THYROID CANCER;ACCESS PROGRAM","36;19;15;13;13;13;11;11;10;10;10;9;9;9;9;8;8;7;7;6;6;6;6;6;6;6;6;6;6;5","HR CI;MONTHS CI;BREAST CANCER;CLINICAL TRIAL;ECOG PS;ENTITY RESPONSIBLE;LEGAL ENTITY;BRISTOL-MYERS SQUIBB;PROGRESSION-FREE SURVIVAL;BRAIN METASTASES;CELL LINES;PERSONAL FEES;SURVIVAL OS;HAZARD RATIO;MEDIAN PFS;ADVERSE EVENTS;RESPONSE RATE;ADVISORY BOARD;CERVICAL CANCER;TRIAL IDENTIFICATION;CLINICAL TRIALS;MEDIAN AGE;MEDIAN OS;MEDIAN TIME;SURVIVAL PFS;RESEARCH FUNDING;BOEHRINGER INGELHEIM;MEDIAN FOLLOW-UP;PATIENTS TREATED;CONFIDENCE INTERVAL","46;44;38;35;32;32;32;29;29;28;28;28;28;27;27;26;26;24;23;23;22;22;22;22;22;21;19;19;19;18",127,0.42,2.6,61.22,2,447,3.31,1,12,1.69,1,5,1.7,1,3,10,1,65,4.22,1,11,0,0,0,1.33,1,3,76.41,2,533,1,1,1,1,1,1,48.87,1,395,1.5,1,2,2,1,3,2.94,1,8,10.6,1,83,29.23,1,221,14.8,1,84,0.06,0,1,0,0,0,253.47,10,1120,253.53,10,1120
"IRCCS_PASCALE",2019,366,16.2021857923497,3.32786885245902,0.300492610837438,0.26775956284153,0.278688524590164,0.262295081967213,0.592896174863388,1,215,74,34,11,0.59,0.2,0.09,0.03,50.57,2.07966742279647,0.505464480874317,0.926229508196721,7.91603439554881,0.566223851688234,0.567029218689664,0.545602311721149,0.573059790451095,"PAOLO A. ASCIERTO;GERARDO BOTTI;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;ALESSANDRO MORABITO;NICOLA NORMANNO;DIRK SCHADENDORF;PAOLO MARCHETTI;CAROLINE ROBERT;REINHARD DUMMER;ANTONIO PINTO;MARCO CASCELLA;GEORGINA V. LONG;SABINO DE PLACIDO;ANTONIO AVALLONE;NICOLETTA COLOMBO;CLAUDIO ARRA;ANTONELLA PETRILLO;MARIO MANDALÁ;ANTÔNIO BARBIERI","70;38;29;26;25;22;19;16;16;15;14;14;14;14;14;14;13;13;12;12","PAOLO A. ASCIERTO;MARCO CASCELLA;GERARDO BOTTI;MICHELINO DE LAURENTIIS;SANDRO PIGNATA;DIRK SCHADENDORF;NICOLA NORMANNO;CLAUDIO ARRA;ALESSANDRO MORABITO;ANTONELLA PETRILLO;ANTÔNIO BARBIERI;NICOLA MAUREA;ROBERTA FUSCO;FRANCO M. BUONAGURO;FRANCESCO IZZO;ANTONIO AVALLONE;VINCENZA GRANATA;ANDREA BELLI;REINHARD DUMMER;FRANCESCO PERRONE","4.84;4.71;3.08;2.39;1.96;1.54;1.53;1.5;1.49;1.27;1.19;1.15;1.11;1.07;1.02;0.98;0.98;0.97;0.96;0.96","PAOLO A. ASCIERTO;GERARDO BOTTI;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;ALESSANDRO MORABITO;NICOLA NORMANNO;PAOLO MARCHETTI;ANTONIO PINTO;MARCO CASCELLA;SABINO DE PLACIDO;ANTONIO AVALLONE;CLAUDIO ARRA;ANTONELLA PETRILLO;ANTÔNIO BARBIERI;FRANCESCO PERRONE;FABIANA TATANGELO;VINCENZA GRANATA;MARIA CARMELA PICCIRILLO;SALVATORE TAFUTO;NICOLA MAUREA","70;38;29;26;25;22;16;14;14;14;14;13;13;12;12;11;11;11;10;10","PAOLO A. ASCIERTO;MARCO CASCELLA;GERARDO BOTTI;MICHELINO DE LAURENTIIS;SANDRO PIGNATA;NICOLA NORMANNO;CLAUDIO ARRA;ALESSANDRO MORABITO;ANTONELLA PETRILLO;ANTÔNIO BARBIERI;NICOLA MAUREA;ROBERTA FUSCO;FRANCO M. BUONAGURO;FRANCESCO IZZO;ANTONIO AVALLONE;VINCENZA GRANATA;ANDREA BELLI;FRANCESCO PERRONE;LUCIA DEL MASTRO;FABIANA TATANGELO","4.84;4.71;3.08;2.39;1.96;1.53;1.5;1.49;1.27;1.19;1.15;1.11;1.07;1.02;0.98;0.98;0.97;0.96;0.94;0.84","PAOLO A. ASCIERTO;REINHARD DUMMER;DIRK SCHADENDORF;PIOTR RUTKOWSKI;GEORGINA V. LONG;CÉLÈSTE LEBBÉ;IVÁN MÁRQUEZ‐RODAS;MICHAEL SMYLIE;MICHELE MAIO;VANNA CHIARION‐SILENI;RENÉ GONZÁLEZ;PIER FRANCESCO FERRUCCI;SANDRO PIGNATA;JAMES LARKIN;IGNACE VERGOTE;JEDD D. WOLCHOK;MATTEO S. CARLINO;JEAN‐JACQUES GROB;JOHN B.A.G. HAANEN;C. LANCE COWEY","8408;3880;3803;3481;3436;3433;3422;3395;3359;3354;3222;3194;3176;3166;3109;3103;3071;3042;3018;3003","PAOLO A. ASCIERTO;SANDRO PIGNATA;ALESSANDRO MORABITO;MICHELINO DE LAURENTIIS;GERARDO BOTTI;NICOLA NORMANNO;STEFANO GREGGI;ALFREDO BUDILLON;ANTONIO PINTO;GABRIELE MADONNA;VINCENZA GRANATA;FRANCESCO PERRONE;SIMONA LOSITO;ANTONIO AVALLONE;ANTONELLA PETRILLO;FRANCA AVINO;ROBERTA FUSCO;GIOSUÈ SCOGNAMIGLIO;FABIANA TATANGELO;LUIGI BUONAGURO","8408;3175;1731;984;815;765;529;422;414;374;257;251;234;232;226;226;226;220;217;214","PAOLO A. ASCIERTO;GERARDO BOTTI;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;ALESSANDRO MORABITO;NICOLA NORMANNO;ANTONIO AVALLONE;ANTONIO PINTO;CLAUDIO ARRA;MARCO CASCELLA;ANTONELLA PETRILLO;ANTÔNIO BARBIERI;FRANCESCO PERRONE;VINCENZA GRANATA;FABIANA TATANGELO;NICOLA MAUREA;SALVATORE TAFUTO;FRANCESCO IZZO;ALFREDO BUDILLON;GIOSUÈ SCOGNAMIGLIO","70;36;28;26;25;22;14;14;13;13;13;12;12;11;11;10;10;10;9;9","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;BUSINESS;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;ART;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;HISTORY","342;126;39;31;15;9;9;8;7;6;6;5;5;3;3;2;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;GENETICS;IMMUNOLOGY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;CELL BIOLOGY;PHARMACOLOGY;NUCLEAR MEDICINE;GYNECOLOGY;UROLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;FAMILY MEDICINE;NURSING;OPTICS","303;207;93;81;70;60;50;43;37;31;28;28;24;24;17;15;15;13;12;11;11;11","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;MELANOMA;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;POPULATION;IMMUNE SYSTEM;LUNG CANCER;STAGE (STRATIGRAPHY);CONFIDENCE INTERVAL;TOXICITY;COHORT;DISEASE;RECEPTOR;ADJUVANT;RETROSPECTIVE COHORT STUDY;HEPATOCELLULAR CARCINOMA;LYMPHOMA;PROPORTIONAL HAZARDS MODEL","237;86;49;47;47;36;35;28;25;23;22;22;21;17;16;16;16;14;14;12;12;12","IMMUNOTHERAPY;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;PHASES OF CLINICAL RESEARCH;PLACEBO;PROGRESSION-FREE SURVIVAL;METASTATIC MELANOMA;CISPLATIN;MUTATION;OVARIAN CANCER;BEVACIZUMAB;HAZARD RATIO;EPIDERMAL GROWTH FACTOR RECEPTOR;PACLITAXEL;RITUXIMAB;DOCETAXEL;GENOTYPE;INTERIM ANALYSIS;NEUTROPENIA;PROSTATE CANCER","73;53;49;47;26;24;20;18;17;17;17;16;15;13;10;10;9;9;9;9;9","NIVOLUMAB;PEMBROLIZUMAB;IPILIMUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;METASTATIC BREAST CANCER;VEMURAFENIB;IRINOTECAN;CARBOPLATIN;ERLOTINIB;KRAS;TAMOXIFEN;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;CETUXIMAB;OXALIPLATIN;GEFITINIB;GERMLINE MUTATION;IMMUNE CHECKPOINT;ANDROGEN RECEPTOR;HORMONE RECEPTOR;LENVATINIB;MICROSATELLITE;TAXANE;TRAMETINIB","30;26;17;14;12;12;9;8;8;8;8;8;8;7;7;6;6;6;5;5;5;5;5;5",";HUMANS;FEMALE;MALE;MIDDLE AGED;MELANOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;ADULT;SKIN NEOPLASMS;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;NEOPLASMS;AGED, 80 AND OVER;LUNG NEOPLASMS;OVARIAN NEOPLASMS;ANTINEOPLASTIC AGENTS;TREATMENT OUTCOME;CARCINOMA, NON-SMALL-CELL LUNG;RETROSPECTIVE STUDIES;ITALY","211;149;107;85;83;79;71;70;60;51;47;46;40;36;34;32;30;29;29;28","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MELANOMA;HEPATOCELLULAR CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;COLORECTAL CANCER RESEARCH AND TREATMENT;GYNECOLOGIC ONCOLOGY;HER2 SIGNALING IN BREAST CANCER TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;ECONOMIC BURDEN OF CANCER TREATMENT","45;17;17;15;15;14;13;9;8;7;7;6;5;5;5;5;5;4;4;4","CLINICAL ENDPOINT;MELANOMA;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;METASTATIC COLORECTAL CANCER;BREAST CANCER;BIOMARKERS FOR IMMUNOTHERAPY;CANCER IMMUNOEDITING;DISCONTINUATION;CANCER THERAPY;EGFR MUTATIONS;REFRACTORY (PLANETARY SCIENCE);TARGETED THERAPY;ADJUVANT THERAPY;AFATINIB;INTERIM ANALYSIS;INTRATUMOR HETEROGENEITY;TREATMENT;TUMOR REGRESSION;CARBOPLATIN","49;37;20;18;17;16;13;12;12;10;10;10;10;9;9;9;9;9;9;8","BREAST CANCER;PHASE II;PATIENTS PTS;PHASE III;COLORECTAL CANCER;CANCER PATIENTS;OVARIAN CANCER;LUNG CANCER;II STUDY;METASTATIC COLORECTAL;COLON CANCER;ADVANCED BREAST;VERSUS PLACEBO;ADVANCED MELANOMA;METASTATIC MELANOMA;RANDOMIZED PHASE;CELL CARCINOMA;FIRST-LINE TREATMENT;CANCER CELLS;CELL LUNG;GROWTH FACTOR;PATIENTS TREATED;ABSTRACT CT;ABSTRACT P--;ADVANCED OVARIAN;ADVANCED PANCREATIC;CANCER ABC;GIOTAG STUDY;HEPATOCELLULAR CARCINOMA;HORMONE RECEPTOR-POSITIVE","37;29;22;21;20;19;18;17;14;14;11;10;10;9;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6","ADVISORY CONSULTANCY;SPEAKER BUREAU;GRANT FUNDING;RESEARCH GRANT;ACCOMMODATION EXPENSES;EXPERT TESTIMONY;TRAVEL ACCOMMODATION;BUREAU EXPERT;FUNDING INSTITUTION;PUBMED SCOPUS;BREAST CANCER;CONSULTANCY SPEAKER;MONTHS CI;BOEHRINGER INGELHEIM;CROSSREF PUBMED;CONSULTANCY TRAVEL;CONSULTANCY RESEARCH;PROGRESSION-FREE SURVIVAL;ADVERSE EVENTS;HONORARIA INSTITUTION;CLINICAL TRIAL;MEDIAN OS;PIERRE FABRE;RESPONSE RATE;CANCER PATIENTS;LUNG CANCER;ROCHE HONORARIA;MD PHD;SPEAKERS BUREAU;ENTITY RESPONSIBLE","453;133;125;125;123;123;123;121;94;71;63;61;55;50;50;47;42;41;36;36;35;35;35;35;34;34;33;32;32;31",166,0.45,3.125,61.14,2,897,2.33,1,7,1.91,1,6,0,0,0,14.47,1,182,3,1,9,0,0,0,1.73,1,4,77.62,2,1113,1,1,1,1,1,1,53.11,1,698,1,1,1,1.5,1,2,2.69,1,15,12.62,1,132,34.94,1,427,11.72,1,124,0,0,0,0,0,0,211.29,8,1706,211.29,8,1706
"IRCCS_PASCALE",2020,451,17.5254988913526,3.18181818181818,0.314285714285714,0.268292682926829,0.286031042128603,0.197339246119734,0.669623059866962,4,247,74,38,29,0.55,0.16,0.08,0.06,33.75,1.33925191043775,0.514412416851441,0.931263858093126,9.79717813051151,0.61449361066093,0.553155637254902,0.521833905088622,0.479235668789809,"PAOLO A. ASCIERTO;GERARDO BOTTI;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;CAROLINE ROBERT;MARIO MANDALÁ;VINCENZA GRANATA;PAOLO DELRIO;DIRK SCHADENDORF;MARCO CASCELLA;GEORGINA V. LONG;NICOLA NORMANNO;CÉLÈSTE LEBBÉ;FRANCESCO IZZO;ROBERTA FUSCO;ANA ARANCE;SEBASTIANO BUTI;REINHARD DUMMER;DANIELE SANTINI;ALESSANDRO MORABITO","89;51;39;34;27;22;22;22;21;19;19;18;18;18;17;16;16;16;16;15","PAOLO A. ASCIERTO;MARCO CASCELLA;GERARDO BOTTI;LUIGI BUONAGURO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;VINCENZA GRANATA;MONICA CANTILE;NICOLA MAUREA;FRANCESCO IZZO;ROBERTA FUSCO;NICOLA NORMANNO;PAOLO DELRIO;CAROLINE ROBERT;ALFREDO BUDILLON;ANTONELLA PETRILLO;MARIA LINA TORNESELLO;VINCENZO QUAGLIARIELLO;ANTONIO GIORDANO;RAFFAÉLE PALAIA","6.63;5.89;4.48;3.47;2.79;2.4;1.95;1.79;1.64;1.57;1.53;1.44;1.37;1.34;1.29;1.25;1.19;1.16;1.15;1.07","PAOLO A. ASCIERTO;GERARDO BOTTI;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;VINCENZA GRANATA;PAOLO DELRIO;MARCO CASCELLA;NICOLA NORMANNO;FRANCESCO IZZO;ROBERTA FUSCO;ALESSANDRO MORABITO;ANTONIO AVALLONE;LUIGI BUONAGURO;ANTONELLA PETRILLO;NICOLA MAUREA;FABIANA TATANGELO;ERNESTA CAVALCANTI;DOMENICO MALLARDO;STEFANO GREGGI;MARILENA DI NAPOLI","89;51;39;34;22;22;19;18;18;17;15;15;14;14;14;13;13;13;11;11","PAOLO A. ASCIERTO;MARCO CASCELLA;GERARDO BOTTI;LUIGI BUONAGURO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;VINCENZA GRANATA;MONICA CANTILE;NICOLA MAUREA;FRANCESCO IZZO;ROBERTA FUSCO;NICOLA NORMANNO;PAOLO DELRIO;ALFREDO BUDILLON;ANTONELLA PETRILLO;MARIA LINA TORNESELLO;VINCENZO QUAGLIARIELLO;ANTONIO GIORDANO;RAFFAÉLE PALAIA;VITTORIO ALBINO","6.63;5.89;4.48;3.47;2.79;2.4;1.95;1.79;1.64;1.57;1.53;1.44;1.37;1.29;1.25;1.19;1.16;1.15;1.07;0.98","PAOLO A. ASCIERTO;MARCO CASCELLA;ARTURO CUOMO;MICHAEL RAJNIK;RAFFAELA DI NAPOLI;SCOTT C. DULEBOHN;CAROLINE ROBERT;PIOTR RUTKOWSKI;MARIO MANDALÁ;HELEN GOGAS;DIRK SCHADENDORF;VICTORIA ATKINSON;RALF GUTZMER;GEORGINA V. LONG;GERARDO BOTTI;ANA ARANCE;JAMES LARKIN;PAUL LORIGAN;MICHELINO DE LAURENTIIS;VANNA CHIARION‐SILENI","4432;3193;3025;2873;2705;2705;2164;1784;1735;1518;1403;1399;1349;1318;1294;1225;1155;1055;1043;1036","PAOLO A. ASCIERTO;MARCO CASCELLA;GERARDO BOTTI;MICHELINO DE LAURENTIIS;ANTONIO PINTO;PAOLO DELRIO;SANDRO PIGNATA;DOMENICO MALLARDO;ADRIANO GRAVINA;VINCENZA GRANATA;LUCA FALZONE;STEFANO GREGGI;ROBERTA FUSCO;ALESSANDRO MORABITO;FABIANA TATANGELO;MARIA GRAZIA VITALE;LUIGI BUONAGURO;ARTURO CUOMO;ANTONELLA PETRILLO;ANNA CRISPO","4429;3193;1259;1043;689;622;590;569;485;477;426;403;394;392;390;360;325;320;312;309","PAOLO A. ASCIERTO;GERARDO BOTTI;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;PAOLO DELRIO;VINCENZA GRANATA;MARCO CASCELLA;FRANCESCO IZZO;NICOLA NORMANNO;ALESSANDRO MORABITO;ROBERTA FUSCO;ANTONIO AVALLONE;LUIGI BUONAGURO;ANTONELLA PETRILLO;DOMENICO MALLARDO;ERNESTA CAVALCANTI;NICOLA MAUREA;FABIANA TATANGELO;ANNA CRISPO;MARILENA DI NAPOLI","87;49;39;34;24;22;19;17;17;15;15;15;14;13;13;13;13;12;11;11","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;POLITICAL SCIENCE;PSYCHOLOGY;MATHEMATICS;ECONOMICS;BUSINESS;PHILOSOPHY;GEOGRAPHY;MATERIALS SCIENCE;SOCIOLOGY;ENGINEERING;HISTORY;ART;GEOLOGY","421;142;52;24;24;14;10;9;6;5;5;4;4;4;3;3;2;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;PALEONTOLOGY;UROLOGY;RADIOLOGY;CELL BIOLOGY;VIROLOGY;ENDOCRINOLOGY;NURSING;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY","379;217;124;96;80;75;70;69;54;45;31;30;26;25;24;20;19;17;16;16","CANCER;CHEMOTHERAPY;GENE;MELANOMA;DISEASE;CLINICAL TRIAL;CONFIDENCE INTERVAL;ADVERSE EFFECT;POPULATION;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;IMMUNE SYSTEM;COHORT;LUNG CANCER;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);OUTBREAK;LUNG;ADJUVANT;RECEPTOR","277;90;78;60;55;52;49;48;42;32;29;29;23;23;23;20;18;17;16;16","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);METASTATIC MELANOMA;PROGRESSION-FREE SURVIVAL;OVARIAN CANCER;PLACEBO;METASTASIS;PHASES OF CLINICAL RESEARCH;BEVACIZUMAB;TOLERABILITY;CISPLATIN;MAPK/ERK PATHWAY;2019-20 CORONAVIRUS OUTBREAK;POLYMERASE;PROSTATE CANCER;CANCER CELL;GENE EXPRESSION","88;58;48;47;37;33;28;28;26;26;23;22;15;15;13;12;11;11;11;10;10","NIVOLUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;VEMURAFENIB;IPILIMUMAB;METASTATIC BREAST CANCER;POLY ADP RIBOSE POLYMERASE;KRAS;TRASTUZUMAB;OXALIPLATIN;TRAMETINIB;TRIPLE-NEGATIVE BREAST CANCER;CARBOPLATIN;CETUXIMAB;ESTROGEN RECEPTOR;TAXANE;CXCR4;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAMOXIFEN;ANDROGEN DEPRIVATION THERAPY;ELECTROCHEMOTHERAPY","38;33;31;20;16;14;11;9;9;8;8;8;7;7;7;7;6;6;6;5;5",";HUMANS;FEMALE;MELANOMA;MIDDLE AGED;MALE;AGED;SKIN NEOPLASMS;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;ANTIBODIES, MONOCLONAL, HUMANIZED;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;BREAST NEOPLASMS;PROTO-ONCOGENE PROTEINS B-RAF;OVARIAN NEOPLASMS;PNEUMONIA, VIRAL","300;148;98;92;77;74;66;62;57;48;46;40;39;37;35;32;31;30;28;27","CANCER IMMUNOTHERAPY;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;RENAL CELL CARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;MELANOMA;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;ROLE OF CHEMOKINE RECEPTORS IN CANCER METASTASIS","43;28;17;17;15;13;12;11;9;8;7;7;7;6;6;5;5;5;5;5","CLINICAL ENDPOINT;MELANOMA;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;IMMUNE CHECKPOINT BLOCKADE;BREAST CANCER;PANDEMIC;OLAPARIB;TOLERABILITY;REGIMEN;CANCER THERAPY;METASTATIC COLORECTAL CANCER;TUMOR REGRESSION;CANCER GENOMICS;PLATINUM-SENSITIVE OVARIAN CANCER;TUMOR MICROENVIRONMENT;2019-20 CORONAVIRUS OUTBREAK;ATEZOLIZUMAB;CANCER;CANCER IMMUNOTHERAPY","47;41;28;23;18;16;16;15;15;13;12;12;12;10;10;10;9;9;9;9","BREAST CANCER;CANCER PATIENTS;PHASE III;OVARIAN CANCER;PATIENTS PTS;COLORECTAL CANCER;PHASE II;CELL CARCINOMA;METASTATIC MELANOMA;ADVANCED BREAST;PROSTATE CANCER;IMMUNE CHECKPOINT;LUNG CANCER;METASTATIC RENAL;ADVANCED MELANOMA;CANCER ABC;II STUDY;METASTATIC COLORECTAL;PATIENTS TREATED;ADVERSE EVENTS;CHECKPOINT INHIBITORS;CLINICAL OUTCOMES;HEPATOCELLULAR CARCINOMA;LOCALLY ADVANCED;MELANOMA PATIENTS;NEWLY DIAGNOSED;RENAL CELL;TRIPLE-NEGATIVE BREAST;ABSTRACT P--;CANCER CELLS","44;26;23;22;22;21;16;13;13;12;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;7;6;6","HR CI;CANCER PATIENTS;BREAST CANCER;MONTHS CI;RESPONSE RATE;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;MEDIAN FOLLOW-UP;HAZARD RATIO;LUNG CANCER;SURVIVAL PFS;PATIENTS TREATED;ADVERSE EVENTS;OBJECTIVE RESPONSE;CLINICAL PRACTICE;STAGE III;CELL LINES;PRIMARY ENDPOINT;PATIENTS PTS;COLON CANCER;PHASE III;COMPLETE RESPONSE;IMMUNE CHECKPOINT;SECONDARY ENDPOINTS;CHECKPOINT INHIBITORS;PHASE II;CANCER CELLS;GENE EXPRESSION;PATIENTS RECEIVING;PLATINUM-BASED CHEMOTHERAPY","77;46;43;41;41;40;35;34;33;33;31;30;28;28;26;26;25;25;23;22;22;21;21;21;20;20;19;19;19;19",234,0.52,2.925,33.53,2,182,1.19,1,2,1.31,1,2,0,0,0,5.51,1,84,1.25,1,2,0,0,0,1.17,1,2,42.32,2,244,1,1,1,1,1,1,29.96,1,177,1,1,1,1,1,1,2.03,1,7,8.74,1,42,17.41,1,84,6.17,1,51,0,0,0,0,0,0,110.32,17,413,110.24,17,413
"IRCCS_PASCALE",2021,493,19.0730223123732,3.37931034482759,0.295918367346939,0.314401622718053,0.316430020283976,0.196754563894523,0.709939148073022,2,243,87,53,23,0.49,0.18,0.11,0.05,20.65,1.33891739520614,0.478701825557809,0.9026369168357,9.86708122813832,0.623441654314194,0.590713053479011,0.474003362151777,0.541477012102607,"PAOLO A. ASCIERTO;SANDRO PIGNATA;GERARDO BOTTI;VINCENZA GRANATA;ROBERTA FUSCO;MICHELINO DE LAURENTIIS;ANTONELLA PETRILLO;MARCO CASCELLA;NICOLA MAUREA;VINCENZO QUAGLIARIELLO;GEORGINA V. LONG;UGO DE GIORGI;MARTINA IOVINE;ANTONIO PINTO;ANTONIO AVALLONE;DIRK SCHADENDORF;ALESSANDRO MORABITO;FRANCESCO IZZO;SIMONA BUCCOLO;ANDREA PACCONE","86;53;44;38;37;31;28;28;28;25;24;23;23;21;21;20;20;20;19;19","MARCO CASCELLA;PAOLO A. ASCIERTO;GERARDO BOTTI;NICOLA MAUREA;VINCENZO QUAGLIARIELLO;MARTINA IOVINE;VINCENZA GRANATA;ROBERTA FUSCO;SANDRO PIGNATA;ANDREA PACCONE;SIMONA BUCCOLO;ALESSANDRO OTTAIANO;ANTONELLA PETRILLO;MICHELINO DE LAURENTIIS;FRANCESCO IZZO;FRANCESCO PERRONE;LUIGI BUONAGURO;ANTONIO AVALLONE;CARMINE PINTO;ROBERTA GRASSI","7.3;5.46;4.35;3.57;3.22;3.15;2.78;2.76;2.61;2.6;2.51;2.32;2.31;1.99;1.51;1.48;1.46;1.46;1.44;1.3","PAOLO A. ASCIERTO;SANDRO PIGNATA;GERARDO BOTTI;VINCENZA GRANATA;ROBERTA FUSCO;MICHELINO DE LAURENTIIS;ANTONELLA PETRILLO;MARCO CASCELLA;NICOLA MAUREA;VINCENZO QUAGLIARIELLO;MARTINA IOVINE;ANTONIO PINTO;ANTONIO AVALLONE;ALESSANDRO MORABITO;FRANCESCO IZZO;SIMONA BUCCOLO;ANDREA PACCONE;NICOLA NORMANNO;ROBERTO GRASSI;LUIGI BUONAGURO","86;53;44;38;37;31;28;28;28;25;23;21;21;20;20;19;19;18;18;16","MARCO CASCELLA;PAOLO A. ASCIERTO;GERARDO BOTTI;NICOLA MAUREA;VINCENZO QUAGLIARIELLO;MARTINA IOVINE;VINCENZA GRANATA;ROBERTA FUSCO;SANDRO PIGNATA;ANDREA PACCONE;SIMONA BUCCOLO;ALESSANDRO OTTAIANO;ANTONELLA PETRILLO;MICHELINO DE LAURENTIIS;FRANCESCO IZZO;FRANCESCO PERRONE;LUIGI BUONAGURO;ANTONIO AVALLONE;CARMINE PINTO;LUCA FALZONE","7.3;5.46;4.35;3.57;3.22;3.15;2.78;2.76;2.61;2.6;2.51;2.32;2.31;1.99;1.51;1.48;1.46;1.46;1.44;1.3","PAOLO A. ASCIERTO;SANDRO PIGNATA;GEORGINA V. LONG;DIRK SCHADENDORF;GIOVANNI SCAMBIA;MATTEO S. CARLINO;MICHELINO DE LAURENTIIS;CÉLÈSTE LEBBÉ;JAMES LARKIN;CHRISTIAN U. BLANK;PIOTR RUTKOWSKI;NICOLETTA COLOMBO;JEAN‐JACQUES GROB;DOUGLAS B. JOHNSON;REINHARD DUMMER;RICHARD T. PENSON;VINCENZA GRANATA;MICHELE MAIO;VANNA CHIARION‐SILENI;GABE S. SONKE","2911;1815;1473;1244;1168;1114;1082;1036;1010;967;956;934;905;896;893;882;863;840;831;799","PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;VINCENZA GRANATA;GERARDO BOTTI;ANTONIO PINTO;ANTONELLA PETRILLO;ANTONIO AVALLONE;ROBERTA FUSCO;FRANCESCO IZZO;PAOLO DELRIO;NICOLA MAUREA;VINCENZO QUAGLIARIELLO;FRANCESCO PERRONE;ANDREA PACCONE;ANTÔNIO BARBIERI;DANIELA REGA;DOMENICA REA;GIOSUÈ SCOGNAMIGLIO;CLAUDIA TROJANIELLO","2911;1808;1080;863;728;697;602;433;414;389;337;303;300;297;280;258;255;255;249;247","PAOLO A. ASCIERTO;SANDRO PIGNATA;GERARDO BOTTI;VINCENZA GRANATA;MICHELINO DE LAURENTIIS;MARCO CASCELLA;ANTONELLA PETRILLO;NICOLA MAUREA;VINCENZO QUAGLIARIELLO;ANTONIO PINTO;ANTONIO AVALLONE;ALESSANDRO MORABITO;MARTINA IOVINE;FRANCESCO IZZO;NICOLA NORMANNO;ROBERTA FUSCO;SIMONA BUCCOLO;LUIGI BUONAGURO;PAOLO DELRIO;ANDREA PACCONE","86;52;42;38;29;28;27;27;26;21;21;20;20;19;18;18;16;16;16;16","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;ENGINEERING;ECONOMICS;SOCIOLOGY;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;ART;ENVIRONMENTAL SCIENCE;HISTORY;BUSINESS;GEOLOGY","470;128;49;36;25;21;16;11;8;7;6;4;4;4;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;GENETICS;RADIOLOGY;PHARMACOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;NURSING;GYNECOLOGY;FAMILY MEDICINE;UROLOGY","412;256;119;107;89;66;58;56;52;48;43;31;29;27;26;26;23;22;19;19","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;ADVERSE EFFECT;DISEASE;MELANOMA;CLINICAL TRIAL;POPULATION;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;IMMUNE SYSTEM;LUNG CANCER;ALTERNATIVE MEDICINE;COHORT;STAGE (STRATIGRAPHY);LYMPHOMA;APOPTOSIS;RECEPTOR;ADJUVANT;OUTBREAK;TOXICITY","292;102;63;62;61;60;58;56;54;44;39;33;30;29;28;23;21;18;18;17;17;17","IMMUNOTHERAPY;BREAST CANCER;HAZARD RATIO;CLINICAL ENDPOINT;COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;PHASES OF CLINICAL RESEARCH;PLACEBO;TOLERABILITY;BEVACIZUMAB;CISPLATIN;METASTATIC MELANOMA;2019-20 CORONAVIRUS OUTBREAK;CARDIOTOXICITY;METASTASIS;BLADDER CANCER;PROGRESSIVE DISEASE;THYROID CANCER","106;56;45;44;43;39;29;26;21;21;19;18;18;17;16;15;13;12;12;12","NIVOLUMAB;PEMBROLIZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);IPILIMUMAB;CARBOPLATIN;TRASTUZUMAB;METASTATIC BREAST CANCER;CETUXIMAB;LENVATINIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CANCER IMMUNOTHERAPY;ELECTROCHEMOTHERAPY;IMMUNE CHECKPOINT;TAMOXIFEN;VEMURAFENIB;KRAS;NEOADJUVANT THERAPY;AXITINIB;CXCR4;MICROSATELLITE;POLY ADP RIBOSE POLYMERASE","42;40;39;27;12;12;11;10;10;9;8;8;8;8;8;7;7;6;6;6;6",";HUMANS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;MELANOMA;MIDDLE AGED;MALE;SKIN NEOPLASMS;AGED;ADULT;NEOPLASMS;IMMUNE CHECKPOINT INHIBITORS;COVID-19;RETROSPECTIVE STUDIES;ANTIBODIES, MONOCLONAL, HUMANIZED;NEOPLASM RECURRENCE, LOCAL;OVARIAN NEOPLASMS;COLORECTAL NEOPLASMS;ITALY;LUNG NEOPLASMS","324;165;88;85;74;65;57;54;53;49;48;45;43;43;40;38;35;32;31;30","CANCER IMMUNOTHERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;RADIOMICS IN MEDICAL IMAGING ANALYSIS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;LYMPHOID NEOPLASMS;GYNECOLOGIC ONCOLOGY;CARDIOTOXICITY OF CANCER TREATMENTS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;COLORECTAL CANCER RESEARCH AND TREATMENT;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;RENAL CELL CARCINOMA;MELANOMA;HEPATOCELLULAR CARCINOMA;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;ADVANCEMENTS IN LUNG CANCER RESEARCH","52;20;19;17;15;13;12;12;11;10;10;9;8;8;8;8;7;6;6;5","CLINICAL ENDPOINT;BIOMARKERS FOR IMMUNOTHERAPY;MELANOMA;PROGRESSION-FREE SURVIVAL;IMMUNE CHECKPOINT BLOCKADE;BREAST CANCER;TOLERABILITY;METASTATIC COLORECTAL CANCER;2019-20 CORONAVIRUS OUTBREAK;CARDIOTOXICITY;PANDEMIC;TUMOR MICROENVIRONMENT;CANCER IMAGING;CANCER IMMUNOEDITING;CARBOPLATIN;DISCONTINUATION;CANCER IMMUNOTHERAPY;REGIMEN;TRASTUZUMAB;LENVATINIB","44;33;33;28;26;21;19;17;16;15;14;14;13;12;12;12;11;11;11;10","BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;PHASE III;OVARIAN CANCER;CELL CARCINOMA;LUNG CANCER;PHASE II;METASTATIC COLORECTAL;IMMUNE CHECKPOINT;PATIENTS PTS;RANDOMIZED PHASE;METASTATIC MELANOMA;ADVANCED BREAST;ENDOMETRIAL CANCER;CHECKPOINT INHIBITORS;LOCALLY ADVANCED;MELANOMA PATIENTS;RECTAL CANCER;ADVANCED MELANOMA;COMPUTED TOMOGRAPHY;FIRST-LINE TREATMENT;RANDOMIZED CONTROLLED;RETROSPECTIVE STUDY;CONTROLLED TRIAL;EPIDERMAL GROWTH;GROWTH FACTOR;MULTICENTER STUDY;ADVANCED ENDOMETRIAL;ADVANCED OVARIAN","34;29;26;23;20;19;19;18;17;16;15;13;12;11;11;10;9;9;9;8;8;8;8;8;7;7;7;7;6;6","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HR CI;HONORARIA MEMBERSHIP;MONTHS CI;SURVIVAL OS;ADVERSE EVENTS;PROGRESSION-FREE SURVIVAL;RESPONSE RATE;BREAST CANCER;BRISTOL MYERS;CANCER PATIENTS;MYERS SQUIBB;PATIENTS TREATED;HONORARIA RESEARCH;SURVIVAL PFS;HAZARD RATIO;IMMUNE CHECKPOINT;CONFIDENCE INTERVAL;CONSULTANCY MEMBERSHIP;NATIONAL RESEARCH;BIOLOGY NATIONAL;CELL BIOLOGY;MEDIAN FOLLOW-UP;STATISTICALLY SIGNIFICANT;CELL CARCINOMA;RESEARCH COUNCIL","174;164;164;88;84;70;62;62;55;54;53;48;45;45;41;40;40;39;39;38;37;35;35;35;34;34;33;33;32;32",257,0.52,2.85,41.88,2,305,1,1,1,1.41,1,3,0,0,0,5.49,1,121,1,1,1,0,0,0,1,1,1,50.32,2,365,1,1,1,1,1,1,41.42,1,200,0,0,0,1.6,1,4,2.22,1,5,10.57,1,39,26.29,1,190,9.44,1,32,0,0,0,0,0,0,69.38,6,314,67.6,6,314
"IRCCS_PASCALE",2022,548,18.6751824817518,3.51094890510949,0.284823284823285,0.306569343065693,0.304744525547445,0.167883211678832,0.720802919708029,6,264,87,64,28,0.48,0.16,0.12,0.05,15.15,1.69729863847332,0.494525547445255,0.89963503649635,9.06044538706262,0.634294207193935,0.596913580246914,0.569877717805629,0.603367815197947,"PAOLO A. ASCIERTO;SANDRO PIGNATA;GEORGINA V. LONG;VINCENZA GRANATA;DIRK SCHADENDORF;DOMENICA LORUSSO;NICOLA MAUREA;NICOLA NORMANNO;MICHELINO DE LAURENTIIS;SIMONA BUCCOLO;VINCENZO QUAGLIARIELLO;FRANCESCO IZZO;ANTONELLA PETRILLO;ROBERTA FUSCO;PIOTR RUTKOWSKI;ANDREA PACCONE;CAROLINE ROBERT;GIOVANNI SCAMBIA;ANTONIO PINTO;MARCO CASCELLA","88;64;33;32;30;30;30;27;27;27;27;26;25;25;25;23;23;22;20;20","PAOLO A. ASCIERTO;MARCO CASCELLA;SANDRO PIGNATA;NICOLA MAUREA;SIMONA BUCCOLO;VINCENZO QUAGLIARIELLO;LUIGI BUONAGURO;ANDREA PACCONE;VINCENZA GRANATA;FRANCESCO IZZO;MARTINA IOVINE;MICHELINO DE LAURENTIIS;LUCA FALZONE;DIRK SCHADENDORF;ROBERTA FUSCO;DOMENICA LORUSSO;NICOLA NORMANNO;ANTONELLA PETRILLO;GUGLIELMO NASTI;ALESSANDRO OTTAIANO","5.06;3.77;3.76;3.68;3.4;3.38;3.3;2.87;2.67;2.54;2.34;2.01;1.89;1.89;1.78;1.76;1.68;1.65;1.63;1.61","PAOLO A. ASCIERTO;SANDRO PIGNATA;VINCENZA GRANATA;NICOLA MAUREA;NICOLA NORMANNO;MICHELINO DE LAURENTIIS;SIMONA BUCCOLO;VINCENZO QUAGLIARIELLO;FRANCESCO IZZO;ANTONELLA PETRILLO;ANDREA PACCONE;ANTONIO PINTO;MARCO CASCELLA;ANTONIO AVALLONE;PAOLO MUTO;ANDREA BELLI;LUIGI BUONAGURO;ANNA CRISPO;GUGLIELMO NASTI;ALFREDO BUDILLON","88;64;32;30;27;27;27;27;26;25;23;20;20;19;18;17;17;17;17;16","PAOLO A. ASCIERTO;MARCO CASCELLA;SANDRO PIGNATA;NICOLA MAUREA;SIMONA BUCCOLO;VINCENZO QUAGLIARIELLO;LUIGI BUONAGURO;ANDREA PACCONE;VINCENZA GRANATA;FRANCESCO IZZO;MARTINA IOVINE;MICHELINO DE LAURENTIIS;LUCA FALZONE;NICOLA NORMANNO;ANTONELLA PETRILLO;GUGLIELMO NASTI;ALESSANDRO OTTAIANO;ANDREA BELLI;CARMEN CUTOLO;MARIA TAGLIAMONTE","5.06;3.77;3.76;3.68;3.4;3.38;3.3;2.87;2.67;2.54;2.34;2.01;1.89;1.68;1.65;1.63;1.61;1.5;1.46;1.42","PAOLO A. ASCIERTO;PIOTR RUTKOWSKI;DIRK SCHADENDORF;GEORGINA V. LONG;JEAN‐JACQUES GROB;NICOLA NORMANNO;HELEN GOGAS;CAROLINE ROBERT;ANA ARANCE;TAKAYUKI YOSHINO;ANTONIO AVALLONE;REINHARD DUMMER;DO‐YOUN OH;STÉPHANE DALLE;HUSSEIN A. TAWBI;MARIO MANDALÁ;MATTEO S. CARLINO;ERIKA MARTINELLI;AIWU RUTH HE;ARNDT VOGEL","2719;1756;1713;1713;1541;1348;1270;1114;1074;999;975;970;922;905;883;873;802;731;705;705","PAOLO A. ASCIERTO;NICOLA NORMANNO;ANTONIO AVALLONE;SANDRO PIGNATA;VINCENZA GRANATA;ANTONELLA PETRILLO;FRANCESCO IZZO;FRANCESCO PERRONE;FABIANA TATANGELO;SERGIO VENANZIO SETOLA;GUGLIELMO NASTI;ALESSANDRO OTTAIANO;MICHELINO DE LAURENTIIS;DOMENICO MALLARDO;LUIGI BUONAGURO;ANNABELLA DI MAURO;ALESSANDRO MORABITO;ANTONIO PINTO;PAOLO DELRIO;MARCO CASCELLA","2719;1340;975;667;503;401;345;293;271;266;246;243;217;154;148;137;131;130;126;124","PAOLO A. ASCIERTO;SANDRO PIGNATA;VINCENZA GRANATA;VINCENZO QUAGLIARIELLO;NICOLA MAUREA;MICHELINO DE LAURENTIIS;NICOLA NORMANNO;FRANCESCO IZZO;SIMONA BUCCOLO;ANTONELLA PETRILLO;ANDREA PACCONE;ANTONIO PINTO;MARCO CASCELLA;ANTONIO AVALLONE;PAOLO MUTO;ANDREA BELLI;ANNA CRISPO;GUGLIELMO NASTI;LUIGI BUONAGURO;MARTINA IOVINE","87;63;31;30;30;27;26;26;24;22;21;20;20;19;18;17;17;17;17;16","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;ENGINEERING;PHILOSOPHY;BUSINESS;HISTORY;ART;GEOGRAPHY;MATERIALS SCIENCE","524;149;68;43;21;20;17;13;13;11;9;6;3;3;2;2;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;BIOCHEMISTRY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;PHARMACOLOGY;RADIOLOGY;FAMILY MEDICINE;PALEONTOLOGY;ENDOCRINOLOGY;NURSING;GYNECOLOGY;CELL BIOLOGY;UROLOGY;GENERAL SURGERY;PHYSICAL THERAPY","468;296;128;121;90;87;77;68;66;64;48;34;33;29;28;28;24;22;20;18;18","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;POPULATION;MELANOMA;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;COHORT;DISEASE;IMMUNE SYSTEM;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;APOPTOSIS;LYMPHOMA;LUNG CANCER;PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE);OVERALL SURVIVAL;RADIATION THERAPY","347;116;89;74;71;69;53;53;51;41;39;35;32;29;24;23;20;20;20;19;19","IMMUNOTHERAPY;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;METASTATIC MELANOMA;TOLERABILITY;PLACEBO;BEVACIZUMAB;POLYMERASE;ENDOMETRIAL CANCER;CISPLATIN;PROSTATE CANCER;ALLELE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);DOXORUBICIN;MAPK/ERK PATHWAY","124;75;60;53;52;44;42;32;30;27;25;24;23;21;18;17;16;16;15;15","NIVOLUMAB;PEMBROLIZUMAB;IPILIMUMAB;POLY ADP RIBOSE POLYMERASE;CORONAVIRUS DISEASE 2019 (COVID-19);MICROSATELLITE;VEMURAFENIB;CARBOPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CETUXIMAB;METASTATIC BREAST CANCER;TAMOXIFEN;DAPAGLIFLOZIN;TRAMETINIB;TRASTUZUMAB;BRCA MUTATION;CYTOREDUCTIVE SURGERY;KRAS;IRINOTECAN;ANTHRACYCLINE;CANNABINOID RECEPTOR;IMMUNE CHECKPOINT;NEOADJUVANT THERAPY","55;42;25;23;16;16;16;13;11;10;10;10;9;9;9;8;8;8;7;6;6;6;6",";HUMANS;MELANOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;SKIN NEOPLASMS;FEMALE;OVARIAN NEOPLASMS;NEOPLASMS;RETROSPECTIVE STUDIES;LUNG NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;COLORECTAL NEOPLASMS;MALE;ANTIBODIES, MONOCLONAL, HUMANIZED;PROTO-ONCOGENE PROTEINS B-RAF;BREAST NEOPLASMS;NIVOLUMAB;AGED;CARCINOMA, NON-SMALL-CELL LUNG;PANCREATIC NEOPLASMS","352;188;123;73;60;51;39;38;37;36;36;35;34;33;33;32;25;22;21;21","CANCER IMMUNOTHERAPY;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GYNECOLOGIC ONCOLOGY;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MELANOMA;IMMUNOBIOLOGY OF DENDRITIC CELLS;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CHOLANGIOCARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;CARDIOTOXICITY OF CANCER TREATMENTS","55;28;21;19;18;14;14;12;12;11;10;10;8;8;8;7;7;7;7;6","CLINICAL ENDPOINT;MELANOMA;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;TOLERABILITY;OLAPARIB;IMMUNE CHECKPOINT BLOCKADE;BREAST CANCER;DISCONTINUATION;INTRATUMOR HETEROGENEITY;MICROSATELLITE INSTABILITY;CANCER IMAGING;TUMOR MICROENVIRONMENT;INTERIM ANALYSIS;CARBOPLATIN;NEOADJUVANT THERAPY;CANCER IMMUNOTHERAPY;METASTATIC COLORECTAL CANCER;TREATMENT;TUMOR REGRESSION","61;45;45;38;26;22;21;20;18;17;16;15;15;14;13;13;12;12;12;12","BREAST CANCER;OVARIAN CANCER;PHASE III;PATIENTS PTS;CANCER PATIENTS;CELL CARCINOMA;PHASE II;ENDOMETRIAL CANCER;PROSTATE CANCER;COLORECTAL CANCER;METASTATIC MELANOMA;RANDOMIZED PHASE;ADVANCED BREAST;LUNG CANCER;SURVIVAL OS;SQUAMOUS CELL;III TRIAL;IMMUNE CHECKPOINT;PHASE TRIAL;MELANOMA PATIENTS;MISMATCH REPAIR;PATIENTS TREATED;PREVIOUSLY UNTREATED;ADVANCED MELANOMA;ADVANCED OVARIAN;LIVER RESECTION;PHASE STUDY;RECURRENT OVARIAN;CELLS EXPOSED;CYTOREDUCTIVE SURGERY","38;34;34;31;22;20;18;17;17;16;16;16;13;13;13;12;11;11;11;10;10;10;10;9;9;9;9;9;8;8","HR CI;PROGRESSION-FREE SURVIVAL;PERSONAL ADVISORY;RESPONSE RATE;CANCER PATIENTS;BREAST CANCER;MONTHS CI;OVARIAN CANCER;SURVIVAL PFS;ADVISORY BOARD;ADVERSE EVENTS;SURVIVAL OS;STATISTICALLY SIGNIFICANT;PATIENTS TREATED;MEDIAN FOLLOW-UP;DISEASE PROGRESSION;CONFIDENCE INTERVAL;CLINICAL PRACTICE;IMMUNE CHECKPOINT;MEDIAN AGE;OBJECTIVE RESPONSE;PRIMARY ENDPOINT;PATIENTS RECEIVED;PUBMED SCOPUS;RATE ORR;INSTITUTIONAL FUNDING;RESEARCH GRANT;CLINICAL TRIAL;CLIN ONCOL;INSTITUTIONAL RESEARCH","82;78;69;64;63;62;62;62;62;60;59;50;46;42;40;39;38;37;37;36;36;36;35;34;34;33;33;32;31;31",252,0.46,2.65,41.46,4,526,1.31,1,4,1.39,1,4,0,0,0,6.8,1,74,2,2,2,0,0,0,1,1,1,50.27,4,670,1,1,1,0,0,0,36.36,1,439,0,0,0,3,3,3,1.97,1,8,8.46,1,88,22.47,2,246,7.67,1,97,0,0,0,0,0,0,51.25,4,513,51.25,4,513
"IRCCS_PASCALE",2023,510,19.5470588235294,3.14901960784314,0.317559153175592,0.294117647058824,0.217647058823529,0.101960784313725,0.709803921568627,12,229,97,42,26,0.45,0.19,0.08,0.05,7.32,1.66996543386611,0.484313725490196,0.92156862745098,8.95244519392917,0.627969195400591,0.58481788517506,0.545300473130429,0.588082677505838,"PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;MARCO CASCELLA;ANTONIO AVALLONE;NICOLA MAUREA;DIRK SCHADENDORF;DOMENICA LORUSSO;VINCENZO QUAGLIARIELLO;GEORGINA V. LONG;DANIELE SANTINI;NICOLA NORMANNO;MASSIMO DI MAÏO;ANTONIO PINTO;MARTINA IOVINE;REINHARD DUMMER;FRANCESCO IZZO;VINCENZA GRANATA;VANNA CHIARION‐SILENI;ANDREA PACCONE","91;48;37;30;27;25;23;23;23;23;22;21;21;21;21;21;21;20;20;20","PAOLO A. ASCIERTO;MARCO CASCELLA;LUCA FALZONE;SANDRO PIGNATA;FALZONE LUCA;NICOLA MAUREA;MICHELINO DE LAURENTIIS;VINCENZO QUAGLIARIELLO;GABRIELE MADONNA;MARTINA IOVINE;ANDREA PACCONE;ARTURO CUOMO;ELENA BIGNAMI;FRANCESCO IZZO;ALESSANDRO OTTAIANO;VINCENZA GRANATA;ALESSANDRO VITTORI;ANTONIO AVALLONE;NICOLA NORMANNO;ANDREA BELLI","5.3;4.96;4.46;3.09;3;2.38;2.21;2.15;2.08;2.03;1.91;1.9;1.73;1.72;1.71;1.71;1.58;1.44;1.44;1.38","PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;MARCO CASCELLA;ANTONIO AVALLONE;NICOLA MAUREA;DOMENICA LORUSSO;VINCENZO QUAGLIARIELLO;NICOLA NORMANNO;ANTONIO PINTO;MARTINA IOVINE;FRANCESCO IZZO;VINCENZA GRANATA;ANDREA PACCONE;DOMENICO MALLARDO;MARILENA DI NAPOLI;GIUSEPPE PALMA;NICOLETTA COLOMBO;ANNABELLA DI MAURO;CORRADO CARACÒ","91;48;37;30;27;25;23;23;21;21;21;21;20;20;18;17;17;17;16;16","PAOLO A. ASCIERTO;MARCO CASCELLA;LUCA FALZONE;SANDRO PIGNATA;FALZONE LUCA;NICOLA MAUREA;MICHELINO DE LAURENTIIS;VINCENZO QUAGLIARIELLO;GABRIELE MADONNA;MARTINA IOVINE;ANDREA PACCONE;ARTURO CUOMO;FRANCESCO IZZO;ALESSANDRO OTTAIANO;VINCENZA GRANATA;ANTONIO AVALLONE;NICOLA NORMANNO;ANDREA BELLI;GIUSEPPE PALMA;FRANCESCA BRUZZESE","5.3;4.96;4.46;3.09;3;2.38;2.21;2.15;2.08;2.03;1.91;1.9;1.72;1.71;1.71;1.44;1.44;1.38;1.36;1.29","MARCO CASCELLA;ELENA BIGNAMI;PAOLO A. ASCIERTO;VALENTINA BELLINI;JONATHAN MONTOMOLI;NICOLETTA COLOMBO;SANDRO PIGNATA;DOMENICA LORUSSO;MICHELINO DE LAURENTIIS;GEORGINA V. LONG;PHILIPP HARTER;TOON VAN GORP;IGNACE VERGOTE;JEAN‐JACQUES GROB;DIRK SCHADENDORF;VANNA CHIARION‐SILENI;MICHAEL METHOD;ANA OAKNIN;REINHARD DUMMER;STÉPHANE DALLE","730;691;671;630;622;576;573;509;338;311;310;303;292;288;280;267;245;229;205;203","MARCO CASCELLA;PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;EMANUELA ESPOSITO;FRANCESCO PERRONE;ANTONIO AVALLONE;STEFANO GREGGI;PIERA GARGIULO;GABRIELE MADONNA;MARIAELENA CAPONE;MARILENA DI NAPOLI;NICOLA NORMANNO;ANTONIO PINTO;VINCENZA GRANATA;SABRINA CHIARA CECERE;FABIANA TATANGELO;MARIA CARMELA PICCIRILLO;CONO SCAFFA;FRANCESCA FALCONE","728;671;573;338;133;133;120;103;96;90;89;79;67;66;66;63;60;60;55;55","PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;MARCO CASCELLA;ANTONIO AVALLONE;VINCENZO QUAGLIARIELLO;NICOLA MAUREA;MARTINA IOVINE;ANTONIO PINTO;NICOLA NORMANNO;VINCENZA GRANATA;DOMENICO MALLARDO;ANDREA PACCONE;MARILENA DI NAPOLI;ALFREDO BUDILLON;CORRADO CARACÒ;ESTER SIMEONE;FRANCESCO PERRONE;ANNABELLA DI MAURO;PAOLO DELRIO","91;48;37;28;27;25;25;21;21;21;20;18;17;17;16;16;16;16;15;15","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHYSICS;POLITICAL SCIENCE;MATHEMATICS;ENGINEERING;PSYCHOLOGY;ECONOMICS;SOCIOLOGY;BUSINESS;PHILOSOPHY;MATERIALS SCIENCE;ART;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE;GEOLOGY","480;141;51;35;30;15;14;13;13;12;12;8;7;5;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GENETICS;PHARMACOLOGY;PALEONTOLOGY;RADIOLOGY;NURSING;ENDOCRINOLOGY;ARTIFICIAL INTELLIGENCE;BIOINFORMATICS;GYNECOLOGY;GENERAL SURGERY;ASTROBIOLOGY;COMPUTATIONAL BIOLOGY;FAMILY MEDICINE;LAW;MEDICAL PHYSICS;UROLOGY","412;288;113;108;79;70;64;54;54;53;35;34;33;26;24;19;17;17;16;15;15;15;15;15;15","CANCER;CHEMOTHERAPY;CLINICAL TRIAL;GENE;MELANOMA;ADVERSE EFFECT;CONFIDENCE INTERVAL;POPULATION;IMMUNE SYSTEM;RANDOMIZED CONTROLLED TRIAL;COHORT;DISEASE;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);LYMPHOMA;RADIATION THERAPY;ADJUVANT;ANTIBODY;INFLAMMATION;OVERALL SURVIVAL;QUALITY OF LIFE (HEALTHCARE)","298;110;67;63;62;54;51;50;39;36;30;28;25;23;21;21;20;19;18;18;18","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;OVARIAN CANCER;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;BEVACIZUMAB;PHASES OF CLINICAL RESEARCH;METASTATIC MELANOMA;TOLERABILITY;POLYMERASE;PLACEBO;CARDIOTOXICITY;DOXORUBICIN;EJECTION FRACTION;GENE EXPRESSION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);RITUXIMAB;TYPE 2 DIABETES","102;61;59;52;36;35;34;24;24;19;18;16;13;12;12;12;12;12;12;12","NIVOLUMAB;PEMBROLIZUMAB;KRAS;IPILIMUMAB;METASTATIC BREAST CANCER;POLY ADP RIBOSE POLYMERASE;CETUXIMAB;TRASTUZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);DAPAGLIFLOZIN;CARBOPLATIN;IRINOTECAN;CANCER IMMUNOTHERAPY;DNA METHYLATION;BRCA MUTATION;IMMUNE CHECKPOINT;VEMURAFENIB;OXALIPLATIN;CHIMERIC ANTIGEN RECEPTOR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS","41;28;21;17;16;16;14;13;12;11;10;10;9;9;8;8;8;7;6;6",";HUMANS;MELANOMA;FEMALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;OVARIAN NEOPLASMS;RETROSPECTIVE STUDIES;SKIN NEOPLASMS;NEOPLASMS;COLORECTAL NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;BREAST NEOPLASMS;LUNG NEOPLASMS;NIVOLUMAB;PROSPECTIVE STUDIES;ANTIBODIES, MONOCLONAL, HUMANIZED;CARCINOMA, OVARIAN EPITHELIAL;IMMUNE CHECKPOINT INHIBITORS;LIVER NEOPLASMS;MALE","301;204;68;60;59;56;39;36;33;32;30;28;28;21;20;19;19;18;18;18","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;LYMPHOID NEOPLASMS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;HER2 SIGNALING IN BREAST CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GYNECOLOGIC ONCOLOGY;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEPATOCELLULAR CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;PANCREATIC CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS","45;21;20;20;20;16;15;14;12;11;10;9;8;8;7;7;7;7;6;6","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;MELANOMA;IMMUNE CHECKPOINT BLOCKADE;METASTATIC COLORECTAL CANCER;BREAST CANCER;CANCER IMMUNOEDITING;TOLERABILITY;TUMOR REGRESSION;REFRACTORY (PLANETARY SCIENCE);CANCER IMMUNOTHERAPY;OLAPARIB;PANITUMUMAB;PLATINUM-SENSITIVE OVARIAN CANCER;TREATMENT;TUMOR MICROENVIRONMENT;ADJUVANT THERAPY;CARDIOTOXICITY;OVARIAN CANCER","55;37;35;33;27;24;21;21;19;16;15;14;14;13;13;13;13;12;12;12","BREAST CANCER;OVARIAN CANCER;COLORECTAL CANCER;CANCER PATIENTS;PHASE III;METASTATIC COLORECTAL;CELL CARCINOMA;PATIENTS PTS;PHASE II;RANDOMIZED PHASE;PRECLINICAL MODELS;IMMUNE CHECKPOINT;ADVANCED BREAST;CHECKPOINT INHIBITORS;PATIENTS TREATED;CLINICAL OUTCOMES;PROSTATE CANCER;RENAL CELL;CANCER TREATED;ADVANCED MELANOMA;DOXORUBICIN CARDIOTOXICITY;MELANOMA PATIENTS;METASTATIC BREAST;METASTATIC MELANOMA;RETROSPECTIVE STUDY;ARTIFICIAL INTELLIGENCE;HODGKIN LYMPHOMA;II TRIAL;LOCALLY ADVANCED;METASTATIC RENAL","45;36;30;27;25;23;22;21;20;16;15;13;12;12;12;11;11;10;9;8;8;8;8;8;8;7;7;7;7;7","MONTHS CI;HR CI;PROGRESSION-FREE SURVIVAL;SURVIVAL PFS;ADVERSE EVENTS;BREAST CANCER;PATIENTS TREATED;SURVIVAL OS;ADVISORY ROLE;CANCER PATIENTS;RESPONSE RATE;IMMUNE CHECKPOINT;HOFFMANN-LA ROCHE;PRIMARY ENDPOINT;OVARIAN CANCER;MEDIAN FOLLOW-UP;CHECKPOINT INHIBITORS;MEDIAN PFS;CONFIDENCE INTERVAL;RESEARCH FUNDING;COLORECTAL CANCER;PATIENTS PTS;STATISTICALLY SIGNIFICANT;HAZARD RATIO;MEDIAN AGE;MEDIAN OS;PHASE III;RR CHL;MONTHS NA;OBJECTIVE RESPONSE","95;91;67;54;48;48;48;47;44;44;44;39;38;38;37;36;35;32;30;30;29;28;28;27;27;27;27;26;25;25",200,0.39,2.725,46.56,2,324,1.13,1,2,1.38,1,3,0,0,0,7.38,1,165,0,0,0,0,0,0,1,1,1,53.48,2,356,1,1,1,1,1,1,46.35,1,194,1,1,1,3,3,3,1.88,1,6,10.32,1,44,26.53,1,118,10.8,1,50,0,0,0,0,0,0,29.46,0,510,29.54,0,510
"IRCCS_PASCALE",2024,426,19.6103286384977,3.35446009389671,0.298110566829951,0.26056338028169,0.246478873239437,0.143192488262911,0.617370892018779,3,208,75,15,21,0.49,0.18,0.04,0.05,1.52,1.59162870233068,0.485915492957746,0.955399061032864,7.29619377162626,0.534747794862418,0.589441109404812,0.592817204301075,0.583460327136036,"PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;GIOVANNI SCAMBIA;ALESSANDRO OTTAIANO;GEORGINA V. LONG;NICOLA NORMANNO;VINCENZA GRANATA;DOMENICA LORUSSO;ANTONIO AVALLONE;CAROLINE ROBERT;PIOTR RUTKOWSKI;DIRK SCHADENDORF;VITO CHIÀNTERA;NICOLA MAUREA;MARILENA DI NAPOLI;SISTO PERDONÀ;MARTINA IOVINE;CARMELA PISANO;ANA ARANCE","62;48;45;26;26;25;21;21;21;21;19;18;17;16;16;15;15;15;14;13","PAOLO A. ASCIERTO;MICHELINO DE LAURENTIIS;SANDRO PIGNATA;ALESSANDRO OTTAIANO;VINCENZA GRANATA;NICOLA NORMANNO;ALESSANDRO MORABITO;GIOVANNI SCAMBIA;VITO CHIÀNTERA;ANTONIO AVALLONE;GEORGINA V. LONG;NICOLA MAUREA;DOMENICA LORUSSO;GERARDO FERRARA;LUIGI ALFANO;MAURIZIO CAPUOZZO;MARTINA IOVINE;ANYOU WANG;ALFREDO BUDILLON;ANTONIO SIMONE LAGANÀ","3.39;2.82;2.59;2.08;1.61;1.6;1.6;1.37;1.34;1.3;1.2;1.19;1.18;1.14;1.13;1.12;1.09;1;0.99;0.98","PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;ALESSANDRO OTTAIANO;NICOLA NORMANNO;VINCENZA GRANATA;ANTONIO AVALLONE;VITO CHIÀNTERA;NICOLA MAUREA;MARILENA DI NAPOLI;SISTO PERDONÀ;MARTINA IOVINE;CARMELA PISANO;ALFREDO BUDILLON;SABRINA CHIARA CECERE;ILARIA GIACOBBE;FRANCESCO IZZO;SALVATORE TAFUTO;FRANCESCA BRUZZESE;LAURA ARENARE","62;48;45;26;21;21;21;16;16;15;15;15;14;13;13;13;13;12;12;11","PAOLO A. ASCIERTO;MICHELINO DE LAURENTIIS;SANDRO PIGNATA;ALESSANDRO OTTAIANO;VINCENZA GRANATA;NICOLA NORMANNO;ALESSANDRO MORABITO;VITO CHIÀNTERA;ANTONIO AVALLONE;NICOLA MAUREA;GERARDO FERRARA;LUIGI ALFANO;MARTINA IOVINE;ANYOU WANG;ALFREDO BUDILLON;ILARIA GIACOBBE;FRANCESCO IZZO;MARCO CASCELLA;FRANCESCA BRUZZESE;ANTONELLA PETRILLO","3.39;2.82;2.59;2.08;1.61;1.6;1.6;1.34;1.3;1.19;1.14;1.13;1.09;1;0.99;0.97;0.95;0.93;0.89;0.86","SANDRO PIGNATA;GIOVANNI SCAMBIA;DOMENICA LORUSSO;ANA OAKNIN;JALID SEHOULI;PAOLO A. ASCIERTO;LUCY GILBERT;ALI AYHAN;KARIN YAMADA;ALEJANDRO ACEVEDO;FERNANDO CONTRERAS MEJÍA;FLORA ZAGOURI;JUNG‐YUN LEE;KOSEI HASEGAWA;LINDA DUSKA;MANUEL LEIVA;PIER RAMOS-ELÍAS;SARPER TOKER;VALERIYA SAEVETS;YANG XIANG","167;163;152;139;139;97;89;86;85;84;84;84;84;84;84;84;84;84;84;84","SANDRO PIGNATA;PAOLO A. ASCIERTO;NICOLA NORMANNO;ALESSANDRO OTTAIANO;MICHELINO DE LAURENTIIS;SALVATORE TAFUTO;ANTONIO AVALLONE;VINCENZA GRANATA;MARIA GRAZIA VITALE;SECONDO LASTORIA;DOMENICO MALLARDO;MIRIAM PAONE;SISTO PERDONÀ;VITO CHIÀNTERA;CARMELA PISANO;ANTONIO TUFANO;FRANCESCO PERRI;GIOSUÈ SCOGNAMIGLIO;FRANCESCO PERRONE;MARIACHIARA SANTORSOLA","167;93;44;42;38;38;36;32;30;28;25;23;23;19;18;17;17;15;13;11","PAOLO A. ASCIERTO;SANDRO PIGNATA;MICHELINO DE LAURENTIIS;ALESSANDRO OTTAIANO;VINCENZA GRANATA;ANTONIO AVALLONE;VINCENZO QUAGLIARIELLO;NICOLA MAUREA;NICOLA NORMANNO;SISTO PERDONÀ;MARILENA DI NAPOLI;MARTINA IOVINE;VITO CHIÀNTERA;CARMELA PISANO;ALFREDO BUDILLON;FRANCESCO IZZO;GERARDO FERRARA;SABRINA CHIARA CECERE;ILARIA GIACOBBE;SALVATORE TAFUTO","61;48;43;26;21;20;18;16;15;15;15;15;14;14;13;13;13;13;13;12","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;ECONOMICS;PSYCHOLOGY;ENGINEERING;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;GEOLOGY;HISTORY;ART","405;117;43;39;21;16;13;9;6;6;6;5;5;5;4;2;2;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;BIOCHEMISTRY;IMMUNOLOGY;GENETICS;PALEONTOLOGY;PHARMACOLOGY;GYNECOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;NURSING;GENERAL SURGERY;PHYSICAL THERAPY;BIOINFORMATICS;ARTIFICIAL INTELLIGENCE;INTENSIVE CARE MEDICINE;UROLOGY","353;234;101;78;75;47;42;37;36;36;31;31;30;26;19;18;18;17;15;15;15","CANCER;CHEMOTHERAPY;MELANOMA;GENE;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);POPULATION;ADVERSE EFFECT;IMMUNE SYSTEM;ALTERNATIVE MEDICINE;DISEASE;CONFIDENCE INTERVAL;ADJUVANT;RETROSPECTIVE COHORT STUDY;RECEPTOR;COHORT;LUNG CANCER;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY","257;74;45;41;32;32;29;26;24;24;23;23;21;19;19;18;15;15;14;13","BREAST CANCER;IMMUNOTHERAPY;OVARIAN CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;PLACEBO;PROGRESSION-FREE SURVIVAL;METASTATIC MELANOMA;METASTASIS;ADJUVANT THERAPY;HAZARD RATIO;ENDOMETRIAL CANCER;POLYMERASE;CARDIOTOXICITY;CISPLATIN;BEVACIZUMAB;BLADDER CANCER;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;CELL CYCLE;GEMCITABINE;MICRORNA","71;67;34;28;19;19;15;14;13;12;12;11;10;9;9;8;8;8;8;7;7;7","NIVOLUMAB;PEMBROLIZUMAB;METASTATIC BREAST CANCER;IPILIMUMAB;POLY ADP RIBOSE POLYMERASE;KRAS;TRASTUZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);IMMUNE CHECKPOINT;IRINOTECAN;UROTHELIAL CARCINOMA;CXCR4;SYSTEMIC THERAPY;TRIPLE-NEGATIVE BREAST CANCER;ADJUVANT CHEMOTHERAPY;BRCA MUTATION;CANCER IMMUNOTHERAPY;DAPAGLIFLOZIN;EPITHELIAL OVARIAN CANCER;HORMONE RECEPTOR;LENVATINIB;NEOADJUVANT THERAPY;PD-L1;PTEN;VEMURAFENIB","27;26;17;15;10;9;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MIDDLE AGED;AGED;ADULT;MALE;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MELANOMA;ITALY;SKIN NEOPLASMS;PROGRESSION-FREE SURVIVAL;BREAST NEOPLASMS;MUTATION;NEOPLASMS;ANTIBODIES, MONOCLONAL, HUMANIZED;NEOPLASM RECURRENCE, LOCAL;OVARIAN NEOPLASMS","266;158;99;80;78;71;63;38;34;23;21;20;18;17;15;15;15;14;14;14","CANCER IMMUNOTHERAPY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;MELANOMA;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;RENAL CELL CARCINOMA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHOLANGIOCARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HER2 SIGNALING IN BREAST CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH","32;18;15;15;14;13;12;11;10;9;7;7;7;7;6;6;6;5;4;4","MELANOMA;BREAST CANCER;CLINICAL ENDPOINT;ADJUVANT THERAPY;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;OVARIAN CANCER;COMBINATION THERAPIES;METASTATIC BREAST CANCER;TREATMENT;TUMOR MICROENVIRONMENT;CARDIOTOXICITY;METASTATIC COLORECTAL CANCER;CHEMOTHERAPY;IMMUNE CHECKPOINT BLOCKADE;NEOADJUVANT THERAPY;OLAPARIB;PLATINUM-SENSITIVE OVARIAN CANCER;REGIMEN;CANCER GENOMICS","31;30;19;15;15;14;13;12;12;12;10;9;9;8;8;8;8;8;8;7","BREAST CANCER;OVARIAN CANCER;CANCER PATIENTS;PHASE III;COLORECTAL CANCER;CELL CARCINOMA;LOCALLY ADVANCED;LUNG CANCER;IMMUNE CHECKPOINT;METASTATIC COLORECTAL;ADVANCED MELANOMA;ENDOMETRIAL CANCER;NEWLY DIAGNOSED;PHASE STUDY;PHASE TRIAL;PROSTATE CANCER;ABSTRACT PO--;ADVANCED CERVICAL;CERVICAL CANCER;LYMPH NODE;RANDOMIZED PHASE;RENAL CELL;VERSUS PLACEBO;MAINTENANCE THERAPY;MEET-URO STUDY;METASTATIC BREAST;PEMBROLIZUMAB VERSUS;PHASE II;RECURRENT OVARIAN;ADVANCED OVARIAN","52;28;16;16;13;12;12;10;9;9;8;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;5","HR CI;BREAST CANCER;CLINICAL PRACTICE;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;OVARIAN CANCER;CANCER PATIENTS;IMMUNE CHECKPOINT;ADVERSE EVENTS;SURVIVAL PFS;CLINICAL TRIALS;LUNG CANCER;MONTHS CI;CELL CARCINOMA;FINANCIAL TOXICITY;CHECKPOINT INHIBITORS;PATIENTS UNDERGOING;LIQUID BIOPSY;MEDIAN FOLLOW-UP;MEDIAN PFS;PATIENTS TREATED;PERFORMANCE STATUS;PHASE III;CELL LINES;DISEASE PROGRESSION;LYMPH NODE;STATISTICALLY SIGNIFICANT;TARGETED THERAPY;CLINICAL TRIAL;DISEASE-FREE SURVIVAL","40;39;38;30;30;29;27;25;23;22;21;20;20;19;19;18;18;17;16;15;15;15;14;13;13;13;13;13;12;12",6,0.01,3.225,37.5,25,50,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,40,27,53,0,0,0,0,0,0,37,24,50,0,0,0,0,0,0,1,1,1,9.5,8,11,23,14,32,4,1,7,0,0,0,0,0,0,8,0,16,8,0,16
